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The human immune system reacts swiftly to pathogens while remaining oblivious to 
self, an important concept termed self-tolerance. Dendritic cells (DCs) are pivotal in 
this process, as they mediate both initiation of adaptive immune responses as well as 
induction of tolerance. Recently, evidence has been accumulating that β₂ integrins, 
heterodimeric adhesion receptors that can assume an active conformation in 
response to stimulation through various receptors, may have both pro-inflammatory 
and immunoregulatory roles on DCs. In this thesis, I investigated the hypothesis that 
dysregulation of β₂ integrin signalling on DCs can contribute to aberrant inflammatory 
responses, such as in the autoimmune disease rheumatoid arthritis (RA).  
To test this hypothesis, I first developed and optimised a multi-colour flow cytometry 
panel to measure both expression (‘total’ β₂ integrin) and expression of the active 
conformation (‘active’ β₂ integrin) of three β₂ integrin subunits: CD11a, CD11b and 
the pairing subunit CD18. As conformational state of integrins is highly important for 
the functionality, this provided important proof of concept that simultaneous staining 
for both ‘total’ and activation-specific epitopes is possible.  
Then I utilised mature and tolerogenic monocyte-derived DCs (Mo-DCs) as a model 
system to explore the role of β₂ integrins in circumstances of immune activation and 
tolerance. I found that tolerogenic Mo-DCs expressed significantly more active 
CD11a, while expressing significantly less active CD11b compared to mature Mo-
DCs. Furthermore, treating mature Mo-DCs with a CD11b-blocking antibody 
significantly decreased their T cell stimulatory ability, suggesting that CD11b might 
have pro-inflammatory roles on DCs. 
Lastly, I compared total and active β₂ integrin expression on DCs and monocyte 
populations in RA patients and healthy controls. While no differences in β₂ integrin 
expression were observed in peripheral blood (PB), comparing synovial fluid (SF) to 
PB of active RA patients showed that expression of total and active CD11a was 
significantly reduced in SF, while CD11b was significantly increased. 
To conclude, I found that CD11a and CD11b might play opposing roles on DCs in 
both tolerogenic and autoimmune environments. From my findings, it could be 
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1.1 Immune tolerance  
The immune system consists of a variety of specialised cells, which work 
concordantly to protect an organism from danger, either in the form of foreign 
pathogens (non-self) or aberrant self, such as cancerous cells. To effectively protect 
an organism from these threats, the immune system needs to correctly distinguish 
between foreign or abnormal non-self, which needs to be eliminated, and the body’s 
own cells (self), which need to remain protected from an immune response to remain 
healthy and functional.  
The state of remaining non-responsive in the presence of self is called immune 
tolerance. If tolerance to self is lost, this can lead to emergence of autoimmunity, 
where the immune system attacks and progressively damages the body’s own 
tissues. Common examples of autoimmune disorders include diabetes, inflammatory 
bowel disease (IBD) and rheumatoid arthritis (RA), where the pancreas, intestines 
and joint tissues, respectively, are targeted by the immune system causing 
pathology. Correctly distinguishing between self and non-self is therefore a highly 
important immunological process (Parijs and Abbas, 1998).  
Recognising pathogens can occur non-specifically, by the innate immune system, 
and specifically, by the adaptive immune system. Briefly, phagocytic cells 
(neutrophils, monocytes, macrophages), cells releasing pro-inflammatory mediators 
(basophils, mast cells, eosinophils) and natural killer (NK) cells, as well as the 
complement system and interferons (IFNs) are all players of innate immunity. They 
recognise highly conserved properties of foreign molecules using so-called pattern 
recognition receptors (PRRs) and act quickly to eliminate them. While the innate 
immune system is therefore a highly important line of first defence against infection, it 
is less effective at reacting to pathogens that do not share conserved pattern 
recognition motifs. Another important role of the innate immune system is therefore 
that it can provide danger signals to activate the antigen-specific adaptive immune 
system. The adaptive immune system consists of T cells and B cells, which, through 
genetic rearrangement of their surface receptors, are able to recognise any novel 
antigens. This is largely due to the huge number of different antigen-specific T and B 
cell clones, which then in turn can be expanded to counteract the pathogen in 
question specifically. Importantly, some of the members of the expanded clone(s) 
can persist after the end of infection as memory cells, thereby providing more swift 




adaptive immune system is therefore the basis of vaccination being an effective 
mechanism to combat otherwise life-threatening diseases (Delves and Roitt, 2000).  
1.2 Role of antigen-presenting cells in the immune system 
Antigen-presenting cells (APCs) provide the important link between innate and 
adaptive immune responses. Importantly, they are also involved in maintaining 
tolerance to self. This is because APCs continuously sample, process and finally 
present self and non-self antigens in so-called major histocompatibility complexes 
(MHC) on their surfaces, which are termed human leukocyte antigens (HLAs) in 
humans. MHCs exist in two classes, MHC class I (MHC I), which present antigen to 
CD8+ cytotoxic T cells and MHC class II (MHC II), which present antigen to CD4+ 
helper T cells. This is where pathogenic and non-pathogenic antigens are presented 
and potentially recognised by both naïve and memory antigen-specific T cells, which 
are the drivers of the adaptive immune response. In contrast, self-antigen presented 
on cell surfaces is the basis of both central and peripheral tolerance (Miller and 
Basten, 1996; Miller and Morahan, 1992), which will be discussed in more detail in 
section 1.3. Although virtually all cells can act as APCs to present their own 
molecules to cytotoxic CD8 T cells via MHC I, only some APCs can present both 
foreign and self-antigen to helper CD4 T cells via MHC II. While macrophages, B 
cells and more recently γδ T cells have all been described to express MHC II 
(Lanzavecchia, 1985; Moser and Brandes, 2006; Unanue, 1984), dendritic cells 
(DCs) have been described as the dominant APC population that have the ability to 
stimulate naïve CD4 T cells, therefore being termed the professional APCs of the 
immune system (Lassila et al., 1988). Even though expression of MHC II was also 
found to be inducible under inflammatory conditions in a variety of cells from 
basophils to neutrophils, there is little evidence that they could replace DCs in any 
meaningful way (Kambayashi and Laufer, 2014). DCs are therefore key players in 
initiating either immune activation or tolerance and will be described in detail in 
section 1.2.1. Additionally, monocytes, which can develop into so-called monocyte-
derived DCs (Mo-DCs) under inflammatory conditions, will also be discussed. 
1.2.1 Dendritic cells 
DCs are large cells with cytoplasmic protrusions of varying lengths, which were 
recognised in their own right by Steinmann and Cohn in murine lymphoid organs 
(Steinman and Cohn, 1973). In their role as ‘professional’ APCs, DCs are highly 




pathogens and conversely limiting aberrant immune activation in response to self. 
The majority of DCs reside in tissues and lymphoid organs, where they are surveying 
the area for antigens. However, DCs make up only 1-2% of peripheral tissues and 
circulating DCs only comprise 1% of PB, making them a comparatively small cell 
population. In addition to patrolling PB and tissues, they can also be found in lymph 
and lymphoid organs. In this section, development of different DC populations will be 
briefly described before exploring their roles in both immune activation and tolerance 
induction. 
Development of DC subsets 
DCs develop from common DC progenitors (CDP) in the bone marrow (Naik et al., 
2007; Rhodes et al., 2019), which give rise to plasmacytoid DCs (pDCs) and pre-
conventional DCs (pre-cDCs). Pre-cDCs then further differentiate into two types of 
conventional DCs: cDC1 and cDC2 DCs. While pDCs exit the bone marrow fully 
differentiated, pre-cDCs circulate in peripheral blood (PB) and enter lymphoid organs 
to differentiate into cDC1 or cDC2 DCs. More recent studies using single cell 
RNAseq have however identified further DC subsets (Villani et al., 2017), yielding a 
total of six DC subsets in PB. To specify, two different subtypes of cDC2 DCs have 
been described, with the newly discovered one (termed DC3 by Villani and 
colleagues) expressing high levels of CD163 and CD36 alongside other cDC2 
markers. Further, one DC subset that lacks both cDC1 and cDC2 markers but 
expresses the monocyte marker CD16 have been described as DC4. Lastly, a pDC 
marker expressing DC subset, which can be delineated by its expression of Axl and 
Siglec6 was termed DC5 (Rhodes et al., 2019; Villani et al., 2017). However, these 
distinctions are still relatively recent, with the ontogeny of some of these previously 
undefined subsets still being unknown and available surface antibodies for flow 
cytometry being limited. This thesis will therefore focus on cDC1, cDC2 and pDCs, 
which will be discuss in more detail in respect to their expression of surface 
molecules, requirements for restriction factors and function. 
cDCs are the major DC population responsible for detecting foreign antigen and 
presenting it to naïve T cells to initiate an adaptive immune response. cDC1 DCs are 
the rarest DC subset with only 0.1% of leukocytes belonging to this group. They are 
characterised by high expression of the thrombomodulin (CD141) as well as CLEC9A 
and XCR1. Their development is dependent on the transcription factor BATF3 




CD103 expression. In contrast, cDC2 DCs, which are of myeloid origin, have been 
shown to be dependent on the presence of IRF4 (Guilliams et al., 2016) and express 
CD1c, a member of the CD1 family responsible for presenting lipids, as well as 
CLEC6A and CLEC7A. In mice, cDC2 DCs are mainly characterised by their high 
expression of the β₂ integrin CD11b. Lastly, pDCs have a specialised role in 
response to viruses, where they produce large amounts of Type I IFNs (IFNα, IFNβ) 
to block viral replication and activate other immune cells (Asselin-Paturel and 
Trinchieri, 2005; Barchet et al., 2002). pDCs are characterised by expression of 
CD123 in human and Siglec H, BST-2 and B220 in mouse, as well as the absence of 
CD11c from their surface, which is a common marker for cDCs. The development of 
pDCs depends on the transcription factor E2-2 (Cisse et al., 2008).  
Role of DCs in immune activation during infection 
To appreciate the importance of DCs in the process of immune activation, a more 
detailed overview of antigen presentation and activation of adaptive immune 
responses is necessary. I will focus here on the presentation of a pathogenic antigen 
to illustrate how immune activation occurs when presented with a threat, but it has to 
be kept in mind that several steps in this process will occur similarly when a self-
antigen is presented to induce tolerance. This aspect will be explored in detail in the 
following section, ‘Role of DCs in tolerance’. 
Tissue-patrolling DCs, which make up the largest proportion of these APCs, as well 
as circulating DCs are largely in an immature state, meaning they can efficiently 
capture, process and present antigen on their surface, but have low T cell stimulatory 
abilities (Bell et al., 1999). Immature DCs are therefore characterised by high 
endocytic activity and expression of Fc receptors to mediate highly efficient antigen 
capture. While they have been reported to have high intracellular levels of MHC, 
surface expression is low, as is expression of costimulatory molecules such as CD80, 
CD83 and CD40. Lastly, immature DCs express little to no pro- or anti-inflammatory 
cytokines, explaining their low T cell priming abilities (Dudek et al., 2013). Upon 
encountering so-called danger signals, DCs rapidly increase surface expression of 
costimulatory molecules and MHC II while simultaneously downregulating processes 
of antigen capture. Furthermore, they undergo extensive cytoskeleton rearrangement 
and start expressing adhesion receptors, such as the integrin CD49 (Puig-Kröger et 
al., 2000), on their surface. However, a study comparing injection of wild type (WT) 




showed that they arrived in the lymph node (LN) in similar numbers, suggesting that 
integrins are not required for migration of mature DCs to LN (Lämmermann et al., 
2008). Much more importantly for migration, mature DCs also up-regulate the 
chemokine receptor CCR7, which mediates DC migration towards CCL19 and 
CCL20, chemokines produced by fibroblastic reticular cells (FRCs). These stromal 
cells are located in the T cell zone of secondary lymphoid organs and thereby guide 
DCs to their appropriate location within the LN (Geissmann et al., 2002). This cluster 
of processes enabling DCs to migrate from peripheral tissues to LNs and efficiently 
stimulate T cells is known as DC maturation (Théry and Amigorena, 2001). The 
danger signals eliciting this process can be exogenous by pathogen-associated 
molecular patterns (PAMPs), for example through presence of the bacterial cell wall 
component lipopolysaccharide (LPS) (Smedt et al., 1996), unmethylated CpG motifs 
in bacterial DNA (Sparwasser et al., 1998) or double-stranded viral DNA (Cella et al., 
1999). To detect these PAMPs, DCs utilise so called pattern recognition receptors 
(PRRs), including Toll like receptors (TLRs), such as TLR2 and TLR4, and C-type 
lectin receptors (CLRs), such as CLEC9A and Dectin-2 (Lundberg et al., 2014). DC 
maturation can however also be induced by endogenous signals or damage-
associated molecular patterns (DAMPs), such as the presence of heat-shock protein 
(HSPs) (Singh‐ Jasuja et al., 2000), breakdown products of extracellular matrix 
(ECM) such as heparin sulfates (Kodaira et al., 2000) and cytokines released by 
other activated leukocytes, such as interleukin 1β (IL-1β) and Tumour necrosis 
factor-α (TNF-α) (Zepter et al., 1997). Recognition of DAMPs can occur via DAMP 
receptors, such as TLR 4 and TLR9, but also via the receptor for advanced glycation 
end products (RAGE) (Nace et al., 2012).  
After having acquired non-self antigen and undergone maturation, DCs migrate to the 
draining LN to present it to the resident naïve T cells. Once arrived in the LN, DCs 
present the antigen to a range of T cell clones, until a clone that specifically binds to 
the presented antigen is found (Ingulli et al., 1997). This antigen-specific interaction 
between DC and T cell is known as the immunological synapse. Three signals have 
been established to be necessary to initiate T cell activation and clonal expansion, 
which initiates the adaptive immune response (Figure 1.1A) (Gutcher and Becher, 
2007). Signal 1 is the interaction between MHC II-bound peptide expressed by the DC 
and the T cell receptor (TCR) on the T cell side, ensuring that the response to the 




costimulatory factors CD80 and CD86 on DCs binding to CD28 expressed on CD4 T 
cells, thereby stimulating the T cell. Lastly, signal 3, mediated by cytokine released by 
DCs into the immunological synapse polarises T cell differentiation thereby targeting 
the immune response to the type of infective agent. For example, T cell stimulation 
occurring in the presence of IL-12 produced by APCs stimulates Th1 T cell responses 
targeted at bacteria and intracellular pathogens, while PGE2 stimulates Th2 T cell 
responses, specifically targeting extracellular parasites such as helminths (Kaliński et 
al., 1999). Signal 3 can, therefore, provide valuable additional information collected by 
DCs in the periphery during maturation to naïve T cells in the LN. Furthermore, DCs 
play an important role in stimulating CD8 T cells in a process termed cross-
presentation. This is a process whereby particularly cDC1 DCs present exogenous 
antigens via MHC I, which is usually reserved for cell-endogenous peptides, to 








To summarise, DCs do not merely present antigens to T cells, they also actively 
stimulate T cell activation via costimulatory signals and shape the type of T cells 
responses elicited by polarising them towards pathogen-appropriate T cell phenotypes. 
Figure 1.1 Antigen-specific T cell activation and tolerance induction 
An APC, such as DC, and a T cell form an immunological synapse where the APC presents antigen in 
its MHC II, which is recognised by a TCR on the T cell (Signal 1). A. Initiation of immune activation 
occurs when DCs also provide co-stimulatory signals in the form of CD80/86 binding to CD28 on T 
cells (Signal 2) and produce cytokines that stimulate T cell responses (Signal 3). B. Non-pathogenic 
self-antigen is presented in the absence of Signal 2, Signal 3 or both, or in the presence of a 
immunoregulatory Signal 3 signalling involving IL-10 or TGF-β, thereby causing T cells specific for this 
antigen to become unresponsive, thereby maintaining peripheral tolerance to self. Adapted from 





However, they also have important roles in maintaining tolerance, which I will explore 
in the following section.  
Role of DCs in tolerance 
As previously mentioned, DCs are not only important for the initiation of an immune 
response in the event of infection, they are also indispensable in preventing immune 
response to self-antigens, as well as commensals and harmless antigens ingested 
with food. The immense importance of DCs for tolerance is highlighted by the fact 
that complete ablation of DCs in a mouse model led to severe fatal multi-organ 
autoimmunity, suggesting that DCs play a highly important role in induction of 
tolerance to self (Ohnmacht et al., 2009). 
There are a variety of ways in which DCs induce tolerance. To induce central 
tolerance, DCs induce cell death of T cells showing high affinity for self-antigen in the 
thymus, a process termed negative selection (Brocker et al., 1997). However up to 
25-40% of self-reactive T cells were found to escape negative selection, 
necessitating further mechanisms to maintain tolerance to self (Bouneaud et al., 
2000). Further contributing to central tolerance, DCs have also been found to 
contribute to the induction and expansion of FoxP3+ regulatory T cells (Tregs) in the 
thymus (Proietto et al., 2008). Tregs are potent regulators of aberrant immune 
responses and depletion or reduction in numbers of Tregs has been associated with 
the emergence of autoimmune disease (Ochs et al., 2005; Singh et al., 2001). In fact, 
mutations in FoxP3 cause the fatal IPEX syndrome (immune dysregulation 
polyendocrinopathy enteropathy X-linked), an X-linked genetic disorder being 
characterised by excessive autoimmunity due to the absence of functional Tregs 
(Bennett et al., 2001). Furthermore, DCs are also involved in peripheral tolerance, by 
presenting self-antigen to T cells in the absence of costimulatory signals (signal 2) or 
pro-inflammatory cytokines (signal 3) in an immunological synapse (Figure 1.1B). In 
in vitro studies, absence of costimulation via CD28 rendered T cells anergic to 
stimulation with lectins, with low production of IL-2 and a decrease in IL-2 receptor 
expression, which was not possible to be reversed by external provision of IL-2 
(Shahinian et al., 1993). The same study also reported that effective T cell responses 
were reduced in vivo studies when costimulation was absent, suggesting that 
absence of costimulation negatively impacts the ability of T cells to mount an immune 
response. Another possibility for DCs to mediate peripheral tolerance is by altering 




immune response. For example, DCs matured in the presence of the anti-
inflammatory cytokine IL-10 were found to induce anergic T cells expressing low 
levels of IL-2, thereby being unlikely to elicit sustained T cell proliferation (Steinbrink 
et al., 1997). Furthermore, T cells activated by these so-called tolerogenic DCs did 
not only show reduced abilities raise an immune response themselves, they were 
also shown to actively suppress syngeneic T cells not exposed to IL10 in an antigen-
specific manner (Steinbrink et al., 2002), thereby suggesting that these tolerised T 
cells can themselves tolerise other T cells. In addition to their roles in Treg induction 
in the thymus, DCs have also been shown to be able to induce Treg differentiation 
from CD4 T cells in the periphery (Coombes et al., 2007; Sun et al., 2007), further 
underlining their importance for tolerance induction. 
In addition to routes to tolerance, it is also important to consider which types of DCs 
are able to induce tolerance. For a long time, it was believed that only immature or 
semi-mature DCs were able to induce tolerance, as they provided antigen 
presentation (signal 1) in the absence of costimulation and cytokines (signals 2 and 
3). Immature DCs were repeatedly described to induce T cell anergy, which resulted 
in production of anti-inflammatory cytokine IL-10 by T cells (Jonuleit et al., 2000; Lutz 
et al., 2000b, 2000a). More recently, however, mature DCs have also been shown to 
have tolerogenic functions in certain immune environments. For example, introducing 
DCs matured with TNF-α , which was shown to produce an incomplete maturation of 
DCs in contrast with LPS+CD40 in respect to DC cytokine production, were shown to 
protect against the development of experimental autoimmune encephalomyelitis 
(EAE), a mouse model of multiple sclerosis (MS), in an antigen-specific manner 
(Menges et al., 2002). In fact, in the complete absence of TNF-α, mice were shown to 
be more susceptible to EAE, further supporting that the cytokine had protective 
functions. In in vitro studies of Mo-DCs, a range of other compounds was found to 
drive a tolerogenic phenotype in DCs. For example, DCs matured in the presence of 
the anti-inflammatory cytokine IL-10 were shown to have reduced abilities to 
stimulate T cells (Steinbrink et al., 1997), as in the presence of transforming growth 
factor β (TGF-β) (Fogel-Petrovic et al., 2007), IL-6 (Hegde et al., 2004) or a 
combination thereof (Torres-Aguilar et al., 2010). Furthermore, non-immune 
compounds such as Vitamin D3, or the dietary compounds sulforaphane or curcumin 
were shown to have similarly suppressive effects on DC maturation and enhance 




2010). Overall, this suggested that tolerogenic functions of DCs are not necessarily 
dependant only on immaturity, but also on surrounding factors.  
Furthermore, different DC populations might have differential capacity to induce 
tolerance. For example, both thymus resident and migratory cDCs seem to be highly 
important for negative selection in the thymus, while pDCs were not shown to 
contribute to deletion of self-reactive T cells to the same degree (Guerri et al., 2013). 
In contrast, while ablation of all DCs caused fatal autoimmunity in mice, ablation of 
only cDCs specifically caused problems with raising an immune response but did not 
result in failure of either negative selection or Treg induction (Birnberg et al., 2008). 
Although these results have to be scrutinised due to the potential redundancy 
between different DC types, leading to pDCs potentially compensating functionally in 
the absence of cDCs, this suggests that pDCs might also contribute to self-tolerance. 
A role for pDCs in tolerance is further supported by studies reporting their tolerogenic 
functions in inflammatory models in the lung (Heer et al., 2004), the joint (Jongbloed 
et al., 2009) and models of organ transplantation (Ochando et al., 2006). While this 
suggests that both cDCs and pDCs contribute to induction of tolerance, they have 
also both been shown to be able to contribute to a breach of tolerance causing 
autoimmunity, which I will explore in more detail in the following section. 
Role of DCs in breach of tolerance 
While the previous section expanded on the important roles DCs play in immune 
tolerance, they can also be important contributors to development and progression of 
autoimmunity.  
A range of autoimmune conditions show increased numbers of DCs within the 
affected tissue, suggesting that DCs play an important role in breach of tolerance and 
maintenance of autoimmunity. In the autoimmune disease RA, proportion and total 
number of DCs were found to be increased in synovial fluid and synovial membranes 
(Harding and Knight, 1986; Jongbloed et al., 2009; Lebre et al., 2008; Poulter et al., 
1983). Similarly, in Sjögren’s syndrome, an autoimmune condition targeting glands 
that produce moisture, increased numbers of DCs were observed in salivary glands 
(Blokland et al., 2000; Wildenberg et al., 2009). In MS, large numbers of circulating 
DCs expressing pro-inflammatory cytokines such as TNF-α and IL-6 (Huang et al., 
1999). The study also reported increased levels of IFN-γ, which is likely to be due to 




Furthermore, animal studies have shown that DCs can effectively drive autoreactive 
T cell responses to cause autoimmunity. Introduction of DCs specific to a transgenic 
protein exclusively expressed in pancreatic β cells caused onset of diabetes in mice 
(Ludewig et al., 1998) and a similar study showed that adoptive transfer of DCs 
exposed to thyroglobulin were able to induce thyroiditis (Knight et al., 1988). 
Interestingly, high IFN levels due to persistent activation of pDCs has been described 
to contribute to systemic lupus erythematosus (SLE) and potentially other 
autoimmune disorders (Banchereau and Pascual, 2006), suggesting that pDCs can 
also play important roles in breach of tolerance.  
There are different ways in which DCs could contribute to the initiation of 
autoimmunity. It is possible that DCs simply fail to provide tolerogenic signals to self-
reactive T cells, either in the thymus, letting self-reactive T cells escape negative 
selection, or in the periphery, where presentation of innocuous self-antigen could 
falsely occur in the presence of costimulatory signals (signal 2) and pro-inflammatory 
cytokine release (signal 3). A third option is that T cells fail to react to self-antigen, 
but have strong affinity for self-antigen altered through post-translational modification. 
As post-translationally altered peptides would not be presented in the thymus, this 
means that T cells specific for altered peptides would not undergo deletion and could 
therefore become activated in the presence of post-transcriptionally altered peptide in 
the periphery.  
To summarise, DCs are integral to the decision between immune activation and 
tolerance. If this careful balance is disturbed however, DCs can equally be important 
contributors to a breach of tolerance and thereby lead to autoimmune disease. In the 
next section I will explore the role monocytes play in these contexts before 
discussing the role these APCs play in the autoimmune condition RA. 
 
1.2.2 Monocytes 
Similar to DCs, monocytes arise from common monocyte progenitors (cMop) in the 
bone marrow before exiting to circulate in PB (Hettinger et al., 2013). Monocytes 
were originally characterised by their expression of the LPS co-receptor CD14 and 
occur in three distinct subsets: classical, intermediate and non-classical monocytes 




Classical monocytes show high expression of CD14 and are negative for CD16, a 
Fcγ receptor type III. Transcriptomic analysis of CD14+ monocytes, thereby including 
both classical and intermediate monocyte populations, suggested roles in anti-
bacterial and pro-inflammatory responses (Anbazhagan et al., 2014). While it was 
shown that CD14+ monocytes do not undergo differentiation into DCs in the steady 
state, they contribute to antigen surveillance (Jakubzick et al., 2013). Under 
inflammatory conditions, such as in the presence of TNF-α and LPS, classical 
monocytes were shown to effectively differentiate into either so-called Mo-DCs or 
assumed a macrophage-like phenotype (Mo-macrophages) (Iwamoto et al., 2007) 
and CD14+ monocytes could even differentiate into osteoclasts, when exposed to 
macrophage-colony stimulating factor (M-CSF) and RANK ligand (Sørensen et al., 
2007). The question which cell type CD14+ monocytes differentiate into is strongly 
reliant on the signalling factor present in the peripheral tissues where differentiation 
occurs. In vitro studies have shown that presence of IL-4 and GM-CSF produces 
differentiation of classical monocytes into DCs, while presence of M-CSF induces 
differentiation into either M1-like macrophages (+LPS) or M2-like macrophages (+IL-
4) (Geissmann et al., 2010). Non-classical monocytes on the other hand express 
high levels of CD16 and low levels of CD14. They were shown to express higher 
levels of MHCII compared to classical monocytes and produce increased levels of 
TNF in response to TLR stimulation. Furthermore, non-classical monocytes were 
shown to expand in inflammatory conditions (Fingerle et al., 1993; Nockher and 
Scherberich, 1998), suggesting that they play a more important role in inflammation. 
This is further supported by a study reporting that CD16+ monocytes expressed 
increased levels of TLRs and costimulatory molecules CD80 and CD86, as well as 
the previously mentioned HLA-DR, compared to CD14+ monocytes, produced higher 
levels of pro-inflammatory cytokines TNF-α and IL-1β and showed low phagocytic 
activity (Mukherjee et al., 2015). The authors of the study therefore suggested that 
non-classical monocytes might contribute to antigen presentation. Indeed, others 
have suggested that studies detailing antigen-presentation to splenic marginal zone 
B cells by CD11c-low cells is not mediated by DCs but actually by CD16+ monocytes 
(Balázs et al., 2002; Randolph et al., 2008), thereby mediating inflammatory immune 
responses directly. Additionally they are major producers of TNF in response to 
inflammatory signals (Belge et al., 2002). However, in the murine model of MS, EAE, 
immature non-classical monocytes were found to occur in high numbers in the CNS 




(Zhu et al., 2007), suggesting that CD16+ monocytes also have anti-inflammatory 
roles. Intermediate monocytes, expressing high levels of CD14 as well as CD16, are 
found in much smaller numbers compared to the other two subsets in PB. While they 
were long thought to be merely a developmental intermediate, gene expression 
studies have confirmed that they are a transcriptomically distinct subset (Wong et al., 
2011; Zawada et al., 2011). Although their distinct roles are still unclear, specifically 
intermediate monocytes have been described to be increased in RA, sarcoidosis and 
severe asthma (Hijdra et al., 2012; Moniuszko et al., 2009; Rossol et al., 2012). In 
contrast to the more pro-inflammatory roles of non-classical monocytes, intermediate 
monocytes were shown to express high amounts of IL-10 in response to LPS 
stimulation with decreased antigen-presentation but increased phagocytic capabilities 
(Skrzeczyńska‐ Moncznik et al., 2008). This suggested potential anti-inflammatory 
roles for intermediate monocytes. 
In addition to their roles in inflammation and tolerance, it is also important to consider 
how monocytes can contribute to either a breach of tolerance or subsequent 
maintenance of autoimmunity. For example, activated CD14+ monocytes isolated 
from inflamed RA joints were shown to induce exclusively Th17 T cells via cell-
contact, thereby suggesting that classical monocytes actively contribute to 
autoimmunity and might be attractive targets to limit harmful Th17 responses (H. G. 
Evans et al., 2009). Furthermore, CD16+ monocytes were found to be increased in 
both PB and SF of RA patients (Kawanaka et al., 2002). The same study suggested 
that increased CD16 expression on monocytes was likely due to increased cytokines 
such as IL-10, TGF-β1 and M-CSF, which recruited large numbers of CD16+ 
monocytes to the joint, thereby sustaining joint inflammation. In EAE, non-classical 
monocytes expressing CCR2 were furthermore shown to be required for disease 
initiation, suggesting again that monocytes have important roles in contributing to 
autoimmunity. 
As previously mentioned, an important characteristic of monocytes is their ability to 
exit the PB, enter tissues and differentiate into both macrophages and DCs 
(Randolph et al., 1999). While monocytes were originally believed to be the main 
precursor for both cell types, it is now known that macrophages are largely tissue-
resident, where they arise from embryonic cells, while conventional DCs arise from a 




to differentiate into Mo-DCs at the infection site was found to be important in eliciting 
an effective Th1 response in Leishmania infection (León et al., 2007).  
To summarise, both DCs in their capacity as professional APCs and monocytes in 
their ability to differentiate into potent APCs play a deciding role in initiating adaptive 
immune responses but also maintaining immune tolerance to avoid immune-
mediated damage to self. Dysregulation of DC or Mo-DC function, especially in their 
communication with T cells, could therefore be a powerful contributor to the 
development of autoimmune diseases such as RA. 
1.3 Breach of tolerance: the autoimmune disease RA 
Especially as APCs mediate the decision between immune activation and tolerance, 
they also have an important role in breach of tolerance, which can contribute to 
emergence of autoimmune diseases. One example of such a disease is RA, where 
an aberrant immune response is raised targeting joint tissues thereby resulting in 
pain and progressive disability if unmedicated. In the following section, I will discuss 
the pathogenesis of RA in detail, including the role of specifically DCs in disease 
initiation and maintenance, before exploring DCs as potential therapeutics for RA.  
1.3.1 Pathology of RA 
The autoimmune disease RA is characterised by painful inflammation and swelling of 
joints, which can lead to progressive loss of function and disability due to destruction 
of cartilage and bone tissue. In addition to joint-specific symptoms, patients with RA 
are also more likely to suffer from systemic problems, such as a high vascular risk, 
metabolic syndrome and depression, which overall results in increased mortality 
(Mitchell et al., 1986; Pincus et al., 1984; Wolfe et al., 1994). Around 0.5-1% of 
people worldwide suffer from RA (Alamanos and Drosos, 2005), with women being 
twice as likely to be affected as men. While the reason for this discrepancy is not fully 
resolved, it is likely that hormonal differences, for example overproduction of prolactin 
in women who breastfed extensively or suffered from infertility or lower levels of the 
anti-inflammatory hormone testosterone, contribute to disease onset (Brennan and 
Silman, 1995). 
RA is diagnosed using several indicators, including number of inflamed joints, 
serologic tests for the presence of auto-antibodies (Rheumatoid factor, RF, Anti-
citrullinated peptide antibody, ACPA), increased inflammatory markers (e.g. 




symptoms (Aletaha et al., 2010). Disease severity and response to treatment is most 
commonly measured using the disease activity score 28 (DAS28). This is a 
composite score calculated by the number of swollen and tender joints out of 28 
(shoulders, elbows, wrists, knees and finger joints on each side), measurement of 
inflammation using either ESR or CRP and a global assessment of health of the 
patient using a health assessment questionnaire (HAQ) (Prevoo et al., 1995). 
Currently, a ‘treat to target’ therapy strategy is employed in the UK, meaning that 
treatment is adjusted regularly until improvement of symptoms as measured in a low 
disease activity DAS28 score is reached (National Institute for Health and Care 
Excellence, 2018). As a first line treatment a conventional disease-modifying anti-
rheumatic drug (DMARD) is recommended as a monotherapy, with further DMARDs 
being added if neither remission (DAS28<2.6) or low disease activity (DAS28<3.2) 
can be achieved. DMARDs usually decrease immune system activity and include 
drugs such as methotrexate (MTX), hydroxychloriquine (HCQ) or sulfasalazine 
(SSZ). If multiple DMARDs do not achieve either low disease activity or remission or 
if side effects elicited by DMARDs are not acceptable, treatment can be further 
escalated to include biologics. These are drugs targeting specific molecules 
important for the immune system, such as abatacept, a CTLA4 fusion protein 
blocking T cell activation, or etanercept or infliximab, which both block TNF-α (Curtis 
and Singh, 2011). While this strategy has been proven efficient to decrease the level 
of disability that accumulates over time (Pincus et al., 2005), medicinal side effects 
(Bernatsky et al., 2007), persistence of pain in the absence of joint inflammation 
(Boyden et al., 2016) and difficulties in achieving stable long-term remission for 
treatment refractory patients (Gallego‐ Galisteo et al., 2012) remain to be solved to 
ensure patient well-being. 
There is strong evidence that in RA tolerance to self is lost through a combination of 
genetic predisposition (susceptibility genes) and environmental factors, such as 
smoking, air pollution or periodontitis, which cause epigenetic changes (McInnes and 
Schett, 2011). This is believed to alter post-translational protein modification 
processes, which in turn leads to an increase in citrullination of self-proteins, where 
the amino acid arginine is replaced by citrulline. These alterations in self-proteins 
lead to the immune system falsely identifying them as non-self, causing immune 
activation and in turn eliciting the infiltration of the synovium with leukocytes (Hill et 




peptide (CCP), or RF are therefore a common hallmark of disease and contribute to 
diagnosis. The presence of autoantibodies can contribute to more aggressive 
disease progression and might therefore alter the clinical treatment strategy (Rycke 
et al., 2004), although they are currently used in the UK to expedite referral or 
patients with suspected RA from their primary care physician to specialist care. It is 
common that people with RA display autoantibodies years before the onset of 
symptoms, suggesting that dysregulation of the immune system occurs long before 
overt joint inflammation (Aho et al., 1991; Nielen et al., 2004; Rantapää‐ Dahlqvist et 
al., 2003). Especially considering that disease outcomes improve with early 
intervention (Emery, 2002; Quinn et al., 2001), it has been hypothesised that 
intervening before symptom onset might have merit. However, this idea is faced by 
two major challenges: first, the difficulty to correctly distinguish between the 1-2% of 
healthy people who are ACPA positive or the 4% who are RF positive and people 
who will definitely develop symptoms (Prüßmann et al., 2014; Ursum et al., 2009), 
and second, the question of how to induce the immune system to remain in a state of 
tolerance to self. This is especially important as current RA treatment strategies can 
only ameliorate symptoms of the disease not cure it. To achieve a cure for RA, the 
ultimate goal is therefore to re-establish tolerance that has been lost and is causing 
pathology. 
To conclude, RA is an autoimmune disease where immune dysregulation leads to 
joint inflammation. If untreated using immunosuppressive drugs, joint tissue is 
destroyed leading to progressive accumulation of disability and significant morbidity.  
1.3.2 Role of dendritic cells in Rheumatoid Arthritis 
Auto-reactive Th1 and Th17 T cells have been implicated in driving the autoimmune 
response in RA (Chabaud et al., 1998; Yamada et al., 2008). Therefore, it is likely 
that DCs play a pivotal role in the initiation of RA due to their unique role as APCs in 
initiating T cell responses. Furthermore, recent evidence suggests that DCs also play 
a role in maintaining joint-specific immune responses in RA, making them a potential 
therapeutic target. For example, cDC2 DCs isolated from RA synovial fluid (SF) were 
shown to spontaneously activate autologous PB CD4 T cells and elicit increased 
production of pro-inflammatory cytokines such as IL-17, IFN-γ and IL-4 by co-cultured 




In a mouse line expressing the RA susceptibility gene HLA-DRB1*0401, which was 
shown to contribute to altered citrullination levels (Snir et al., 2011), citrullination was 
shown to increase affinity between MHC II and peptide and thereby increase CD4 T 
cell activation by DCs (Hill et al., 2003). Further support for an important role of DCs 
in the initiation of RA was shown in a murine model of RA, where injection of 
collagen-pulsed mature DCs caused antigen-specific joint inflammation, mediated by 
both activation of autoreactive T cells and production of pro-inflammatory cytokines 
by DCs (Leung et al., 2002). It has been furthermore shown that induction of an RA 
murine model is critically dependant on cDCs (Benson et al., 2010), while pDCs were 
described to have immunoregulatory roles in this context and reduced autoimmune 
responses by adaptive immune cells (Jongbloed et al., 2009). In human, the 
strongest evidence for an important role for DCs in RA pathogenesis is that disease 
is strongly associated with specific alleles encoding the antigen-binding groove of 
MHC II (Winchester and Gregersen, 1988). This so-called shared epitope theory 
suggests that a number of alleles, specifically HLA-DRB1, all code for either the 
same or highly similar amino acid sequences, thereby conferring a higher risk of RA. 
This is interesting as patients with different HLA-DRB1 alleles were found to show 
distinct clinical phenotypes (Weyand et al., 1992), and presence of some alleles was 
found to be a reliable biomarker for efficacy of abatacept (Oryoji et al., 2018), an RA 
therapeutic blocking costimulation of T cells by DCs. Together, this provides strong 
evidence that DCs contribute to pathogenesis of RA by mediating the breach of 
tolerance via immunogenic presentation of altered self-antigen to T cells. 
In addition to DCs contributing to onset of RA, there is also evidence that DCs 
contribute to the maintenance of RA pathology once it has been triggered. For 
example, DCs are found in much higher numbers in RA SF compared to synovium 
derived from patients with osteoarthritis (OA) (Harding and Knight, 1986; Zvaifler et 
al., 1985). Furthermore, while DCs have been described to be absent from healthy 
synovial tissue (ST), both cDC2s and pDCs occur in high numbers in RA ST, where 
they were shown to express cytokine profiles concurrent with maintaining RA 
pathology (Lebre et al., 2008). For example, cDC2 DCs were shown to produce large 
amounts of IL-12, which enhances Th1 differentiation and effector functions via 
increasing IFN-γ production by CD4 T cells and NK cells, and IL-23, a major driver of 
the Th17 response. pDCs produced high levels of both IL-18, which induces IFN-γ 




and autoreactive T cell responses, although IFNβ has been recently implied to also 
have some immunoregulatory roles in RA (van Holten et al., 2002). Lastly Lebre and 
colleagues reported that, cDC2 and pDCs from RA ST were shown to produce IL-15, 
which drives both sustained T cell and B cell responses. Therefore, it was suggested 
that DCs are an important contributor to on-going RA pathology. An on-going role of 
DCs is also likely due to the clinical success of the previously mentioned fusion 
protein of CTLA-4 and an IgG, abatacept, which competitively binds to CD80/CD86 
on DC surfaces and thereby reduces their ability to stimulate potent T cell activation 
via CD28. In clinical trials, treating MTX-resistant RA patients with high disease 
activity with abatacept caused increased rates of remission and significantly lower 
disease activity scores (Kremer et al., 2005), strongly suggesting that on-going 
activation of auto-reactive T cells was partially responsible for RA disease severity. 
To conclude, evidence suggests that DCs play not only a role in initiating an 
autoimmune response but also in maintaining active disease. DCs are therefore 
considered a valuable target for therapeutic intervention, which I will expand on in the 
next section.  
1.3.3 Dendritic cell therapy for Rheumatoid Arthritis  
Given the vast evidence indicating a dominant role for DCs in the initiation and 
progression of RA, DCs might hold the key to re-establish tolerance to self to achieve 
full remission. Tolerogenic Mo-DCs are promising cell therapeutics to re-educate the 
immune system by promoting T cell tolerance instead of restricting T cell activation 
using DMARDs or biologics. In this section I will introduce tolerogenic cell therapy 
approaches already underway in other autoimmune conditions, before discussing the 
properties of therapeutic tolerogenic Mo-DCs and exploring their potential 
significance in the treatment of RA. 
As mentioned previously, DCs play a wide range of tolerogenic roles both in the 
thymus, where they delete self-reactive T cells, and in the periphery, where T cells 
that have escaped thymic selection are rendered unresponsive (Brocker et al., 1997; 
Proietto et al., 2008; Shahinian et al., 1993). These functions can be exploited for 
therapeutic causes, either by targeting endogenous DCs in vivo or by extracting 
monocytes, which are the precursors of Mo-DCs, culturing them to become 
tolerogenic Mo-DCs and reintroducing them into the patient. There is the potential to 




specific and thereby more effective, which is however hindered by the absence of a 
singular antigen causing RA. A ‘disease-relevant’ antigen would therefore have to be 
highly specific to the patient or patient subset, in which pathology is caused by 
autoimmune reaction to this antigen, or a variety of RA-associated antigens, such as 
citrullinated peptides and collagen, would have to be used. The question of an RA 
relevant antigen thereby has implications for both availability of therapy to a wide 
range of patients, as therapeutic intervention might only be helpful if specific for the 
antigen causing disease in a patient, and cost of therapy, as the more personalised 
the tolerogenic Mo-DCs are, the more expensive the treatment would be. A further 
potential challenge in the use of tolerogenic Mo-DCs is the correct timing of cell 
therapy administration. Especially as breach of tolerance has been implied to occur 
years before disease onset, it is possible that only patients with very early disease 
would benefit from the treatment. However, when considering evidence of 
therapeutic use of tolerogenic Mo-DCs in other autoimmune diseases, a positive role 
for tolerogenic Mo-DCs even in established disease is likely. 
Tolerogenic cell therapy has been successfully explored in a range of different 
autoimmune conditions. In Crohn’s disease, an autoimmune disorder targeting the 
intestine, intraperitoneal injection of tolerogenic Mo-DCs in Phase I clinical safety trial 
into patients refractory to treatment showed that tolerogenic Mo-DCs were safe with 
clinical responses in 2 of 9 study participants, with one further participant reaching 
full remission (Jauregui-Amezaga et al., 2015). A similar phase I clinical safety trial 
assessing intradermal injection of autologous tolerogenic Mo-DCs for Type 1 
Diabetes showed no safety concerns either (Giannoukakis et al., 2011). Interestingly, 
injection with Mo-DCs caused increased presence of a B220+CD11cneg B cell 
population, which was hypothesised to be regulatory in nature and might therefore 
positively contribute to disease outcomes. While tolerogenic cell therapy is still in its 
infancy, clinical safety trials in the last ten years show promise that this approach if 
feasible, safe and potentially beneficial to patients even at low doses. Although 
targeting DCs in vivo has shown promising results in other diseases, and is 
potentially more cost-effective because of the high cost of personalised cell therapy, 
the failure to identify a singular specific antigen in RA pointed to tolerogenic Mo-DCs 
as the more viable option in RA.  
Tolerogenic Mo-DCs can be generated in culture in a variety of ways, but commonly 




monocytes (Sallusto and Lanzavecchia, 1994). To achieve a tolerogenic phenotype, 
a stimulating signal, such as LPS (Anderson et al., 2009), which would usually induce 
maturation of Mo-DCs, is combined with immunosuppressive drugs, such as blocking 
NF-κB , Dexamethasone and/or Vitamin D3 (Piemonti et al., 2000; Xia et al., 2005). 
The resulting tolerogenic Mo-DCs are described to exhibit a semi-mature state, 
marked by reduced expression of costimulatory molecules, decreased production of 
pro-inflammatory cytokines, such as IL-12, IL-6, IL-23 and TNF-α, and increased 
production of anti-inflammatory cytokines, such as IL-10, compared to mature DCs 
(Anderson et al., 2009; Harry et al., 2010). Therefore, tolerogenic Mo-DCs show 
reduced ability to stimulate T cells. Specifically, they have been described to cause 
skewing of naïve CD4 T cells towards a immunoregulatory cytokine profile low in IFN-
γ and high in IL-10, while memory T cells were found to be rendered hyporesponsive 
to reactivation when co-cultured with tolerogenic DCs (Anderson et al., 2008). If 
injected, tolerogenic Mo-DCs could therefore render autoreactive T cells 
unresponsive either in the periphery or in the nearest LN, thereby returning the body 
to a state of self-tolerance. More specifically, Mo-DCs tolerised with Dexamethasone 
as well as Vitamin D3 are thought to induce their tolerogenic effects by their complete 
lack of IL-12 production, their high expression of LAP/TGF-β and lastly their ability to 
induce Type I Tregs, thereby indirectly promoting tolerance (Anderson et al., 2017, 
2008; Spiering et al., 2019). 
As immature DCs share many tolerising features of tolerogenic DCs, but can easily 
undergo maturation and become immunogenic in the presence of pro-inflammatory 
cytokines, it was important to ensure stability of tolerogenic DCs in the presence of 
inflammation to avoid further exacerbating disease when considering this as a cell 
therapy. However, re-stimulation of tolerogenic Mo-DCs with various pro-
inflammatory mediators such as cytokines (IL-1β, IL-6, TNFα and IFNγ), LPS or 
peptidoglycan (PGN) did not alter their cytokine expression or semi-mature 
phenotype, strongly suggesting that tolerogenic Mo-DCs were stable and therefore 
unlikely to become reactivated in the presence of inflammation (Harry et al., 2010).  
Another challenge in optimising tolerogenic Mo-DC therapy is considering their 
migratory ability and localisation in vivo, to ensure that tolerogenic cell therapy would 
not only suppress self-reactive T cells once they arrive in the periphery but also 
migrate to the nearest LN and present self-antigen in the absence of activating 




provide lasting protection from autoreactive T cells that is not dependent on 
continuous presence of large numbers of therapeutic tolerogenic Mo-DCs. Indeed, 
tolerogenic Mo-DCs were found to migrate less effectively in a transwell system 
towards CCL19, which was proposed to be due to their reduced expression of CCR7 
(Anderson et al., 2009). However, tolerogenic Mo-DCs maintained CCR7-mediated 
migration towards CCL19, albeit at lower levels, suggesting that tolerogenic Mo-DCs 
have the ability to migrate towards the nearest LN. Lastly, it is important to consider 
the antigenic stimulation that will be provided to tolerogenic Mo-DCs. The specific 
antigen eliciting RA is unknown and hypothesised to vary between patients, therefore 
making it difficult to achieve antigen-specific protection using tolerogenic Mo-DCs. 
To date, the use of tolerogenic Mo-DC therapy for RA has been successfully tested 
in a range of animal models. For example, in mice, Mo-DCs tolerised using NF-κB 
inhibition and pulsed with collagen, were able to reduce the antigen-specific T cell 
response to collagen in the CIA model, thereby improving clinical scores when given 
12 days after first injection with collagen but before onset of disease at 28 days 
(Popov et al., 2006). A different group found that intravenous injection of tolerogenic 
BMDCs pulsed with collagen but not without were able to migrate to draining LNs, 
decrease Th17 T cell responses and simultaneously increase the level of circulating 
IL-10 producing CD4 T cells (Stoop et al., 2010). A more recent study showed that 
murine tolerogenic BMDCs induced using vasoactive intestinal peptide could similarly 
improve clinical outcome in the CIA model when injected after onset of disease at 
day 40, suggesting that tolerogenic DC therapy could not only work preventatively 
but also in established disease (Wu et al., 2019). 
In recent years, a range of early clinical trials has explored the viability of tolerogenic 
DC therapy in humans. One strategy involved tolerogenic Mo-DCs established 
through blocking NF-κB and exposed to four different citrullinated peptides, which 
were injected intradermally into patients positive for anti-CCP and carriers of the 
HLA-DRB1 shared epitope (Benham et al., 2015). Benham and colleagues showed a 
reduction in peripheral effector T cells with a concurrent increase in regulatory T cell 
numbers one month after injection. In addition, serum levels of pro-inflammatory 
cytokines and chemokines such as IL-15, IL-29 and CX3CL1 were reduced 
compared to untreated controls. These mediators have all be associated with 
worsened outcomes in RA, with IL-15 being described to sensitise TCRs to RA 




expression of TLR4 in both ST and PB (Xu et al., 2015) and expression of CX3CL1 
being reduced inversely to clinical improvements in patients treated with infliximab 
(Odai et al., 2009). Furthermore, a phase I clinical trial was undertaken in 2016 to 
test the safety of injecting tolerogenic Mo-DCs directly into an inflamed joint (Bell et 
al., 2016). In the absence of a known common RA antigen, tolerogenic Mo-DCs were 
exposed to autologous SF, thereby providing a range of antigens that were likely to 
be relevant for the patient in question. Bell and colleagues established that treatment 
with tolerogenic Mo-DCs was feasible and safe, with minor symptom improvement 
observed in the small group of patients receiving the highest dose of tolerogenic Mo-
DCs. While this paves the way for future clinical trials involving tolerogenic Mo-DCs 
to treat RA, determining a suitable antigen to benefit the largest amount of RA 
patients and finding the most suitable route of administration remain challenging. 
However, work on solving these problems is currently underway, with a Phase II 
clinical trial of tolerogenic Mo-DCs for RA currently in preparation. 
To conclude, tolerogenic Mo-DCs represent a viable therapeutic opportunity for RA. 
Instead of current treatment strategies that aim to dampen unwanted immune 
activation, tolerogenic DC-based cell therapy aims to exploit the immune system’s 
own mechanism to maintain tolerance to re-establish tolerance to self. However, 
while animal studies using tolerogenic Mo-DCs have been promising and clinical 
safety trials have been successful, certain challenges remain to be solved before this 
therapy can become available to patients. This includes the correct time and location 
to administer cell therapy as well as defining viable read-outs for therapeutic success 
(Hilkens and Isaacs, 2013). 
1.4 β₂ integrins: immune regulation versus activation 
As discussed in the previous section, APCs can both initiate and modulate T cell 
responses by direct contact with T cells. This can occur either at the site of 
inflammation or in the LN. One way that contact between DCs and T cells is 
established and maintained is by adhesion receptors, one group of which are 
integrins. β₂ integrins in particular, well known for their pro-inflammatory roles in 
lymphocytes, have recently been suggested to have immunoregulatory roles in DCs. 
In this section, I will give a brief outline of the family of integrin receptors before 
focusing on the roles of β₂ integrins, specifically in DCs. Lastly, I will explore the 
feasibility of targeting β₂ integrins therapeutically to influence the balance between 




1.4.1 Integrins  
Integrins are heterodimeric transmembrane receptors, which consist of two non-
covalently associated proteins, more specifically one α- and one β-subunit (Hynes, 
1987). To date, 18 α- and 8 β-subunits have been identified, which occur in various 
combinations yielding the 24 currently known members of the integrin family (Figure 
1.2). While their large N-terminal extracellular domain can bind and interact with a 
number of different ligands, their short C-terminal cytoplasmic domain interacts 
directly and specifically with cytoskeletal proteins such as talin and filamin and 
induces downstream signalling pathways (Pfaff et al., 1998). This means that 
information between extracellular and intracellular space can be relayed and vice 
versa (Hynes, 1987). These properties make integrins important for a wide variety of 
biological functions including adhesion, cell migration and extravasation into tissues 




Integrin subunits consist of highly conserved domains, a visual representation of 
which can be seen in Figure 1.3 (Hynes and Naba, 2012). Briefly, integrin subunits 
consist of a head region, which forms part the ligand binding site, and a leg region, 
Figure 1.2 Integrin α and β subunit pairings 
Adapted from Hynes & Naba, 2012. Integrin receptors consist of an α subunit and a β subunit. 18 α 
subunits (circles) and 8 β integrin subunits (squares) can pair to form a total of 24 recognised integrin 
receptors. Integrin receptors circled in red are expressed on leukocytes, but this thesis focuses on 




important in positioning the head regions of each integrin subunit. An integrin α-
subunit consists of one 7-bladed β propeller domain, followed by three β sandwich 
domains termed thigh and two calf domains (calf1, calf 2), forming the leg region of 
the integrin. Furthermore, 9 of the 18 α-subunits also have an I domain, which is 
located over the β propeller domain and thereby makes it an important factor in the 
integrin binding site. Interestingly, all four α-subunits (CD11a, CD11b, CD11c, 
CD11d) pairing with the β₂ integrin subunit (CD18), which is the focus of this thesis, 
have an I-domain as well as the β propeller and the thigh domain in their head 
region. The β₂ subunit CD18 on the other hand is made up of an I-like domain and a 
β sandwich hybrid domain forming the head of the integrin protein. The leg part of the 
protein consists of a cysteine rich plexine-semaphorin-integrin (PSI) domain, four 
EGF-like repeats and lastly a β tail domain (βTD) (R. Evans et al., 2009), which is 
located immediately above the transmembrane domains traversing the membrane 




Due to the wide variety of roles integrins can play on cell surfaces, adhesion to 
ligands has to be tightly controlled. Integrins have therefore been described to exist 
in three distinct of conformational states, which can limit or expand the access of 
Figure 1.3 Protein domains of integrins 
Adapted from Byron et al., 2009 and Evans et al., 2009. Both α and β subunits consist of distinct 
domains making up a leg region anchored in the cell membrane, a neck region and a head region, 




ligand binding sites and thereby control the level of binding and signalling through the 
transmembrane receptor. The three integrin conformational states are: inactive, 
intermediate and active. Movement from an inactive over an intermediate to an active 
integrin conformational state occurs via the so-called switchblade model (Jin et al., 
2004). In an inactive state, the head regions of both integrin subunits are bent down 
towards the cell surface and the leg regions are clustering closely together, yielding 
the ligand binding site closed and the integrin receptor with low affinity for ligand 
(Figure 1.4) (Byron et al., 2009; R. Evans et al., 2009). Through chemokine or 
cytokine receptor activation, the leg regions move further apart from each other and 
extend upwards from their bent position, thereby forming an intermediate state. Even 
though the leg regions are extended, the head regions forming the ligand binding 
sites are still closed in this state, and were presumed to show intermediate affinity for 
ligand. To achieve full activation, the head regions have to open, exposing the ligand-
binding sites to the extracellular environment. Due to the free availability of the 
binding sites, the active conformation of an integrin has the highest affinity for 
ligands, with up to 4,000 times higher affinity compared to the bent-closed inactive 













Due to the need for tight regulation of integrin signalling, integrins have been 
described to be largely inactive on cell surfaces (Li and Springer, 2017), with 99.75% 
of α5β1 integrins being in the bent-closed formation on a human leukaemia cell line. 
This poses the question how integrins can assume the extended-open (active) 
conformation efficiently and rapidly to mediate adhesion. The answer lies in integrin 
signalling, which consists of both inside-out and outside-in signalling (Figure 1.4). 
Fundamentally, inside-out signalling translates cell-internal signal into receptor 
affinity and clustering, thereby altering how the cell interacts with its immediate 
environment. Inside-out signalling is triggered by cell stimulation via chemokine or 
cytokine receptors (Shamri et al., 2005). This causes an increased formation of 
diaglycerol (DAG) and increase Ca2+ levels, which either activates protein kinase C 
(PKC) or a Rap-guanine nucleotide exchanger (Rap-GEF). Both of these signalling 
Figure 1.4 Integrin signalling and conformational states 
Adapted from Evans et al., 2009. Integrins exist in three distinct conformational states: inactive with 
low affinity for ligand, intermediate with intermediate affinity for ligand and active with high affinity for 
ligand. Transition between inactive and active conformation is regulated by inside-out signalling, by 
which chemokine or cytokine receptor activation initiates the recruitment of talin and kindlin to the 
intracellular portion of the integrin subunits. This causes extension of neck regions and leg regions 
move apart from each other, thereby exposing the active ligand binding site to the extracellular 
space. When ligand binds to the ligand binding site, downstream signalling cascades transmit 




proteins function in activating Rap1 by exchanging GDP for GTP (Han et al., 2006). 
This in turn causes relocation of Rap1-GTP to the cell membrane, where it was 
shown to interact with Rap1-GTP interacting adaptor molecule (RIAM) (Lee et al., 
2009), which in turn causes the recruitment of talin and kindlin to the NPxY motifs of 
the integrin β subunit (Calderwood et al., 2002; Moser et al., 2008). By connecting 
the short cytoplasmic tail to the cytoskeleton, talin and kindlin function to separate the 
closely associated leg regions of the integrin alpha and beta subunits and stabilise 
them in the extended high-affinity conformation. Outside-in signalling then occurs 
once a ligand has bound to the integrin receptor. This is characterised by a 
downstream signalling cascade altering cell function in response to its environment 
(Shen et al., 2012), for example by activation and interaction with the g-protein 
coupled receptor Gα13 (Gong et al., 2010). Outside-in signalling can mediate a range 
of possible outcomes for cells, including migration and motility, survival, cytoskeletal 
rearrangement and differentiation. 
For the work done in this thesis, I focused specifically on β₂ integrins, due to their 
reported importance in immune function. In the following section, I will describe 
specific properties of β₂ integrins, particularly in our cell types of interest, namely 
monocytes and DCs.  
1.4.2 A special role in the immune system: β₂ integrins 
As mentioned previously, the β₂ integrin subunit (CD18) can pair with one of four α 
subunits (αL-CD11a, αM-CD11b, αX-CD11c, αD-CD11d) and are exclusively 
expressed by leukocytes. Due to their importance in immune function including 
adhesion, cell migration and cell-cell communication, they are known under a variety 
of names including lymphocyte function associated antigen I (LFA-1) (CD11a/CD18), 
macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3) (CD11b/CD18), 
p150/95 or complement receptor 4 (CR4) (CD11c/CD18) and CD11d/CD18. For 




The β₂ integrin receptor family can bind a variety of ligands, detailed in Figure 1.5. 
Briefly, CD11a/CD18 binds intracellular adhesion molecule-1 to 5 (ICAM-1 to ICAM-
5) preferentially (Arnaout, 2016), as well as to junction adhesion molecule 1 (JAM-1) 
(Ostermann et al., 2002). CD11b/CD18 is the most promiscuous of all β₂ integrins 
with over 40 reported ligands (Podolnikova et al., 2015). CD11b binds a variety of 
complement proteins, including iC3b and C4b (Graham et al., 1989), as well as the 
adhesion molecules ICAM-1-4 and JAM-3, and ECM proteins fibrinogen and 
fibronectin. CD11c is highly homologous to CD11b, which makes it unsurprising that 
it shares many of its ligands, including iC3b, ICAM-1 as well as ICAM-4. Additionally, 
CD11c binds vascular cell adhesion protein 1 (VCAM-1). Lastly, CD11d was reported 
to bind specifically ICAM-3 and VCAM-1, as well as having many overlapping ECM-
derived ligands with CD11b, such as fibronectin and fibrinogen as well as vitronectin 
(Van der Vieren et al., 1995; Yakubenko et al., 2006), which has also been described 
to be bound by CD11b (Kanse et al., 2004). Expression of CD11a, CD11b, CD11c 
and CD11d on human and mouse DCs and monocytes can found in Table 1.1. A 
more thorough review of the expression of beta2 integrin subunits in different DC and 




Figure 1.5 β₂ integrins and their ligands 
Adapted from Schittenhelm et al., 2017. Shown are the four members of the β₂ integrin receptor 
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The importance of β₂ integrin function for the immune system is highlighted by a 
group of congenital autosomal-recessive disorders termed leukocyte adhesion 
deficiencies (LAD), where a defective immune system arises from deficiencies in 
immune cell adhesion and migration. There are three different types of LAD, two of 
which show loss of expression or functionality of β₂ integrins. This is the case for 
LAD-I, where ITGB2, the gene coding for CD18 is mutated (Fischer et al., 1988), or 
the more recently identified LAD-III, where a mutation in kindlin-3 (FERMT3), a major 
cytoplasmic regulator of β₂ integrin activation, causes a failure of kindlin-3 binding to 
the β₂ integrin subunit, which directly results in the integrins inability to assume it 
active conformation and bind ligand (Jurk et al., 2010). Symptoms of LAD are 
recurrent bacterial and fungal infection and leukocytosis due to the inability of 
immune cells, especially neutrophils, to extravasate into tissue sites of infection in 
absence of β₂ integrins. Extravasation and homing into tissues is a major function of 
β₂ integrins (Grabbe et al., 2002), which will be discussed in more detail in the next 
section on immunoregulatory and pro-inflammatory roles of β₂ integrins. Many 
different mutations have been described to cause LAD of varying severity due to 
either a reduction of CD18 function or its complete absence. Furthermore, it has 
been shown that disease severity of LAD-I is directly correlated with the level of 
CD18 function preserved (Novoa et al., 2018). Together with the knowledge that 
effective β₂ integrin signalling is diminished in LAD-III, this strongly suggests the 
immense importance of β₂ integrins for raising effective immune responses. 
Interestingly, it was also shown that some symptoms of LAD are not due to the failure 
of raising an immune response, but rather due to an unregulated increase in 
inflammation. For example, bone destruction in periodontitis, another condition 
associated with LAD, was found to be driven by an increase in IL-17 production 
(Moutsopoulos et al., 2014), and was found to be mitigated by blocking IL-12 and IL-
23, thereby reducing IL-17 signalling (Moutsopoulos et al., 2017). Furthermore, some 
patients with LAD have been described to suffer from ulcerative colitis (D’Agata et al., 
1996; Uzel et al., 2001). While the exact causes for emergence of this autoimmune 
condition in LAD are not clear, it again suggests that impairment or complete 
absence of β₂ integrins might not only contribute to the failure to raise an appropriate 
immune response, but also the ability to regulate and dampen inappropriate immune 




To conclude, β₂ integrins are leukocyte-specific adhesion molecules with a wide 
range of ligands which are highly important for an effective response. In the following 
section, I will explore their roles in immune activation as well as more recent 
discoveries that suggest they play a distinct immunoregulatory role especially in DCs 
and other APCs.  
1.4.3 Roles of β₂ integrins in immune activation and regulation 
For a long time, β₂ integrins were primarily known for their various roles in initiating 
and maintaining immune responses. However, more recently, β₂ integrins have also 
been reported to be involved in a wide variety of functions involving immune 
regulation. In this section I will briefly summarise the roles of β₂ integrins in immune 
activation before exploring their important roles in immune regulation that form the 
basis of my thesis.  
β₂ integrins in immune activation 
β₂ integrins are involved in many stages of an effective immune response. I will 
highlight their immunostimulatory roles in the areas of antigen presentation/APC-T 
cell contact, cell migration and cell signalling.  
Firstly, especially CD11b and CD11c are important mediators of phagocytosis by 
recognising iC3b- or C3b-opsonised particles or bacteria. The importance of these 
integrins for phagocytic activity can be supported by their high expression in 
immature DCs, which becomes downregulated upon DC activation, when 
phagocytosis is similarly downregulated in mature DCs (Rieckmann et al., 2017). 
Furthermore, macrophages, known primarily for their ability to phagocytose 
opsonised compounds, express both CD11b and CD11c at high levels on their 
surface (Beller et al., 1982; Drevets et al., 1993; Gautier et al., 2012). Phagocytosis 
is an important factor for effective downstream processing of antigen and final 
presentation on the cell surface, thereby contributing to immune activation. However, 
an allele of the gene coding for CD11b and being marked by reduced phagocytic 
ability is one the most common risk factors for SLE, suggesting that CD11b-mediated 
uptake of apoptotic cells and cellular debris also has important roles in maintaining 
immune tolerance (Fossati-Jimack et al., 2013; Rhodes et al., 2012). Furthermore, β₂ 
integrins play an important role in immunological synapse, where CD11a on T cells 
binding to ICAM-1 on APCs was found to cluster in the peripheral supramolecular 




connection between MHC:peptide and TCR (Grakoui et al., 1999; Monks et al., 
1998). By this process, CD11a was found to be an effective costimulatory signal, 
enhancing TCR signal transduction (Seventer et al., 1990). Furthermore, blocking 
either CD11a, CD18 or the integrin ligand ICAM-1 on human Langerhans cells from 
the skin significantly blocked their ability to stimulate T cells in vitro by over 70% 
(Simon et al., 1991), suggesting an important role of β₂ integrins on these DC-like 
cells in immune activation. However, examples of activating roles of β₂ integrins in 
‘true’ DCs are difficult to find, as current research primarily focuses on the role of β₂ 
integrins on the T cell side. 
In addition, β₂ integrins are important for cell adhesion and migration. While migration 
of leukocytes within tissues was found to occur independently of β₂ integrins 
(Lämmermann et al., 2008), the adhesion receptors are absolutely required for 
migration of leukocytes to inflamed tissues, as this requires adhesion to ICAM-1 on 
endothelial cells under shear-flow conditions (Alon and Dustin, 2007; Lämmermann 
et al., 2008). However, while blocking either CD11a specifically or all β₂ integrins by 
blocking CD18 caused a reduction in adherence of monocytes to vessel walls and 
migration (Chuluyan and Issekutz, 1993; Geissmann et al., 2003b), migration of 
monocytes to an inflammatory site was found to occur independently of either CD11a 
or CD11b (Henderson et al., 2003). Similarly, DCs deficient for all integrins migrated 
to the LNs to the same degree as WT DCs when injected into the footpad of a 
mouse, suggesting that DC migration towards the LN also occurred independently of 
integrins (Lämmermann et al., 2008). This suggests that in monocytes and DCs, β₂ 
integrin-mediated migration does not majorly contribute to inflammation, although this 
is not the case for all cell types. For example, increased expression of CD11d on 
macrophages was found to retain macrophages at the site of inflammation, while 
monocytes expressing lower levels could still migrate (Yakubenko et al., 2008).  
Lastly, β₂ integrins play a pro-inflammatory role in signalling. As mentioned above, 
CD11a signalling in T cells acts a co-stimulatory signal, directly contributing to T cell 
activation. Additionally, ligation of both CD11b and CD11c on human monocytes 
elicited production of pro-inflammatory mediators such as macrophage-inflammatory 
protein 1-α (MIP1α), MIP1β and IL-8 (Rezzonico et al., 2001). Further supporting this, 
both CD11b in macrophages and CD11c in monocytes were shown to mediate 
activation in the presence of LPS (Fan and Edgington, 1991; Ingalls and Golenbock, 




TLR4 signalling. For example, CD14, CD11b and TLR4 on murine macrophages 
were reported to react in synergy to LPS stimulation (Perera et al., 2001). In DCs, 
CD11b was found to positively regulate TLR4, with loss of CD11b-mediated TLR4 
signalling resulting in reduced ability to stimulate T cells (Ling et al., 2014). 
β₂ integrins in immune regulation 
While β₂ integrins, especially CD11a, were described to have pro-inflammatory 
functions in T cells, there is evidence suggesting that the opposite might be true in 
APCs. In murine models, increasing expression of both active CD11a (Balkow et al., 
2010) and active CD11b (Varga et al., 2007) in DCs was found to decrease T cell 
activation, suggesting that β₂ integrin activation status on DCs is immunoregulatory. 
In humans, a similar mechanism has been described, whereby CD11b on APCs 
binding to ICAM-1 on inflamed lymphatic endothelial cells in the absence of 
pathogen-associated danger signals reduced expression of costimulatory molecule 
CD86 on APCs and suppressed their ability to stimulate T cells (Podgrabinska et al., 
2009). Furthermore, expression of CD11b has been described to play an active role 
in Th17 T cell suppression, potentially by limiting IL-6 production by DCs (Ehirchiou 
et al., 2007), which was further supported by the finding that ligating CD11b on Mo-
DCs resulted in a reduced ability to induce Th17 T cells, thereby conferring 
tolerogenic qualities on the Mo-DCs (Nowatzky et al., 2018a). Ligation of CD11b on 
murine bone marrow-derived DCs (BMDCs) was further shown to increase 
expression of MHC and costimulatory molecules, while production of inflammatory 
cytokine was blocked (Behrens et al., 2007), thereby suppressing T cell stimulatory 
capability.  
While β₂ integrins on DCs were not found to be an important factor in mediating 
migration to the LN, they were reported to be indispensable for DCs strongly 
adhering to endothelium and extravasating into tissues (Alon and Dustin, 2007; 
Lämmermann et al., 2008). Interestingly, injecting murine BMDCs deficient in integrin 
signalling into the footpad of a mouse without LPS stimulation, BMDCs migrated to 
the LN in higher numbers, suggesting that β₂ integrins actually retain DCs in the 
periphery in the steady state. Furthermore, the study showed that BMDCs with 
deficient β₂ integrin function stimulated more IFN-γ production by T cells, indicative of 
driving a Th1 phenotye, thereby suggesting that β₂ integrins function in keeping DCs 




This strongly suggests an active role for β₂ integrins on DCs in immune regulation. In 
a murine model of skin inflammation, a larger number of signalling-deficient DCs 
were found both in the LN and at the site of inflammation, potentially suggesting that 
failure of β₂ integrin signalling further enhanced disease severity (Savinko et al., 
2015). As mentioned above, some studies report that β₂ integrins have pro-
inflammatory roles in immune cell signalling, especially in the context of TLR4. 
However, in the absence of β₂ integrins (CD18 KO mice), TLR signalling is 
increased, suggesting a regulatory role of β₂ integrins on TLR signalling (Yee and 
Hamerman, 2013). This however contradicts another study mentioned above, that 
specifically CD11b actually positively mediates TLR4 signalling (Ling et al., 2014). 
The discrepancy in these findings can potentially be explained by Yee and 
Hamerman utilising a complete CD18 knockout (KO), thereby not distinguishing 
between the potentially different roles of β₂ integrin α subunits, while Ling and 
colleagues focused specifically on the effects of CD11b deficiency. While this 
provides some insight into the distinct β₂ integrin subunit functions, other studies 
support the finding that β₂ integrins restrict TLR signalling. For example, TLR 
signalling was found to be restricted by β₂ integrins on both macrophages and DCs 
(Savinko et al., 2015). However, the role of β₂ integrins in immune cell signalling is 
complex. For example, a lack of CD11b in murine BMDCs was found to decrease 
signalling via TLR4, but simultaneously upregulated microRNA-146a, which 
functioned to increase DC-mediated cross-priming of cytotoxic T cells (Bai et al., 
2012).Considering this evidence it becomes apparent that the literature exploring the 
role of β₂ integrins in immune cell signalling is complex, which makes it likely that the 
effect of β₂ integrins on TLR signalling might be dependent on cell type and 
environment. 
To conclude, β₂ integrins play a wide variety of pro-inflammatory roles in the immune 
system. However, evidence specifically in DCs and monocytes suggests that they 







1.4.4 Evidence suggesting a role of β₂ integrins in RA 
While β₂ integrins have not been identified as genetic risk factors for RA in gene wide 
association (GWAS) studies to my knowledge, there is still a wide range of evidence 
that suggests β₂ integrins might play a role in RA pathogenesis or progression. 
However, having explored the opposing functions of β₂ integrins, it is also possible 
that β₂ integrins might regulate or dampen aberrant immune processes. In the 
following section, I will give an overview of the published literature in this field and 
highlight where the limitations of current knowledge lie. 
A range of autoimmune diseases and inflammatory disorders share β₂ integrins as 
genetic risk factors, which seem to be β₂ integrin α-subunit-specific. For example, the 
autoimmune condition IBD showed increased expression of alleles for CD11a 
(ITGAL), as well as its main ligand ICAM-1 (ICAM1) (de Lange et al., 2017). On the 
other hand, a genetic polymorphism of the gene coding for CD11b (ITGAM) was 
found to show increased risk of the autoimmune disease SLE (Nath et al., 2008), 
 
 Figure 1.6 Roles of β₂ integrins in DCs 
Adapted from Schittenhelm et al., 2017. Involvement of β₂ integrins in the immune system can be 
broadly categorised into interactions with immune cells, homing to LNs and recruitment to tissues 
as well as immune cell signalling. Evidence is accumulating that β₂ integrins have both pro-
inflammatory and immunoregulatory roles in these areas. Dysregulation of β₂ integrins could 





which shares genetic risk factors with RA (Remmers et al., 2007). Lastly, in obesity, a 
condition marked by increased systemic inflammation, expression of CD11d was 
found to be increased in white adipose tissue of female study participants (Thomas et 
al., 2011). Furthermore, an increase in CD11d activation was found to elicit 
production of IL-1β (Miyazaki et al., 2014), a pro-inflammatory cytokine associated 
with autoinflammatory conditions (Dinarello, 2011). This suggests involvement of β₂ 
integrins in dysregulated immune responses including autoimmune conditions.  
There is a large body of evidence in both animal models and human studies that 
suggest that beta2 integrins contribute to RA. For example, blocking all β₂ integrins in 
a rabbit model of arthritis using antigen directly injected into the joint reduced 
inflammation (Jasin et al., 1992). A different study showed that absence of CD11a 
specifically in a KB x N transfer mouse model caused animals to remain completely 
resistant to disease induction (Watts et al., 2005). Additionally, mice deficient for the 
β₂ integrin ligand ICAM-1 similarly showed reduced susceptibility to a collagen 
induced arthiritis (CIA) model (Bullard et al., 1996), suggesting that CD11a and 
ICAM-1 especially might have a role in RA initiation. It was furthermore shown that in 
the CIA model, treatment with either a mAb or a small-molecule antagonist targeting 
CD11a was protective and markedly reduced both inflammation-mediated joint 
destruction and synovial cytokine mRNA levels (Kakimoto et al., 1992; Suchard et al., 
2010). However, these positive effects of blocking CD11a function in RA animal 
models are likely mediated by reduced cell recruitment to the joint, thereby improving 
symptoms. 
In humans, surface expression of CD11a was found to be increased in cells isolated 
from RA ST but not from PB, where it was hypothesised to contribute to cell 
activation and maintenance of inflammation (Cush and Lipsky, 1988; Takahashi et 
al., 1992). However, considering that CD11a has a role in cell migration as well as 
immune cell activation and this study did not distinguish different cell types, it is 
possible that expression of CD11a is high due to the increased influx of immune cells 
into the joint cavity during synovitis. Another study did find CD11a, CD11b and CD18 
to be elevated on PB monocytes from RA patients compared to healthy controls, an 
effect which was normalised after 4-6 weeks of low-dose steroid treatment 
(Torsteinsdóttir et al., 1999), suggesting that expression of β₂ integrins was 
associated with disease activity. Furthermore, while a wide range of self-peptides can 




commonly identified in RA include several β₂ integrin ligands, such as fibrinogen, 
fibronectin and vimentin (McInnes and Schett, 2011). One could therefore 
hypothesise that altered self-protein might also alter β₂ integrin downstream 
signalling, for example by altering binding affinity of ligand to β₂ integrin. This is 
supported by a recent study showing that citrullination of fibronectin, a β₂ integrin 
ligand, altered clustering behaviour and adhesive capabilities of integrins α5β1 and 
αvβ3 on stromal cells (Stefanelli et al., 2019). Similarly, RA synovial fibroblasts were 
found to show reduced adhesion and cell spreading on citrullinated fibonectin but not 
uncitrullinated fibronectin (Shelef et al., 2012). This suggests that citrullination of self-
peptides might alter β₂ integrin function in RA.  
To conclude there is a range of evidence suggesting β₂ integrins contribute to the 
development and/or progression of autoimmune disorders. Interestingly, roles of β₂ 
integrins are often α-subunit specific, highlighting that different β₂ integrins, while 
highly homologous, have distinct and potentially opposing functions. This is 
supported by the fact that different β₂ integrin subunits show differential expression in 
leukocyte subsets. Lastly, while extensive research in the role of β₂ integrins in RA 
exists, it is mostly focused on T cells and neutrophils, with no discernible reports on 
β₂ integrins specifically on APCs in RA. Considering especially the importance of 
DCs for initiation and maintenance of RA discussed at length in section 1.4.2, 
understanding how β₂ integrins on DCs might contribute to RA could reveal novel 
therapeutic pathways for the disease. 
1.4.5 Targeting β₂ integrin receptors therapeutically 
As discussed, β₂ integrins have a variety of important roles in the immune system 
from immune cell adhesion and migration to immune cell communication.  This 
makes them a promising therapeutic target in conditions that are marked by 
dysregulation or aberrant activation of the immune system, such as autoimmune 
conditions. While the possibility of targeting β₂ integrins to control such conditions is 
encouraging, the wide range of roles played by β₂ integrins also make off-target 
effects a likely risk that will have to be circumvented. In this section, I will provide an 
overview of therapeutics that target integrins and the β₂ family specifically, and 
comment on their respective successes and failures. Lastly, I will identify the gaps in 
our understanding of the roles of β₂ integrins, the understanding of which will help to 




To date, few examples of drugs targeting β₂ integrins specifically exist in the clinic. 
One exception is efalizumab, a monoclonal antibody (mAb) targeted against CD11a, 
which was originally licenced to treat psoriasis (Leonardi et al., 2005) and resulted in 
significant improvement in psoriatic plaque size and severity in 30-40% of patient 
after 12 weeks and up to 50-60% of patients after 24 weeks of efalizumab treatment. 
However, around 1 in 500 of patients several treated with the drug developed 
progressive multifocal leukoencephalopathy (PML), a rare, severe and potentially life-
threatening condition where demyelination of brain white matter of the brain occurs 
due to reactivation of the human polyomavirus 2 (JC virus) (Khalili et al., 2019; Major, 
2010). Due to the associated safety concerns, efalizumab was therefore withdrawn 
from European and American markets in 2009. Although the specific mechanism of 
action causing the increased incidence of PML in patients treated with efalizumab 
was not investigated, it was hypothesised to be either due to insufficient immune cell 
recruitment to the brain or the mAb itself entering the brain (Pavlovic et al., 2015; 
Schwab et al., 2012). However, in an animal model of joint inflammation, both a 
CD11a-targeting small-molecule antagonist (Suchard et al., 2010) and a mAB 
targeted against CD11a (Kakimoto et al., 1992) were successful in reducing 
inflammatory joint destruction and synovial cytokine levels. While efalizumab 
succeeded in reducing recruitment of leukocytes to inflamed sites, the severe side 
effects associated with its administration were not acceptable. However, lifitegrast, a 
competitive antagonist of CD11a, was found to be successful in treatment of dry eye 
disease by restricting recruitment of T cells to the ocular surface and activation of T 
cells, thereby reducing local inflammation and symptoms (Perez et al., 2016). 
Similarly to CD11a, blocking of CD11b showed great promise in animal models. For 
example, in mice, a CD11b blocking antibody reduced liver injury in response to 
ischaemia due to reduced recruitment of neutrophils (Jaeschke et al., 1993) and in a 
rabbit model of arterial injury, blocking CD11b caused reduced intimal thickening due 
to reduced recruitment of cells to the site of injury (Rogers et al., 1998). This provided 
important proof of concept that blocking CD11b might be a viable therapeutic 
strategy to reduce the amount of immune cell influx into injury sites and the resulting 
tissue damage. However, results of blocking CD11b in human have largely been 
disappointing, with small or no visible improvement compared to placebo was found 
in most cases (Dove, 2000; Harlan and Winn, 2002). More recently, a different 




(Faridi et al., 2009; Park et al., 2007), has shown great promise in reducing 
inflammation. The rationale for this counterintuitive approach was that increasing 
adhesion of immune cells to the vasculature due to the increase in CD11b activation 
led to a reduction in cell recruitment to the site of inflammation. As cells were less 
likely to transmigrate into tissues due to their strong adhesion to endothelium, 
inflammatory responses in a variety of animal inflammation models, including 
peritonitis, vascular injury and nephritis, were reduced (Maiguel et al., 2011). While 
this poses the risks of side effects in the form or endothelial damage or leakage due 
to increased adhesion of leukocytes to endothelium, this was not observed by the 
same group, suggesting that this approach is safe, although there is the possibility 
that recruitment to LNs of cells who are dependent on CD11b might be impaired. 
Another study on vascular injury confirmed that while both an CD11b activating 
antibody and the small-molecule agonist significantly increased adhesion to 
Fibrinogen, a reduction in inflammation was only observed in the animals treated with 
the leukadherin and not the activating antibody (Faridi et al., 2013). This was 
suggested to be due to the specificity of leukadherin, which only affected adhesive 
ability of cells, while the activating antibody furthermore induced both clustering of 
integrins and mediated outside-in signalling, suggesting that either or both of these 
properties made the activating antibody less effective. Clinically, the use of small-
molecule agonists targeted at CD11b might be important for treatment of cancer: 
ADH-503, a different CD11b small molecule agonist, was shown to reduce 
recruitment of immunosuppressive myeloid cells to pancreatic tumours while 
simultaneously increasing DC-mediated immunogenic T cell responses (Panni et al., 
2019). The positive effect on anti-tumour T cell response was proposed to be due to 
increased recruitment of cross-presenting cDC1 DCs into the tumour in the presence 
of ADH-503, which was in turn mediated by their naturally low expression of CD11b 
and increased expression of both MHCI and MHCII in the presence of CD11b 
agonism. Another option to avoid off-target negative side effects of drugs targeting β₂ 
integrins is by blocking β₂ integrin function in a ligand-specific way. For example, a 
mAb specifically blocking interaction between CD11b and one of its ligand CD40L 
was found to be protective in an animal model of sepsis, probably due to leukocytes 
not being able to adhere to CD40L on inflamed endothelium to extravasate into 




In summary, there are a variety of drugs targeting β₂ integrins available. A big 
challenge is the wide variety of roles β₂ integrins play in the immune system, 
meaning that blocking these leukocyte-specific adhesion receptors has many 
unwanted off-target effects. Recent advances in β₂ integrin therapeutics highlight that 
activating rather than blocking β₂ integrins might be a viable option to prevent 
excessive immune activation by harnessing the immunoregulatory roles of these 
integrins. However, even though β₂ integrins were reported to have an 
immunoregulatory role specifically in DCs and macrophages, positive effects of 
CD11b activating drugs seem to be largely mediated by neutrophils (Celik et al., 
2013; Dickinson et al., 2018). Understanding how these drugs that interfere with β₂ 
integrins affect DCs more specifically might therefore be important for the successful 
translation of these drugs into the clinic. 
1.5 Hypothesis and Aims 
Published literature suggests that β₂ integrins play an important role in DCs at the 
interface between immune activation and tolerance. While immunoregulatory roles of 
β₂ integrins especially on DCs have been reported in murine studies (Morrison et al., 
2014; Savinko et al., 2015) as well as in human (Balkow et al., 2010; Podgrabinska 
et al., 2009; Varga et al., 2007), published knowledge in human DCs is still limited 
due to the complexity of β₂ integrin function. However, a range of evidence suggests 
that imbalance between β₂ integrins is able to potently contribute to aberrant immune 
activation (Torsteinsdóttir et al., 1999; Watts et al., 2005). Therefore, it was 
hypothesised that dysregulation of integrin signalling in APCs could alter the balance 
between activation and tolerance, thus contributing to the aberrant inflammation 
present in autoimmune diseases such as RA. 
The hypothesis this thesis is based on can therefore be summarised as such: β₂ 
integrins on DCs play important pro-inflammatory and immunoregulatory roles. 
Dysregulation of β₂ integrins on DCs might therefore contribute to autoimmune 
conditions such as RA which would make β₂ integrins a viable therapeutic target. To 
investigate this hypothesis, I focused on three main questions.  
First, integrin signalling is strongly reliant on conformational status of its subunits in 
response to cell-internal (inside-out signalling) and external signals (outside-in 
signalling) (Carman and Springer, 2003; Li et al., 2017). Whilst some studies suggest 




abilities and functions (Sándor et al., 2016a), activity status of β₂ integrins is not 
commonly measured. Due to published evidence suggesting that integrin 
conformation is highly important for their function, I hypothesised that alterations in 
conformational states of β₂ integrins might have functional effects on cells they are 
expressed on. Dysregulation in β₂ integrin signalling that could interfere with 
appropriate immune activation could therefore occur at the level of surface 
expression, as well as conformational state of β₂ integrin subunits. I therefore aimed 
to quantify both total β₂ integrin expression as well as the level of active conformation 
present on APCs, specifically DCs and monocytes. To this end, optimisation of 
staining for both ‘total’ β₂ integrin subunit expression as well as ‘active’ β₂ integrin 
expression, which used antibodies specific to an epitope exposed only when the β₂ 
integrin subunit was in its extended conformation is detailed in Chapter 3. This will 
tell us if either surface expression or regulation of conformational state of β₂ integrins 
differs between conditions or patient samples and healthy controls.  
Second, tolerogenic Mo-DCs are not only a potential therapeutic option for DC-
mediated therapy of RA, they also present a unique modelling system of DCs 
between immune activation and tolerance. Chapter 4 therefore aimed to characterise 
‘total’ and ‘active’ β₂ integrin expression on tolerogenic compared to mature Mo-DCs 
to identify any potential differences in the respective immunoregulatory and pro-
inflammatory model settings. In addition, this also allowed me to generate DC-like 
cells in large enough numbers for functional experiments, which is a challenge when 
using circulating human DCs, due to their low frequency in PB. Tolerogenic Mo-DCs 
were furthermore chosen as an optimal model system to investigate the pro-
inflammatory and immunoregulatory function of β₂ integrins in DCs. This was 
because they show altered migration and adhesion abilities (Anderson et al., 2009) 
as well as altered T cell stimulatory activity (Anderson et al., 2008), which suggested 
differences in β₂ integrin expression or functionality. Investigating tolerogenic Mo-
DCs was therefore also suited to explore the possibility of interfering with β₂ integrin 
function to potentially improve therapeutic efficacy of this cell-based therapy for RA. 
Lastly, I aimed to investigate if β₂ integrins were indeed dysregulated in the 
autoimmune setting of RA, thereby potentially contributing to disease pathology. To 
do so, I first collected a comprehensive data set detailing ‘total’ and ‘active’ β₂ 
integrin expression on different human PB DC and monocyte subsets in health to act 




to RA pathology, I aimed to compare this healthy data set to β₂ integrin expression 
and conformation status in patients with RA. My findings comparing active RA, to 
remission and to healthy controls, as well as comparing RA PB to SF, are detailed in 
Chapter 5. 
To conclude, the aims for my thesis were three-fold. First, I aimed to develop and 
optimise usage of flow cytometry to detect both expression and conformational status 
of β₂ integrins on APCs simultaneously. Second, I utilised mature and tolerogenic 
Mo-DCs as a model system to investigate both pro-inflammatory and 
immunoregulatory functions of β₂ integrins in DCs. Third and last, I collected a cohort 
of healthy, active RA and RA in remission PB and SF samples to investigate if either 
expression or conformational status of β₂ integrins was altered in the dysregulated 







































2.1 Cell isolation 
2.1.1 Ethical approval 
All healthy human samples were acquired under MVLS ethical approval 2012073, 
while patient samples collected in the clinic were acquired under REC approval 
14/WS/1035 (additional tissue) and 16/WS/0207 (surplus tissue) for PB and SF/ST, 
respectively. Appropriate consent was given by all participants prior to sample 
collection. Additionally, every sample received a unique identifying number to 
anonymise the participant before cell isolation occurred. 
2.1.2 Peripheral blood 
Fresh whole blood was collected into 9ml VACUETTE® EDTA tubes (Greiner Bio-
One). To isolate peripheral blood mononuclear cells (PBMCs), fresh human peripheral 
blood (PB) was mixed 1:1 with room temperature (RT) Hanks Balanced Salt Solution 
(HBSS, Gibco) + 2mM Ethylenediamine Tetraacetate Acid (EDTA, Fisher Scientific) 
before slowly layering onto 15ml RT lymphoprep (Axis-Shield PoC AS). Blood was 
centrifuged at 895g for 30min at RT and PBMCs were recovered from the surface of 
the high density medium with a sterile Pasteur pipette. Cell suspension was then 
washed in 50ml cold HBSS+1% Fetal Calf Serum (FCS, Gibco) at 600g, 4°C for 7min. 
Supernatant was discarded and pellet resuspended in HBSS+1%FCS for a further 
washing step at 250g, 4°C for 7min. Cells were filtered using a 70µm cell strainer and 
resuspended in appropriate volume for counting, with dead cells excluded by Trypan 
blue (Sigma), before being washed a third time at 400g, 4°C for 7min. 
2.1.3 Synovial fluid 
SF was collected into uncoated 20ml universal tubes as part of joint aspiration 
procedure and processed on the same day. To isolate cells from synovial fluid, the 
viscous sample was mixed 1:2 with RT HBSS + 2mM EDTA and filtered through a 
100µm cell strainer before being carefully layered onto 15ml lymphoprep. After this cell 
isolation proceeded exactly as described for peripheral blood. 
2.1.4 Synovial membrane 
Synovial membrane or ST was collected as part of joint replacement operations and 
kept at 4°C suspended in RF10, consisting of RPMI-1640 (Gibco), 10% FCS, 2mM L-
Glutamine (200mM, Invitrogen) and 100 units/ml of Penicillin and 0.1mg/ml 
Streptomycin solution (10,000 units of Penicillin and 10mg of Streptomycin per ml in 




any visible fat and bone fragments before being cut into 1mm fragments using a 
scalpel. Care was taken to keep tissue immersed in RF10 to avoid drying out. 
Mechanically digested tissue in medium was resuspended in warm RF10, Then 
Liberase TH (high Thermolysin concentration, Roche) at a final concentration of 
15µg/ml and DNase (Roche) at a final concentration of 30µg/ml were added. Samples 
were then transferred to a shaking incubator set at 260rpm at 37°C for 45min, with 
additional manual vigorous shaking every 15min. The solution was then filtered 
through a 70µm nylon filter. Whilst the filtrate was placed on ice immediately to prevent 
further enzymatic digestion, the tissue remaining in the filter was subjected to a second 
digestion of 45min, 260rpm at 37°C. Afterwards, filtrates were pooled, washed and 
cells counted. 
2.2 Generating Mo-DCs  
2.2.1  CD14+ monocyte isolation 
PBMCs were isolated from human peripheral blood as described above. After the last 
washing step at 400g, 4°C for 7min, cells were resuspended in 80µl of ice-cold sterile-
filtered MACS cell separation buffer per 10x106 PBMCs, consisting out of Phospate 
Buffered Saline (PBS, Ca2+ free, Mg2+ free, Gibco), 5% FCS and 2mM EDTA. Then 
10µl of human CD14 microbeads (MACS Miltenyi Biotec) per 10x106 PBMCs were 
added and cells were incubated on ice for 20min, throughout which cells were gently 
shaken every 5min. Then, cells were washed in 25ml ice-cold MACS buffer as before. 
During this time, a cooled positive selection column (LS, MACS Miltenyi Biotec) was 
placed onto MACS separator magnet and pre-rinsed with 3ml ice-cold MACS buffer. 
Cell supernatant was discarded and cells were resuspended in 2ml ice-cold MACS 
buffer before being added to the column. CD14neg cells were allowed to pass through 
the column, and it was washed a further three times using 3ml MACS buffer to ensure 
all negative cells had been flushed through. The MACS column was then removed 
from magnet and 5ml MACS buffer were added before releasing cells from column 
using a plunger. Cells were counted, washed in cold MACS buffer as described above 
and resuspended at 0.5x106 cells/ml in cold RF10 medium. 
2.2.2 Culture of Mo-DCs 
Cells were seeded into an uncoated 24 well plate at 0.5x106 cells in 1ml of cold RF10 
per well. Human IL-4 (Immunotools) and GM-CSF (Immunotools) were added to 




at 37°C in 5% CO2. Cells were fed by removing 450µl of old culture medium and 
replacing with 500µl warm fresh RF10 supplemented with IL-4 and GM-CSF on day 3 
of culture. 
2.2.3 Generation of immature, mature and tolerogenic Mo-DCs 
To culture immature Mo-DCs no further reagents were added. Mature Mo-DCs were 
stimulated with 0.1µg/ml LPS (Sigma-Aldrich) on day 6. To yield tolerogenic MO-DCs, 
cells received Dexamethasone (Sigma-Aldrich) at a final concentration of 10-6M per 
well on day 3. The same amount of Dexamethasone was added on day 6 of the culture, 
together with Vitamin D3 (Tocris, Biotechne) at a final concentration of 10-10M and 
0.1µg/ml LPS per well. All cells were harvested on day 7 for experimental use. To 
harvest, 24 well plates were placed on ice for 1hr to loosen cells. Cells were then gently 
scraped and removed from the wells. Cell suspension in RF10 was washed at least 
three times in ice-cold HBSS+1%FCS at 400g, 7min at 4°C, after which they were 
counted for further use.  
2.3 Flow cytometry 
All flow cytometry staining and washing steps were executed using cold FACS buffer, 
consisting out of PBS +3%FCS, 0.01% Sodium Azide (NaN3, Sigma-Aldrich) and 1mM 
EDTA. Unless otherwise noted SytoxTM 7-AADvanced dead cell stain (Invitrogen) was 
added to cell suspension after washes at least 15min before analysis and was not 
washed off. Ultracomp beads (Invitrogen, Thermofisher Scientific) were used for 
compensation. 200µg/ml of human IgG was added to all staining mixes to act as a 
blocking agent to reduce non-specific binding to Fc receptors on human cell surfaces. 
In addition to controls mentioned specifically. Fluorescence Minus One (FMO) controls, 
containing all antibodies except for the one of interest, were used to ensure correct 
gating of populations, especially where data spread introduced by the use of multiple 
fluorochromes was likely. An overview of all antibodies used for flow cytometry with 
corresponding dilution used can be found in Table 2.1. Flow cytometry samples were 
acquired using a BD Fortessa and data was analysed using Flowjo software (Treestar).  
2.3.1 Mo-DC phenotyping  
After Mo-DC-harvest, cells were divided into two 96 well round bottom plates, to stain 
for β₂ integrin expression (at 37°C, as above) and phenotyping the different Mo-DC 
populations (at 4°C), respectively, for 30min in FACS buffer. For phenotyping Mo-DCs, 




CD14negCD1c+. Furthermore, respective expression of HLA-DR, costimulatory 
molecules CD80 and CD86, as well as TLR2 and the latency-associated protein (LAP) 
portion of TGFβ1 were stained for. Cells were washed three times in cold FACS Buffer 
and resuspended in 200µl FACS buffer for acquisition. 
2.3.2 Integrin activation staining 
PBMCs were prepared as described. After the last wash, cells were rested for 60min 
in a 96 well plate in 200µl HBSS+2%FCS per staining condition in an incubator (37°C, 
5% CO2). This resting period was introduced to avoid DC death due to strenuous cell 
isolation process. In addition to 200µg/ml human IgG (Sigma), 1mM Magnesium 
Chloride (MgCl2, Sigma) was added to the FACS buffer to ensure conditions in which 
β₂ integrins could fully extend. When staining for active β₂ integrins, an unstained 
control, a negative control containing no β₂ integrin antibodies, an isotype control and 
a positive control with the addition of 100ng/ml phorbol 12-myristate 13-acetate (PMA) 
were always included. After the resting period, cells were spun down in the plate for 
5min, 400g at 4°C and stained for 30min at 37°C, 5% CO2. Cells were then washed 
three times in 200µl cold FACS buffer as before and kept on ice between washes 
before being filtered and resuspended in 300µl for flow cytometry analysis.  
2.3.3 Fluorescence activated cell sorting (FACS) 
After PBMC isolation, cells were stained for 30min at 37°C with panel including HLA-
DR, CD11c, CD14, CD16, CD1c and CD141 to yield cDC2s. CD3, CD19, CD20 and 
CD56 were also included to exclude T cells, B cells and NK cells. A representative 
gating strategy can be seen in Figure 2.1. Cells were washed three times in ice-cold 
FACS buffer and resuspended at 2x107 cells/ml in FACS buffer, with further dilution of 
cells as needed to ensure optimal sorting conditions of ca. 7000 events/second. Cells 
were sorted into 5ml FACS tubes containing FACS buffer with 50%FCS to ensure cell 
survival. All sorting was done on a FACS Aria IIU or a FACS Aria II (BD Biosciences) 
using a 85µm nozzle. After sorting, cDC2s were rested overnight in RF10 in the 







Figure 2.1 Gating strategy for sorting cDC2 DCs from human PB 
cDC2s were sorted from healthy PBMCs under exclusion of doublets, T cells, B cells 
and NK cells. HLA-DR+CD11c+, bur CD14-CD16- cells were then shown in respect 
to their CD1c and CD141 staining and CD1c+ population was delineated using an 
unstained control. CD1c+ population was then sorted for. Representative plot of 3 










CD11a active MEM-83 AF 700 Novus bio 1:100 9.5μg/ml 
CD11a total  HI111  PE BioLegend 1:50 2μg/ml 
CD11b active CBRM1/5  APC BioLegend 1:50 4μg/ml 
CD11b total ICRF44  BV785 BioLegend 1:100 1.5μg/ml 
CD11c BU15  APC-Cy7 BioLegend 1:100 4μg/ml 
CD14 M5E2  BUV737 BD Biosciences 1:50 1μg/ml 
CD141 M80 PE-Cy7 BioLegend 1:50 4μg/ml 
CD16  3G8  PE-Dazzle594 BioLegend 1:200 0.25μg/ml 
CD18 active m24  AF 488 BioLegend 1:10 10μg/ml 
CD18 total 6.7 BV421 BD Biosciences 1:20 10μg/ml 
CD19 SJ25C1 PE-Cy5.5 eBioscience 
 
1:50 0.1µg/ml 
CD1c  L161  PerCP-Cy5.5 BioLegend 1:100 2μg/ml 
CD20 2H7 PE-Cy5.5 eBioscience 
 
1:50 0.3µg/ml 
CD3 SK7 PE-Cy5.5 eBioscience 
 
1:100 5µg/ml 
CD4 OKT4 PerCP-Cy5.5 Biolegend 1:50 2µg/ml 
 
CD45 HI30  BUV395 BD Biosciences 1:50 2μg/ml 
CD45RO UCHL1 APC-Cy7 Biolegend 1:50 8µg/ml 
CD56 CMSSB PE-Cy5.5 eBioscience 
 
1:100 0.06µg/ml 
CD83 HB15e PE BD Biosciences 1:10 25µg/ml 
CD86 2331 
 (FUN-1) 
V450 BD Biosciences 1:50 4µg/ml 
HLA-DR G46-6 BV480 BD Biosciences 1:50 2μg/ml 
HLA-DR L243 APC BD Biosciences 1:100 Unknown 
h-LAP 
(TGFβ1) 
27232 PE R&D systems 1:10 Unknown 
Isotype control  
Mouse IgG1, κ 





Table 2.1 Antibodies used for flow cytometry 
 
2.4 Static adhesion assay 
Static adhesion assays were used to quantify Mo-DC adherence to various β₂ integrin 
ligands. ICAM-1 (R&D systems), iC3b (Merck Millipore), C4b (Merck Millipore), 
Fibrinogen (Merck Millipore) and Fibronectin (R&D systems) diluted in PBS were 
coated overnight at 4°C onto COSTAR 96 well high-binding assay plates (Corning) at 
low, medium and high concentrations, which can be found in Table 2.2. Fibronectin 
was included as a positive control, while wells treated with PBS without any addition 
of ligand were included as a negative control. After 24h, wells were washed twice with 
PBS, before blocking with 1% Milk in PBS for 1h15min at 37°C. Plates were washed 
twice with cold PBS, left with 200µl PBS per well and placed on ice. Harvested Mo-
DCs were resuspended in adhesion medium consisting of RPMI 1640, 0.1% Bovine 
Serum Albumin (BSA, Sigma), 20mM HEPES (pH 7.25) and 2mM MgCl2 (Sigma), 
before adding 25x103 Mo-DCs per well in duplicate or triplicate (400µl at a 
concentration of 0.0625x106cells/ml). 
 
After the addition of cells, plates were incubated for 8min on ice to allow cells to settle 
to the bottom of the well before being transferred to 37°C for 15min to allow cell 
adherence. Plates were then carefully placed upside down in 2.5 litre PBS+2mM MgCl2 
for 50min at RT to allow non-adhered cells to exit the well. Then, plates were inverted 
Isotype control  
Mouse IgG1, κ 
MOPC-21 APC BD Biosciences 1:50 4µg/ml 
Isotype control  
Mouse IgG1, κ 
MOPC-21 AF488 Biolegend 1:5 10µg/ml 
TLR2 TL2.1 AF647 Biolegend 1:10 40µg/ml 
Table 2.2 Ligand concentrations for static adhesion assay 
Ligand 
Concentration (in µg/ml) 
Low Medium High 
ICAM-1 0.1 1 10 
iC3b 1 3.3 10 
C4b 1 3.3 10 
Fibrinogen 1 10 100 




and 350µl buffer was removed to leave 50µl per well, to which 100µl of lysis buffer, 
consisting out of p-nitrophenyl phosphate (PNPP, Calbiochem) dissolved in 1%Tx-
100/50mM acetate buffer (pH 5) at a final concentration of 3mg/ml, was added. 
Adhered cells were lysed for 60min at 37°C protected from light and reaction was 
stopped by adding 50µl Sodium Hydroxide (NaOH) per well. Absorbance was 
measured using a Sunrise Absorbance Reader (Tecan) at 405nm. In order to quantify 
cell adhesion as a percentage of total cells, a ‘total’ plate was prepared by pelleting 
25x103 cells per Mo-DC subtype (400µl of 0.0625x106 cells/ml cell suspension) and 
resuspending cells in 200µl PBS. 50µl of each cell suspension (i.e. x number of cells) 
was then transferred to a fresh uncoated COSTAR 96 well high-binding assay plate in 
triplicate, together with PBS in triplicate as a negative control. This ‘total’ plate was 
lysed and measured as described with the experimental plate. 
2.5 18h PBMC stimulation 
To understand the effects of extracellular factors on β₂ integrin expression and 
activation, PBMCs were stimulated with various factors for 18h. PBMCs were 
resuspended in RF10 and plated into 48 well plates (Corning) at 1.5x106 cells per well. 
Then, stimuli diluted in RF10 were added to yield five conditions (untreated, LPS, IL-
1β+TNFα, IL-10+TGF-β, SF), each in duplicate. Details of concentrations used can be 
found in Table 2.3. Cells were then returned to 37°C, 5% CO2 for 18h before being 
harvested and stained for flow cytometry as above.  
 
 
Table 2.3 Treatment conditions for 18h PBMC stimulation 
Condition Final concentration Supplier 
Untreated - - 


















2.6 Mixed Lymphocyte Reactions 
To investigate the role of β₂ integrins on DCs in T cell activation, mixed lymphocyte 
reactions (MLRs) were set up with mature or tolerogenic Mo-DCs, or sorted cDC2s, 
together with CD4 T cells isolated from a different donor. 
2.6.1 Naïve CD4 T cell isolation  
5-10ml of buffy coat was taken to yield approximately 20-40x10⁶ naïve CD4+ T cells. 
Rosettesep Human CD4+ enrichment cocktail (Stemcell Technologies) was added at 
75µl/ml and incubated at RT for 20min. Sample was then diluted 1:2 using 
PBS+2%FCS at RT and gently layered onto 15ml lymphoprep. Density centrifugation 
occurred at 895g, 21°C for 30min after which enriched T cells were removed from the 
high density medium interface using a sterile Pasteur pipette. Cells were washed in 
warm PBS+2%FCS for 7min at 600G, RT, and again at 400G. Then, cells were 
counted and washed a third time in cold HBSS+1%FCS at 400G, 4°C for 7min. The 
pellet was then resuspended in 80µl ice-cold MACS buffer per 10x106cells. 20µl of 
human CD45RO Microbeads (MACS Miltenyi) per 10x106cells were added and gently 
mixed before cells were placed in the fridge for 15min. After incubation, non-adhered 
beads were washed off using ice-cold MACS buffer for 7min at 400g, 4°C, and 
resuspended in 500µl MACS buffer. A MACS separator column was pre-washed with 
3ml MACS Buffer, before cells were added. CD45ROneg cells passed through the 
column, while unwanted CD45RO+ T cells remained bound to the column. The column 
was washed a further three times with 3ml MACS buffer each. Cells present in flow-
through were counted for further analysis.  
2.6.2 CellTrace Violet Proliferation Staining 
After counting, naïve CD4 T cells were washed twice in PBS for 7min at 400g, 4°C. 
They were then stained with 5µM CellTrace Violet Proliferation Dye (CTV, Invitrogen, 
Thermofisher Scientific) in PBS for 15min at RT protected from light. After the 
incubation period, 1/5 of the staining volume of FCS was added for 5min to quench the 
reaction. Cells were then washed twice more in cold PBS+1%FCS for 7min at 400g, 
4°C to remove excess dye. Cells were counted again and resuspended at 
2x106cells/ml in cold RF10. 
2.6.3 Setting up Mixed Lymphocyte Reaction 
Mature and tolerogenic Mo-DCs, as well as overnight rested sorted cDC2s, were 




with 250µl of CTV-stained naïve CD4 T cells at 2x106 cells per ml (0.5x106 T cells per 
well) and 250µl of the respective DCs (0.05x106 Mo-DCs or cDC2s per well) per well. 
This gives a DC:T cell ratio of 1:10. Where indicated, the CD11b agonist, Leukadherin-
1 (R&D systems, Biotechne) in concentrations from 1µM to 10µM, with a corresponding 
DMSO control (0.1-1%) or a CD11b blocking antibody (Biolegend) at 20µg/ml with a 
corresponding isotype control (Biolegend) also at 20µg/ml were added to the culture. 
MLRs were cultured at 37°C, 5% CO2 for 4 or 6 days. CD11b antagonists were 
replenished on Day 4, with a further 10µl of 1mg/ml stock solution of either CD11b 
blocking antibody or isotype control being added to respective culture dishes. CD11b 
agonist and DMSO control were not replenished on Day 4, but only added to the culture 
on Day 0 due to the inhibitory effect of even low DMSO concentrations on cell 
proliferation. 
2.7 ELISA 
Supernatants of MLRs were collected on Day 6 of culture and frozen at -80°C for 
cytokine measurements using enzyme-linked immunosorbent assay (ELISA). IL-10 
and IFN-γ were measured using Human IL-10 ELISA MAXTM Deluxe (Biolegend) and 
human IFN-γ ELISA MAXTM Deluxe (Biolegend) kits, respectively, according to the 
manufacturer’s protocol.  
Briefly, capture antibodies against IL-10 and IFN-γ were coated overnight at 4°C onto 
COSTAR 96 well high-binding assay plates (Corning) at 50µl per well. Unbound 
capture antibody was washed off the following morning using PBS-T (PBS, 0.05% 
Tween-20) three times before blocking for 1h with the manufacturer’s blocking solution. 
Plates were washed 3 times and 50µl of prepared stock solutions and sample dilutions 
were added to respective wells in duplicate. Plates were incubated for 2h on a shaker 
at RT for cytokine binding. After washing plates three times, 50µl of detection antibody 
was added to the plates and incubated a further 1h at RT on a shaker. Plates were 
washed three more times and 50µl of Avidin-HRP solution was added for 30min. For 
final 4 washes, plates were soaked in washing buffer for 30-60sec for each wash to 
reduce background signal. After the last washing step, 50µl of freshly mixed TMB 
substrate solution (components provided by the manufacturer) were added to each 
well and incubated in the dark. Once the characteristic blue colour appeared, after ca. 
10-20min, the reaction was stopped by the addition of 50µl 10% Sulfuric Acid (H2SO4). 
A Sunrise absorbance reader (Tecan) was used to measure absorbance at 450nm and 




Furthermore, background signal was removed by subtracting values measured in 
assay diluent-only negative control wells. Unknown cytokine concentrations were 
interpolated from a standard curve constructed using Graphpad Prism software and a 
defined series of 10 serial dilutions performed in duplicate, beginning with the top 
standard at 1000pg/ml and ending with a well without any top standard added to assay 
diluent (12 standards in total). 
2.8 Microscopy  
Microscopic imaging was used to validate cell blasting in MLRs and overall cell 
morphology as well as quantify cell clustering of different Mo-DC subtypes. 
2.8.1 Quantification of Mo-DC clustering on glass bottom plates 
To measure Mo-DC clustering a Leica DMi8 (Leica Microsystems) was used with a live 
cell chamber attachment at 37°C and 5% CO2. Immature, mature and tolerogenic Mo-
DCs were plated onto glass-bottom 24 well plates at a concentration of 200,000 cells 
per well in 1ml RF10 and kept at 37°C, 5% CO2. Wells were then imaged 6h after 
plating to observe respective clustering behaviour. Up to 40 Bright field images of each 
well were taken at 10x magnification and stitched together to yield an overview of the 
whole well. Imaging acquisition software provided by Leica was used for all images 
acquired on this instrument. 
To quantify clustering of Mo-DCs, a cellprofiler pipeline was designed with the help of 
Dr. Leandro Lemgruber (Imaging Technologist, Glasgow Imaging Facility), to identify 
both clusters of cells and single non-clustered cells respectively for measurement. An 
example of an image analysed by the pipeline can be found in Figure 2.2. Briefly, the 
origininal images were pre-processed to yield a high threshold black and white image 
showing cells as bright objects on a dark background (Step 2, using CellProfiler 
modules ColourToGrey, RescaleImage, ImageMath, EnhanceOrSuppressFeatures 
and Threshold). Each individual cell was then identified as an object, using parameters 
ranging between 30-40 pixels (ca. 18-24µm), which was based off repeated 
measurements of cells visualised (Step 3, IdentifyObjects). Then, to identify clusters of 
cells, cells which had one or more ‘neighbours’, which were defined as separate 
objects that were immediately adjacent to a cell, were identified (Step 4, 
MeasureObjectNeighbours). Clusters of cells were defined as cells that had 
neighbouring cells with touching borders. To enable measurement of these clusters, a 






 Figure 2.2 Visual representation of CellProfiler pipeline for cell clustering analysis 
Analysis of sample image (mature Mo-DCs) with CellProfiler pipeline for cell clustering 
analysis, with different relevant steps shown to identify and quantify both clusters of cells as 
well as individual non-clustered cells. CellProfiler image processing modules utilised to yield 





identified as an object (Step 5, Threshold, IdentifyObjects). To detect single cells, that 
did not cluster together, the threshold image of clusters (Threshold 
ObjectsWithNeighbours) was overlaid as a mask onto the original threshold image 
(Threshold of original image), leaving only non-clustered cells. Then each non-
clustered cell was identified as an object (Step 6, MaskImage, IdentifyObjects). After 
both cell clusters and single cells were identified as objects, measurements of object 
number, size and radius could be obtained (Step 7, MeasureImageAreaOccupied, 
MeasureObjectSizeShape) and compared between immature, mature and tolerogenic 
Mo-DCs.  
2.9 Sample size estimation and power calculations 
As very little is known about the expression levels of β₂ integrins, particularly in the 
active conformation, on human APCs, it was not possible to conduct a formal power 
calculation before beginning sample acquisition. It was therefore decided to utilise 
both a priori and compromise power calculations with Cohen’s standard effect sizes 
(Cohen’s d) (Cohen, 1992) initially and adapting these after 10 samples per group 
(healthy, active RA, remission) were collected to provide the preliminary data needed 
to estimate an appropriate effect size (Jones et al., 2003).  
The null hypothesis for the clinical part of this thesis states that there is no difference 
in β₂ integrin expression or activation between RA patients (active or in remission) 
and healthy controls. The alternative hypothesis therefore states that there is a 
difference between these groups of people, with power calculations serving to avoid 
Type I (falsely accepting the null hypothesis) or Type II (incorrectly rejecting the null 
hypothesis) statistical errors. For all power calculations and sample size estimation 
Gpower 3.1 was used.  
For a priori (Test family: F tests), a one-way ANOVA, fixed effects was used with 
varying levels of effect sizes (large – 0.4, medium – 0.25, small – 0.1, Cohen’s d) and 
the lowest acceptable power (0.8) was compared to 0.95, which should be aimed for. 
Results of these calculations can be found in Table 2.4. For example, when acquiring 
31 samples per group, medium effects would be detected correctly in 80% of cases.  
For power calculations using compromise (Test family: F tests), the same statistical 
test was used with the difference that power was calculated from a respective sample 




32 per group (total sample size 96). Results of these calculations can be found in 
Table 2.5. For example, with a sample size of 25 samples per group, large effects 
could be correctly identified with 91% probability, neither medium nor small effects 
could be detected at high enough power to be reliable. Overall both a priori and 
compromise power calculations suggest that it would be impossible to detect small 







Compromise Power if total sample size= 
Effect size 60 75 96 
LARGE:  
0.4 
0.88 0.91 0.95 
MEDIUM: 
 0.25 
0.73 0.76 0.81 
SMALL:  
0.1 
0.55 0.56 0.58 
Table 2.5 Compromise power calculation 
 
However, there is some criticism of using Cohen’s small, medium and large effect 
sizes, as they are based on a normally distributed population and therefore might not 
fit all experiments (Rice and Harris, 2005). It is therefore recommended to calculate 
experiment-specific effect sizes using Cohen’s d from means and standard deviation 
(SD) of relevant preliminary data. 
The general formula states that (Ferguson, 2016): 
𝐸𝑓𝑓𝑒𝑐𝑡 𝑠𝑖𝑧𝑒 =
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑔𝑟𝑜𝑢𝑝 𝐴 − 𝑀𝑒𝑎𝑛 𝑜𝑓 𝑔𝑟𝑜𝑢𝑝 𝐵
𝑆𝐷 𝑜𝑓 𝑏𝑜𝑡ℎ 𝑑𝑎𝑡𝑎 𝑠𝑒𝑡𝑠
 




A priori POWER 0.95 POWER 0.8 










102 34 39 13 
MEDIUM: 
0.25 
252 84 93 31 
SMALL: 
0.1 
1548 516 570 190 




However, as three groups are compared to each other instead of two, effect sizes 
have to be calculated taking SDs and means of all three groups into account. 
Therefore, g*power was utilised to calculate respective effect sizes from the means of 
10 samples per group. SD pooled from all three groups was calculated by the 
programme by providing the square root of the mean squared residual value (MS 
residual), which describes the mean difference between estimated sample mean and 
sample (Dekking, 2005).   
2.10 Statistical Analysis 
Data is shown as mean +SD if not specified otherwise. For all other statistical analysis 
Graphpad Prism software was used. Student’s t-tests were used to compare two 
groups, while one-way ANOVA was utilised to compare single variables between 2 or 
more groups. In this case, Tukey’s multiple comparison test was used to determine 
where differences between groups specifically occurred. P-values shown are as 

















 Development and optimisation of a flow cytometry panel 





The heterodimeric β₂ integrin receptors are exclusively found on leukocytes, where 
they play important role in cell adhesion and migration. However, evidence is growing 
that β₂ integrins can also regulate immune functions specifically in DCs (Schittenhelm 
et al., 2017) It was, therefore, hypothesised that dysregulation of β₂ integrin immune 
cell signalling is associated with the pro-inflammatory autoimmune environment 
prevalent in inflammatory diseases such as RA. To this end, the aim was to establish 
if total and active forms of β₂ integrins can be assessed in the same sample, and to 
develop a flow cytometry panel that will enable us to measure these β₂ integrin 
conformations on a range of APCs.  
3.1.1 The β₂ integrins of interest 
Receptors of the β₂ integrin family consist of a shared β₂ subunit (CD18) that non-
covalently pairs with one of four α-subunits (CD11a, CD11b, CD11c or CD11d). These 
integrins are expressed on the cell surface and possess two main signalling modes. In 
inside-out signalling, cell internal signals drive activation or avidity of integrins on the 
cell surface to interact with the cells’ immediate environment. On the other hand, 
outside-in signalling is triggered when an integrin encounters its ligand, which causes 
integrin activation and downstream signalling processes within the cell (Hogg et al., 
2011). Importantly, both inside-out and outside-in β₂ integrin signalling is therefore 
modulated by conformational changes, which can increase ligand affinity between 
4000 to 6000-fold between the inactive low affinity and active high-affinity state (Li et 
al., 2017). Considering the importance of these conformational changes for integrin 
signalling and function in immune cells, it is key to not only assess expression of a 
subunit but also consider its activation state. While published literature extensively 
explores differential expression of total β₂ integrins on various cell types (see Chapter 
1, section 1.4.2, Table 1.1), a comprehensive overview of β₂ integrin activation status 
on different immune cell types has not been attained to date. 
To address this knowledge gap, the aim was to quantify not only expression of the 
respective subunit (total β₂ integrin expression) but also the proportion of receptors 
present in the active high-affinity conformation (active β₂ integrin expression). This 
could provide important insights into the relationship between surface expression and 
activation, which are not well understood so far. CD11a, CD11b and the pairing subunit 
CD18 all have commercially available antibodies against binding sites that are exposed 




sites that only become exposed when the β₂ integrin is extended into its high affinity 
conformation (active β₂ integrin antibodies) (Diamond and Springer, 1993). Comparing 
the α-subunits CD11a and CD11b is especially interesting, as they share ligands and 
are highly homologous, but have been described to have different functions (Ding et 
al., 1999). Measuring CD18 on the other hand yields slightly different information. As 
it pairs with both CD11a and CD11b, CD18 provides valuable information on how the 
different subunits can potentially compensate for each other if changes in one should 
occur. While an activation-specific antibody is commercially available for CD11c 
(Sadhu et al., 2007), this marker was not included as total CD11c was used to delineate 
APCs in the gating strategy (see Figure 2.1). CD11d, which is the most recent β₂ 
integrin subunit identified (Van der Vieren et al., 1995) and the least well-described, 
does not have flow cytometry antibodies targeted at either total CD11d or an activation-
specific epitope, so it was not included. While CD11c and CD11d could not be 
assessed directly, CD18 might give us some information about these subunits 
indirectly. 
3.1.2 Cells of interest 
As my main focus was to investigate the roles of β₂ integrins in immune regulation, 
specifically in DCs, different subtypes of these professional APCs present in peripheral 
blood were of interest. This included both conventional DC subtypes, differing in the 
presence of CD141+ staining (cDC1) and CD1c+ staining (cDC2). Additionally, pDCs 
were considered. However, as there is some evidence that respective integrin 
expression or activation might contribute to the differing antigen-presenting capabilities 
between cell types (Sándor et al., 2016b), non-professional APCs were also included 
for comparison, such as classical and non-classical monocytes. Lastly, as the scope 
of my work was to investigate the role of β₂ integrins on myeloid APCs, lymphocytes 
such as T cells, B Cells and NK cells were not considered. 
To conclude, expression of total and active forms of the β₂ integrin α-subunits CD11a 
and CD11b, as well as their common paired β-subunit CD18, were assessed in MO-
DCs (in vitro work) and APCs present in peripheral blood (ex vivo work). 
3.1.3 Application of the β₂ integrin flow cytometry panel 
As I was interested in exploring β₂ integrin expression and conformation not only in 
peripheral blood of healthy controls, but in the context of autoimmune disease, further 




panel. While RA is a systemic disease, many symptoms are joint-specific so it was 
important to test if synovial tissue could also be assessed. Developing a panel that can 
be dynamically used between different tissues is also important for potential future use 
in different disease contexts. To this end, I wanted to make sure this panel could also 
be used to measure total and active β₂ integrin expression in cells isolated not only 
from peripheral blood, but also from synovial fluid and synovial tissue samples. CD45 
was therefore included as a marker into the panel to be able to distinguish between 
CD45neg stromal cells present in high numbers in these tissues and the CD45+ APCs 
of interest. Furthermore, application of the panel to fresh and frozen samples alike 
would be tested, to make future use of the panel on samples stored in biobanks or 
other repositories possible. 
3.2 Aims 
To explore the potential roles β₂ integrins play in immune regulation on DCs, 
expression of both total and active forms of specific β₂ integrin subunits needed to be 
quantified in the different types of DCs. In this chapter, I aimed to develop and optimise 
a flow cytometry panel that will enable us to do this. 
The specific aims of this chapter were: 
1. To optimise staining conditions for total and active β₂ integrins in terms of 
staining temperature and time. 
2. To validate an appropriate positive control for β₂ integrin staining. 
3. To ensure concurrent staining of total and active β₂ integrins was not hindered 
by signal loss due to steric hindrance or FRET. 
4. To titrate antibodies for optimal signal and develop a gating strategy to 
distinguish a range of APCs present in PB. 
5. To assess potential future applications of the panel on both biobanked samples 






3.3.1 Temperature sensitivity of active integrin staining 
Published literature suggests that integrin-mediated adhesion is highly temperature-
sensitive (Cai and Wright, 1995; Rico et al., 2010), with little to no adhesion to ligand 
being observed at 4°C or even at RT. As integrin activation confers functionality, 
including adhesive capability of cells, it was hypothesised that integrins do not expose 
their activation-specific epitope under cold conditions, which hinders the binding of 
antibodies to active integrins. Differences between staining for an activation-specific 
epitope cold or at 37°C have been shown previously with the CD11b/CD18 activating 
clone KIM127 (Andrew et al., 1993). Different approaches concerning this limitation 
can be found in the literature, including bringing cells to 37°C for 30min before staining 
at 4°C (Kooyk et al., 1999) or staining separately for activation-specific epitopes at 
37°C for a reduced time period of 10min (Shamri et al., 2005). 
To test whether temperature influences the staining of active integrins, binding of 
antibodies to active and total CD11a, CD11b and CD18 in the fridge at 5.6°C and in 
the incubator at 37°C was compared (Figure 3.1). Staining of active CD11a was slightly 
higher at 37°C than at 5.6°C (Figure 3.1A), a difference which was significant (Figure 
3.1B). Staining of active CD11b was also consistently higher at 37°C, which was 
especially true for the SSC-high (SSChi) population. However, this result was not 
significant due to the comparably small sample size with higher variation. Lastly, active 
CD18 staining could not be detected in any of the three donors when stained at 5.6°C, 
while staining at 37°C yielded a clear staining with distinct SSChi and SSC-low (SSClo) 
populations. This result was also not significant. Staining of total CD11a is also higher 
at 37°C compared to 5.6°C, but the result was not significant. Both total CD11b and 
total CD18 showed significantly higher staining at 37°C than at 5.6°C. Overall, SSC-hi 
and SCC-lo populations were the same between samples stained at different 
temperatures, with staining being shifted to the right in the cells stained at 37°C. 
The aim was to develop a flow cytometry panel that detects both total and active 
expression to investigate the physiological relevance of β₂ integrins for disease. Being 
able to detect and measure active CD18 is a critical part of this aim, which is why 
staining of all samples at 37°C was deemed necessary. This is however associated 











 Figure 3.1: Staining of active β₂ integrin subunits is temperature sensitive.  
Positive staining for the respective antibodies against active and total CD11a, CD11b and CD18 was 
assessed. Healthy unstimulated PBMCs were stained for 30min at 5.6°C or 37°C. A. Representative 
plots show positive staining for active and total β₂ integrins stained at 37°C (shown in red) overlaid onto 
cells stained at 5.6°C (shown in blue). Only live single cells negative for CD3, CD19, CD20 and CD56 







staining, making the antibody staining less specific and reliable. Comparing the higher 
staining of total β₂ integrins at 37°C, it is possible that this is due to non-specific 
antibody binding, even though SSChi and SSClo populations have not changed in 
shape but merely in the brightness of signal recorded. Alternative methods were briefly 
explored, such as consecutive staining of total and active integrins at different 
temperatures. However, continuous integrin trafficking between cytoplasm and cell 
surface is a phenomenon widely described in the literature (Bretscher, 1992; Fabbri et 
al., 1999). To understand the relationship between β₂ integrin expression and 
activation, it is therefore essential that total and active forms are measured on the same 
cells in the same sample at the same time.  
To summarise, staining of active β₂ integrins is highly temperature-sensitive. 
Therefore, staining samples at 37°C is necessary to detect the active integrin 
conformation, especially for active CD18. However, higher staining of total β₂ integrins 
at 37°C means that an increase in non-specific antibody binding could occur. A 
reduction in staining time was therefore tested to potentially recoup this effect. 
3.3.2 Time sensitivity of active integrin staining 
After it became apparent that β₂ integrin staining would have to be performed at 37°C, 
it is likely that molecular processes involved in the staining process, such as an 
antibody binding to its specific target, would occur faster than in cold temperatures. To 
minimise the risk of non-specific staining, it was hypothesised that staining time could 
be reduced from 30min.  
Testing this hypothesis on CD11a showed promising results, as the positive population 
remained stable when comparing only 5min of staining to 30min of staining. The 
isotype control showed reduced non-specific specific binding (A). Approximately 10% 
of cells gained CD11a active staining in the 25min between experimental conditions. 
On the other hand, signal in isotype control was almost absent after 5min of staining 
time (1.48%), but rose to 8.39% after 30min, although the non-specific staining did not 
seem to overlap with cell populations stained with the CD11a active antibody. It was 
therefore considered reducing the staining time to 5min, with the signal lost being the 
caveat to reduce risks of non-specific staining. However, when staining for active 
CD11b for 5min or for 30min, clear separation of positive and negative population only 








Interestingly, while proportion of positive cells only increased by 5.9% when comparing 
5min to 30min of staining time, cells gained signal brightness as staining time 
Figure 3.2 The effect of staining time on active β₂ integrin staining. 
Healthy unstimulated PBMCs were stained for either 5min or 30min at 37°C. Cells were either 
stained with active CD11a (A), active CD11b (B, top) or active CD18 (B, bottom) or matched 
isotype controls. In the case of active CD11a and CD11b the same sample was stained for the 
respective times, while active CD18 was stained on two different samples. Experiment was 
done once for each β₂ integrin subunit. In B, Isotype control staining (shown in black) is 




increased. Furthermore, isotype control staining (shown in black) did not become more 
positive with increased staining time. A similar trend can be observed in active CD18 
(Figure 3.2B, bottom), where only 0.31% of cells are positive for active CD18. After 
30min of staining, not only signal brightness has increased but the percentage of active 
CD18+ cells has risen to 16.3%. Similar to CD11b, non-specific binding in isotype 
control (shown in black) does not seem to increase with a longer staining time of 30min. 
As no clear positive populations could be distinguished in either active CD11b or active 
CD18 stain, the staining time experiments were not repeated further.  
Clearly, β₂ integrin subunits differ in their optimal staining time. Even though β₂ integrin 
staining at 37°C risks increased levels of non-specific binding, this is not the case for 
every sample. From the different samples considered in Figure 3.2, this was only a minor 
problem in active CD11a, where non-specific binding was very low compared to active 
CD11a specific staining. For active CD11b and active CD18, non-specific staining 
could not be observed at all. Based on these results, all staining was performed for 
30min so all active β₂ integrins could be detected. To ensure staining was not due to 
temperature-mediated non-specific binding isotype controls for the three active integrin 
antibodies were included in all future experiments.  
3.3.3 Validating a suitable positive control 
Before establishing if both total and active β₂ integrin antibodies can be used in the 
same panel, it first had to be ensured active β₂ integrins could be detected reliably and 
a suitable positive control could be validated. The positive control therefore requires 
high levels of active integrins. The three main ways to increase integrin activation are 
through monoclonal antibodies, which stabilise or induce the active conformation of 
the integrin subunit targeted (Byron et al., 2009), provision of divalent cations such as 
Manganese (Mn2+) (Dransfield et al., 1992), and stimulation with phorbol esters (Kucik 
et al., 1996). Adding further antibodies, even if not fluorescently-labelled, was 
immediately eliminated due to likely binding site overlap. While the addition of Mn2+ 
has been described to increase activation specifically of CD11b, the positive effect of 
the divalent cation on β₂ integrins can be diminished by the presence of Calcium (Ca2+) 
(Dransfield et al., 1992). While care was taken to only use Ca2+-free media, the 
potential variability of Mn2+ as a positive control made it a less viable option. Therefore, 
the addition of phorbol esters in the form of PMA to stimulate β₂ integrin activation on 




Phorbol esters, specifically PMA, have been described to increase integrin-mediated 
adhesion via protein kinase C activation (Danilov and Juliano, 1989). When 
considering β₂ integrins specifically, total expression levels of CD11a were unaffected 
by PMA stimulation, but adhesion to ICAM-1 and mobility of the subunit on the cell 
surface were increased (Kucik et al., 1996). This suggests that an increase in active 
CD11a, rather than total, contributed to this effect, making PMA a feasible possibility 
as a positive control. 100ng/ml PMA was added to staining buffer with active β₂ integrin 
antibodies, stained for 30min at 37°C and compared to -PMA (Figure 3.3). In contrast 
to evidence in the literature, the effect of PMA on CD11a was the least pronounced, 
with PMA only inducing a small shift in active CD11a signal (Figure 3.3A and B). Both 
CD11b and CD18, on the other hand, show pronounced increase in activation after 
30min of PMA stimulation, but result was not significant  for any of the β₂ integrin 
subunits of interest (Figure 3.3B). However, increase in activation upon PMA 
stimulation is especially apparent in CD18, which in this donor shows little active 
staining in the absence of stimulation with PMA, an observation that fits with the 
literature describing that most β₂ integrins are inactive on the cell surface in the steady 
state (Li et al., 2017).  
To conclude, PMA stimulation occurring concurrently with antibodies staining induced 
a visible shift in active CD11b and CD18 in the dot plot and histogram overlays. This 
result was not significant due to the variability of the response induced, but the marked 
shift visible in the histogram suggests that PMA stimulation is a viable positive control 
for activation-specific integrin staining. Although the shift observed in CD11a was very 
small, this could be due to the high levels of activated CD11a already detected on cell 
surfaces without stimulation, possibly leaving little room for further increase. This 
possibility could be assessed further when staining both active and total CD11a on the 
same cells, as the % of CD11a total expressing cells expressing CD11a active could 









Figure 3.3 Effect of PMA stimulation on β₂ integrin activation 
A healthy PBMC sample was stained for active CD11a, CD11b and CD18 respectively without or in 
the presence of 100ng/ml of PMA. A. Overlays of PMA-stimulated and unstimulated samples. 
Unstimulated cells are shown in red, PMA-stimulated cells are shown in blue, representative plots of 
both SSC-A (top) and histogram overlays (bottom) are shown for each active β₂ integrin subunit. 
Plots are representative of 3 donor samples in 3 independent experiments for each β₂ integrin 






3.3.4 Assessing steric hindrance and FRET 
After ensuring activation-specific β₂ integrin staining can be detected and controlled 
for, it was then assessed if total and active integrin expression could be measured in 
the same sample. The challenge with this set-up is that an active subunit is the target 
of two antibodies simultaneously binding in close proximity. Furthermore, as α (CD11a 
or CD11b) and β (CD18) subunits are non-covalently associated with each other, up 
to four mAbs (two for determining total expression of the α and β subunits, and two for 
determining the active forms of these subunits) are vying for their epitope on the same 
adhesion protein complex. This could lead to loss or gain of signal either due to steric 
hindrance or fluoresecent resonance energy transfer (FRET), respectively, so both had 
to be kept in mind when designing and optimising this panel. 
Steric hindrance describes the physical inaccessibility of antibody-binding sites due to 
another space-filling molecule, in this case the corresponding antibody, obstructing 
access to the binding site (Rubenstein and Leute, 1976). This would potentially lead to 
loss especially of the total signal, as activation-specific antibodies primarily bind in the 
β₂ integrin binding site only accessible when the respective integrin is in its extended 
form. This extension process rapidly increases binding affinity to its ligand, potentially 
making it a much easier target for activation-specific antibodies compared to total 
antibodies binding in an area which does not increase in binding affinity (Hughes and 
Pfaff, 1998) To assess if the respective total and active antibodies were susceptible to 
steric hindrance, double staining of both total and active integrin subunits was 
performed and compared to the respective single stained sample (for examples of 
CD11a, CD11b and CD18 see Figure 3.4A, B and C respectively). Signal loss as a 
percentage of the single stain was recorded in three separate healthy control samples, 
comparing both -PMA and +PMA samples to ensure that increased activation did not 
increase signal loss (see Figure 3.4D). A significant change in percentage of cells 
expressing either total or active β₂ integrin marker cannot be observed in any of the 
markers when stained simultaneously for active and total markers of CD11a, CD11b 
or CD18. Overall any differences in % seem to be between ±0.1-4.5%, with the highest 
recorded increase of signal in CD18 active at +11%. However, as this was only 
observed in one sample out of three and steric hindrance would not cause an increase 
in signal, this was not further followed up. In addition to % of cells expressing a marker 
after double staining, the staining brightness in the form of MFI was also considered 




surface receptors rather than a % of cells. Figure 3.5A shows the single stains of total 
and active CD11a, CD11b and CD18 compared to their respective signal brightness in 
the double stained sample. While there is no visible signal loss in any of the active β₂ 
integrins, nor CD11b and CD18 total, CD11a total is higher in the single stain when 
comparing it to its respective double stain. This loss of signal brightness when staining 
total and active CD11a together is statistically significant in non-stimulated cells (Figure 
3.5B), with cells stained with both antibodies having a 50-60% lower MFI than cells 
stained with the CD11a total antibody alone. Interestingly, this effect, while visible, is 
not statistically significant in the PMA-stimulated cells. This is puzzling as one could 
expect that higher activation due to PMA would increase steric hindrance and therefore 
CD11a total signal loss. However, when keeping in mind that PMA was less able to 
stimulate CD11a active compared to active CD11b and CD18, this could also point 
towards maximum activation being achieved even without PMA. In this case, one could 
speculate that PMA increased cycling rates of CD11a, which might in turn result in less 
CD11a total signal loss because inactive CD11a subunits are returned to the cell 
surface at a higher rate. It is also surprising that the loss of total CD11a signal does 
not affect active CD11a signal, as one might suspect. However, despite loss of signal, 
total CD11a can still be detected at high levels compared to an unstained control, 




  Figure 3.4 Staining for total and 
active β₂ integrins simultaneously 
does not lead to signal loss in % 
due to steric hindrance 
PBMCs were stained with either total 
(single stain total), active (single 
stain active) or both total and active 
β₂ integrin antibodies (double stain).  
Representative plots show 
unstimulated CD11a (A), CD11b (B) 
and CD18 (C). D. Loss of signal was 
calculated by subtracting % of 
respective double stain from % of 
single stain with (+PMA) or without (-








Figure 3.5 Loss of signal brightness due to steric hindrance 
Data set shown is the same as in Figure 3.4, but in regards to signal brightness measured in MFI 
rather than %positive expression. A. Representative histograms show single total stain (shown in 
blue, top) and single active stain (shown in yellow, bottom) in comparison to respective double 
stain (shown in green). Only unstimulated samples are shown. B. Loss of signal brightness was 
calculated by subtracting MFI of respective double stain from MFI of single stain with (+PMA) or 




FRET describes the non-radioactive energy transfer between two fluorochromes 
where the emission energy of one corresponds with the activation energy of the other, 
resulting in an increase of signal (Horváth et al., 2005). While this can be exploited for 
flow cytometry and microscopy purposes, in this case FRET pairs were deliberately 
avoided when choosing which colours to use for the respective active and total 
antibody fluorochromes. As published literature has shown that the distance between 
associated CD11b and CD18 subunit is only 8.2nm (Fan et al., 2019) and FRET can 
occur over short distances from 1-10nm (or 10-100Å), care was also taken that α-
subunit and β-subunit antibodies were not FRET pairs.  
Overall, no significant signal loss occurs in percentage of cells expressing one of the 
β₂ integrin subunits due to steric hindrance. However, when considering loss in signal 
brightness, CD11a total showed considerable significant signal loss, which was not 
shared by any of the other total or active subunits. This is a valid concern, as loosing 
over half of the signal brightness of CD11a total suggest that signal loss due to steric 
hindrance occurs frequently. On the other hand, the high consistency in % of MFI signal 
lost between repeats using different healthy donors suggests that comparing a double-
stained (i.e. total/active CD11a) sample to another double-stained sample would still 
give accurate results. Especially considering the absence of signal loss in the other 
markers considered, the ability to still record total CD11a expression levels although 
at lower levels and the importance of CD11a for this project, it was decided to proceed 
with simultaneous staining for active and total subunits of CD11b, CD18 and indeed 
CD11a. However, loss of CD11a total brightness due to steric hindrance has to be kept 
in mind when designing experimental controls. 
3.3.5 Active integrin panel: Titration of antibodies 
After having established that total and active β₂ integrins can indeed be stained 
together, although with some signal loss of CD11a total, I then turned to the 
development of an active integrin panel. Before the panel could be used to stain a 
healthy human sample, all antibodies had to be titrated for optimal performance on 
freshly isolated PBMCs (Hulspas et al., 2009). 
 Multicolour dot plots of each titration were compared to a histogram overlay of all four 
titrations. In addition, a titration curve was attained by calculating a stain index (SI) for 
each titration and plotting them against the increasing dilutions of antibodies. All 




cases warranted choosing the titration with a clearly delineated positive population 
over the highest SI value. As an example, the dot plot, histogram overlay and titration 
curve of CD11b total are presented in Figure 3.6. Figure 3.6A shows a representative 
multi-colour flow plot and histogram of positive CD11b total staining (1:100 dilution), on 
healthy PBMCs where debris has been gated out. Histograms of different dilutions, 
1:10, 1:50, 1:100, 1:200, were overlaid and signal brightness as well as cell number 
stained positive were considered (Figure 3.6B). 1:10 dilution showed the lowest signal 
both in brightness and cell numbers stained, followed by 1:50. 1:200 shows highest 
staining brightness, but 1:100 shows the largest number of cells stained positive for 
total CD11b. Then the respective SI values were calculated using the mean of the 
positive and negative populations as well as the SD of the negative population (Figure 
3.6). SI values remained stable before falling off at 1:200, signalling that staining 
efficiency is compromised at this titration. Manufacturer’s recommendation suggested 
1:10 dilution, however 1:100 dilution shows most stained cells in overlay and highest 
stain index before signal intensity falls off. The 1:100 dilution was chosen for the CD11b 









 Figure 3.6: Example titration procedure using CD11b total antibody. 
Healthy unstimulated donor PBMCs were stained with different dilutions of CD11b total 
antibody for 30min. A. Example of multi-colour flow plot for CD11b at 1:100 titration, clearly 
identifying positive (CD11b+) and negative (-ve) population. B. Histogram overlay of four 
titrations: 1:10, 1:50, 1:100 and 1:200 










 are the mean of the +/-ve population respectively and 𝜎𝑛𝑒𝑔 is the standard 
deviation of the –ve population based data spread in flowjo. N=1, although further repeats 










6.7 BV421 BD 
Biosciences 
1:20 10μg/ml 
CD18 active m24  AF 488 BioLegend 1:10 10μg/ml 
CD11a  
total  
HI111  PE BioLegend 1:50 2μg/ml 
CD11a 
active 
MEM-83 AF 700 Novus bio 1:100 9.5μg/ml 
CD11b total ICRF44  BV785 BioLegend 1:100 1.5μg/ml 
CD11b 
active 
CBRM1/5  APC BioLegend 1:50 4μg/ml 
CD11c BU15  APC-Cy7 BioLegend 1:100 4μg/ml 
CD141 M80 PE-Cy7 BioLegend 1:50 4μg/ml 
HLA-DR G46-6 BV480 BD 
Biosciences 
1:50 2μg/ml 
CD1c  L161  PerCP-Cy5.5 BioLegend 1:100 2μg/ml 
CD14 M5E2  BUV737 BD 
Biosciences 
1:50 1μg/ml 
CD16  3G8  PE-Dazzle594 BioLegend 1:200 0.25μg/ml 












































3.3.6 Gating strategy 
After determining optimal antibody titration for this application, a gating strategy was 
devised to distinguish the different cells of interest (cDC1, cDC2 and pDCs, CD14+ and 
CD16+ monocytes) and measure β₂ integrin expression and activation on their 
respective surfaces. 
The full gating strategy is presented in Figure 3.7, after a panel designed by Dr. David 
McDonald, Experimental Scientific Offier, Flow Cytometry Core Facility, Newcastle 
University. Markers chosen were based on a panel that had been successfully used to 
distinguish DCs in the lab before (Wood et al., 2019). First, cell debris and doublet cells 
were excluded, as well as all dead cells and lineage+ cells. Lineage markers included 
CD3, to exclude both CD4+ and CD8+ T cells, as well as CD19 and CD20, to exclude 
B cells, and lastly CD56, to exclude NK cells. Then all CD45+ cells are considered in 
respect to their HLA-DR and CD11c expression, identifying the HLA-DR high but 
CD11cneg pDCs and a HLA-DR+CD11c+ APC population. These APCs were split up 
into classical and non-classical monocytes, using high CD14 and high CD16 
expression respectively. Lastly CD14negCD16neg cells were assessed according to their 
CD1c and CD141 expression, with cDC1 cells expressing high CD141 and cDC2 cells 




3.3.7 Experimental controls 
Experimental controls were included to assess validity of each experiment. In addition 
to a completely unstained control, a ‘negative’ control where no β₂ integrin subunits 
were stained for was included to yield a baseline for integrin expression on the 
background of the lineage markers. As detailed above (Figure 3.3), a +PMA positive 
control was included. Lastly, an isotype control was included, where total β₂ integrin 
antibodies were stained as normal and individual active integrin antibodies were 
replaced by matched isotype controls with the fluorochromes and concentrations 
corresponding to the active β₂ integrin antibodies. This control also doubles a single 
stain reference for CD11a total, enabling us to validate any future results with the total 
stain unaffected by steric hindrance. While this does not satisfy our aim to detect total 
and active β₂ integrin subunits in the same sample at the same time, it can still provide 
a frame of reference how much signal was lost to steric hindrance and if this affects 
any results observed in the samples stained with both active and total CD11a 
simultaneously. 
An example of all experimental controls in a healthy control sample can be seen in 
Figure 3.8. The negative control is void of all total and active integrin staining (2nd row), 
 
 Figure 3.7 Gating strategy for APCs in active β₂ integrin panel 
Demonstration of gating strategy on healthy control, to distinguish between different cell types 
capable of presenting antigen, including CD14+ monocytes, CD16+ monocytes, cDC1 DCs, cDC2 
DCs and pDCs. Representative plots are from a healthy control PBMC sample. This gating strategy 




the isotype control is void of active integrin staining only (3rd row), and the +PMA control 
(4th row) shows increased staining compared to staining for all β₂ integrin antibodies in 
the absence of stimulants (experimental condition, 1st row). Gates shown are based 
on the experimental condition (1st row) to demonstrate respective differences in β₂ 













 Figure 3.8: Experimental controls used in active β₂ integrin staining panel 
Total and active CD11a, CD11b and CD18 are shown in the experimental condition (1st  row), 
as well was three appropriate experimental controls below it. The negative control (2nd row) 
was stained with the lineage markers but without any total or active β₂ integrin antibodies. 
The isotype control (3rd row) was stained with the lineage markers and total β₂ integrin 
antibodies, but active β₂ integrin antibodies were replaced with matched isotype controls. The 
positive control (4th row) was stained exactly as the experimental condition but in the 
presence of 100ng/ml PMA. Representative plots from a single healthy control sample are 
shown, gates shown were drawn around experimental condition and copied to other control 




3.3.8 Potential of using active integrin panel on human tissue 
As this panel was developed for the investigation of β₂ integrin expression and 
activation states on APCs in the context of the autoimmune disorder RA, the joint-
specific nature of the disease had to be taken into account. To this end, it was tested 
if the panel could not only assess β₂ integrins on cells isolated from PB and SF, but 
also on cells that were present in ST. As ST requires both mechanical and enzymatic 
digestion to yield a single cell suspension viable for flow cytometry analysis, it was 
therefore important to test if β₂ integrins would be cleaved or otherwise altered during 
the lengthy tissue digestion protocol.  
To test for this eventuality without utilising precious synovial tissue samples, PBMCs 
were isolated and treated with the enzymatic digestion protocol optimised for ST 
(Wood et al., 2019). While ST is subjected to the enzymatic digestion for up to three 
cycles a 45min, PBMCs were only subjected to one round of digestion with the same 
concentrations used for ST of 15μg/ml Liberase and 30μg/ml DNAse for 45min at 37°C, 
as they already were in the single cell suspension the digestion is supposed to achieve. 
PB and ST cell exposure to the digestion enzymes is, therefore, assumed to be similar. 
Figure 3.9 shows the result of this investigation, with an example overlay of β₂ integrin 
staining in undigested and digested PB samples (Figure 3.9A). No significant signal 
loss occurs in any of the markers but CD18 total (Figure 3.9B), which is significantly 
lower in digested sample compared to undigested sample. On the other hand, CD18 
active signal is not affected by the digestion process. CD11a total surprisingly showed 
an increase in the marker in one experiment, but this appears to be an outlier.  
Overall, enzymatically digesting PBMCs does not cleave the majority of our β₂ integrins 
of interest off cell surfaces and staining of all subunits considered stays viable. The 
exception to this is CD18 total which is significantly reduced in digested samples. 
However, this is not mirrored in signal loss of total CD11a or CD11b, suggesting that 
this is a direct effect on CD18. It is however also possible that digestion enzymes 
preferentially cleave CD11c or CD11d, which would in turn cause the loss of CD18 
total staining. Lastly the increase in sample processing time due the digestion step 
might have a different effect on CD18, or indeed CD11c and CD11d, than on CD11a 
and CD11b. If using this flow cytometry panel on ST samples, direct comparison to 
blood or other tissues would have to be exercised with caution due to the potential 








 Figure 3.9: Effect of ST digestion protocol on total and active β₂ integrin staining 
Healthy PBMCs were either kept on ice or subjected to a 45min digestion protocol in a shaking incubator 
at 37°C in the presence of 15μg/ml Liberase and 30μg/ml DNAse. After washing digestion enzymes off, 
undigested and digested samples were stained with the full active β₂ integrin panel. Cells shown are 
LIN-CD45+HLA-DR+. A. A representative overlay of undigested (shown in red), digested (shown in 
purple) and unstained control cells (shown in grey) in respect to their total and active β₂ integrin 
expression. Statistics shown were determined between undigested and digested sample MFI signals 
using a paired student’s t test. N=3. B. Difference between MFI values of undigested and digested 
samples. A negative value signifies a loss of signal; a positive value indicates that signal has been 





3.3.9 The effect of sample preservation on active integrin staining 
Circumstances of clinical research, including use of biobank samples and short-term 
unavailability of flow cytometers due to technical problems, sometimes make the use 
of sample preservation for later analysis of samples necessary. As the β₂ integrin 
activation panel was meant to be as widely usable as possible for potential future 
applications, the effect of common sample preservation methods on integrin 
expression and activation was assessed. These were (i) paraformaldehyde (PFA) 
fixation of stained samples; and (ii) freezing of PBMCs. This was of importance as 
available literature suggested that integrin expression and especially activation, which 
can occur on very short timeframes, can be heavily influenced by the medium 
surrounding it, such as in the case of cation availability (Zhang and Chen, 2012).  
First, the effect of PFA-fixation, which is a widely accepted method for preserving flow 
cytometry samples for up to a week after staining (Lanier and Warner, 1981), on active 
β₂ integrin expression was assessed. For this, PB samples were stained with total and 
active β₂ integrin antibodies (CD11a, CD11b and CD18) and split in two, one to be 
analysed immediately and one to be fixed using 1% PFA, which was not washed off 
before flow cytometry analysis 6 days later. As visible in Figure 3.10, very little signal 
brightness was lost after 6 days of PFA-fixation. Neither total nor active CD11a, CD11b 
or CD18 showed any significant loss in signal brightness. Interestingly, CD18 total 
increased in signal brightness in two out of three repeats, although the increase was 
not significant. It is not likely that this increase is due to an increase in autofluorescence 
due to PFA fixation (Stewart et al., 2007), as such autofluorescence would affect 
colours in the green/yellow laser range, such as FITC, and not BV421, which is the 
fluorochrome used for CD18 total. Interestingly, active CD18 shows no significant 
difference in signal brightness between freshly stained and fixed samples, but all three 
repeats show variation in the percentage of cells positive at a specific brightness, as 
visible in the larger proportion of fixed cells high in active CD18 expression (Figure 
3.10A). This change in proportions is however not mirrored in active CD18 MFI values, 
which could suggest some cell populations might be more prone to being gated out as 







 Figure 3.10: Effect of paraformaldehyde-fixation on total and active β₂ integrin staining 
A healthy control PBMC sample was stained with the full active β₂ integrin panel and split into two, 
one to be acquired immediately, while the other was fixed using 1% PFA and acquired 6 days later. 
Cells shown are LIN-CD45+HLA-DR+. A. A representative overlay of freshly stained (shown in red), 
paraformaldehyde-fixed (shown in blue) and unstained control cells (shown in grey) in respect to their 
total and active β₂ integrin expression. B. Difference between MFI values of fixed and unfixed 
samples. A negative value signifies a loss of signal; a positive value indicates that signal has been 
increased due to the fixation process. Statistics shown were determined between freshly stained and 





In conclusion, fixation does not alter β₂ integrin staining in any of the active or total β₂ 
integrins, CD11a, CD11b or CD18. However, reasons for the high CD18 total staining 
in two out of three samples could not be completely elucidated. It was therefore 
decided to acquire samples immediately after staining and only rely on fixing samples 
in the event of an unusable flow cytometer. In this eventuality, measurements for total 
CD18 staining would not be included in the analysis to avoid skewing of the data. 
While I had access to fresh samples from Rheumatology clinics and healthy donors 
alike, samples collected for disease-specific biobanks are frequently stored in frozen 
form. To explore the feasibility of using such biobank samples for active integrin 
staining, PBMCs were isolated and stained a proportion of cells immediately, whereas 
the rest was frozen for 2-4 weeks and stained after thawing.  
Results of this enquiry can be seen in Figure 3.11, with an overlay of a healthy control 
sample that was either freshly stained or freeze-thawed before staining. Overall, there 
is no significant increase or decrease in any of the β₂ integrin subunit signals when 
comparing freshly stained to thawed samples (Figure 3.11B). However, when looking 
at the histogram overlays (Figure 3.11A), freshly stained and freeze-thawed samples 
do not overlap neatly, even though the differences are not significant. One possible 
explanation for this could be the freezing protocol utilised, which suspends cells in 
10%DMSO 90%FCS. Both the addition of a high concentration of DMSO and the 
increased availability of FCS might cause subtler variations in β₂ integrins expressed 
and activated on the cell surface. Furthermore, the thawing process, which involves 3 
washing steps to ensure DMSO is removed fully, could equally increase cell activation 
and increase cell death, changing the composition of the live cells gated on.  
To conclude, neither fixing nor subjecting cells to a freeze-thawing cycle caused 
significant cleavage of β₂ integrins off the cell surface or deactivation of subunits, 
making both the use of fixed or biobanked samples possible with this panel. However, 
as small changes in both total expression and activation of β₂ integrins do seem to 
occur, it would be best practice to keep conditions between samples as similar as 
possible. As my project did not involve using biobanked samples, it was therefore 
decided to stain all samples fresh on the day of collection to avoid introducing further 







Figure 3.11 Effect of freeze-thawing on total and active β₂ integrin staining 
Healthy control PB samples were stained with β₂ integrin antibodies (active and total) and split in two 
parts, one to be analysed on the BD LSR Fortessa immediately, while the other was fixed using 
1%PFA and analysed a week later. Cells shown are LIN-CD45+HLA-DR+. A. A representative overlay 
of freshly stained (shown in red), freeze-thawed (shown in green) and unstained control cells (shown 
in grey) in respect to their total and active β₂ integrin expression. B. Difference between MFI values of 
freshly stained and freeze-thawed samples. A negative value signifies a loss of signal; a positive value 
indicates that signal has been increased due to the cryopreservation. Statistics shown were 







The aims of this chapter were the optimisation of detecting both total and active β₂ 
integrins on the surface of APCs. In this chapter, I have developed a flow cytometry 
panel that can measure expression of not only total but also active β₂ integrin subunits 
CD11a, CD11b and CD18 in a defined group of APC populations of interest. The 
staining protocol was optimised in respect to staining time and temperature and signal 
loss due to steric hindrance or FRET was assessed to be kept to a minimum. Positive 
and negative controls for the panel were developed. Furthermore, durability of this 
panel across cells from different sources or from different sample preservation 
methods was revealed, to ensure that the panel can be utilised as broadly as possible. 
This attempt to assess expression and activation on a variety of different APC 
populations present in blood holds both caveats and strengths, which are important to 
consider when evaluating any novel knowledge gained from this approach. 
3.4.1 Limitations of the active β₂ integrin staining protocol and panel 
There are several limitations of both the β₂ integrin staining procedure and the active 
integrin panel that need to be considered.  
Macrophages 
While the active integrin panel distinguishes a range of different APCs, one cell type is 
markedly absent: the macrophage. Although these cells could contribute to the 
initiation of RA, they are better known for their roles in pathology and disease activity 
(Janossy et al., 1981; Kinne et al., 2000). As an example, Haringman and colleagues 
(2005) showed that the number of macrophages present in the synovial sub-lining is a 
potent biomarker for disease activity and correlates well with successful therapeutic 
intervention. The option of including macrophages in our analysis was explored by 
trying to free up a flow cytometry channel to detect autofluorescence. In addition to 
being high in CD14 and HLA-DR, high autofluorescence of macrophages is used in 
the literature to distinguish them from monocytes (Wood et al., 2019). However, CD18 
active, which was not available in a range of colours, already occupied the FITC 
channel and adding further parameters to a 14-colour flow cytometry panel proved 
difficult due to laser and fluorochrome limitations. The addition of further markers to 
allow the identification of macrophages would have had a negative impact on other, 




panel in PB and SF where macrophage numbers are absent or low, respectively, 
exclusion of macrophage markers was thought not to impede the analysis significantly.  
Integrin subunits 
Other markers that had to be left out due to panel size restrictions, CD11c and CD11d, 
could similarly be considered a caveat. However, published literature points especially 
to the similarities as well as the differences between CD11a and CD11b. Research 
shows that adhesion to endothelial cells is 50% due to CD11a and 50% due to CD11b, 
while blocking CD11c had no effect on adhesive capabilities of cells (Lo et al., 1989). 
Similarly, increasing the amount of active CD11a (Balkow et al., 2010) and active 
CD11b (Varga et al., 2007) on DCs was found to inhibit their ability to activate T cells. 
While this highlights the overlapping functions of CD11a and CD11b, published 
literature also shows functions that are unique to either α-subunit respectively. 
Especially mouse KO studies have been helpful in elucidating β₂ integrin α-subunit 
specific functions. For example, CD11b is important for neutrophil adhesion and 
degranulation, but insignificant for cell emigration into tissues, which is mediated by 
CD11a (Lu et al., 1997). However, elucidating β₂ integrin α-subunit specific functions 
is very reliant on mouse KO models of the individual subunits. This means that there 
is very little knowledge about how CD11a and CD11b interact in a healthy person 
compared to someone who has a chronic inflammatory condition. Therefore, 
comparing CD11a and CD11b specifically is of great value to contribute to our 
knowledge of their similarities and differences.  
Integrin signalling 
Another aspect to keep in mind when interpreting results is that there are several 
aspects of integrin signalling that cannot be assessed using the active integrin flow 
cytometry panel. For example, as mentioned above, integrin clustering rather than its 
affinity (conformational state) can be as important for function as activation. Any results 
regarding β₂ integrin activation status will therefore have to be carefully examined to 
not draw conclusions prematurely. Additionally, measuring β₂ integrins using flow 
cytometry is quantitative on the population level and not on a cell-by-cell basis. This 
might potentially lead to misunderstandings or misinterpretation of results. Rather than 
measuring total number of active or total integrins per cell, this method can only state 
signal brightness or the proportion of cells that are positive for a marker. To give an 




conformation on cell surfaces under steady conditions (Li et al., 2017), while my results 
record levels of active integrins between 15-99% (Figure 3.4A, B and C). While this 
disparity could be due to differences between β₂ and β1 integrin subfamilies, it is also 
due to the fact that this method cannot measure the exact number of integrin receptors 
per cell and, instead, measure the percentage of cells that have at least one active 
integrin on their surface. It is possible they have more, due to the potential removal of 
Ca2+ by EDTA (present in FACS buffer), which plays an important role to restrict 
integrin activation in blood (Dransfield et al., 1992), but this can only be measured non-
quantitatively using the respective signal brightness. Therefore, all results gained from 
the active integrin flow cytometry panel will be compared to the same marker on 
different cell types or clinical samples.  
These limitations discussed here should be kept in mind when assessing future results 
generated using the active flow cytometry panel. However, the strengths of this panel 
far outweigh its minor limitations.  
3.4.2 Strengths of the active β₂ integrin staining protocol and panel 
While there are some accepted limitations associated with this newly developed flow 
cytometry panel, it is also important to point out the strengths and scientific potential 
of this method.  
Total and active integrins 
Quantification of expression levels of both the total and active forms of the same β₂ 
integrin subunit in the same sample is of immense value to the scientific community. 
To my knowledge, this has not been done before. This is especially important as our 
knowledge of how integrin activation might differ between cell types or in disease is 
very limited. For example, differences in β₂ integrin expression or activation between 
cell types might contribute to our understanding of their distinct and overlapping 
functions. Furthermore, balance of β₂ integrin expression or activation might be altered 
in disease and either contribute to or further exacerbate symptoms. Assessing total 
and active β₂ integrins in the same sample will therefore give us a breadth of 
information not accessible before. It also provides valuable proof of concept, that will 
allow the practice to become more widespread, providing valuable further information 




It also important to mention here the use of several controls that strengthen any results 
generated using the active integrin panel. An appropriate positive control was validated 
in the form of PMA activation, and the negative control was expanded to include an 
isotype control that is necessary due to the temperature-sensitive nature of detecting 
activated β₂ integrin subunits, especially CD11b and CD18. Although some signal loss 
of CD11a total due to steric hindrance occurs when staining for total and active CD11a 
simultaneously, the isotype control includes a single stain of all total antibodies. 
Therefore, any results involving CD11a total can be confirmed with the single-stained 
CD11a total signal, further strengthening any findings. 
APC populations of interest 
Another strength of the active integrin panel is the wide range of APC populations it 
will assess. This is especially important as, due to the quantification of populations 
rather than single cells described above, comparing different specific cell subtypes 
(such as cDC1 vs. cDC2) will be valuable in understanding how these cells differ from 
each other in regards to their β₂ integrins. pDCs are similarly interesting, as they 
primarily respond to viral infections rather than activating naïve T cells. Comparing how 
conventional DCs differ from pDCs therefore might give insights into how β₂ integrins 
might contribute to these different ways of linking the innate to the adaptive immune 
system. While this project is focused on DCs in particular, monocytes also present 
antigen, although to a lesser level. Including them in our analysis will therefore give us 
valuable insight into how β₂ integrin surface expression and activation relates to a cells 
ability to adhere to β₂ integrin ligands, migrate and contribute to T cell activation. 
Broad applications of the active integrin panel 
Samples that were previously frozen or fixed after staining using PFA show no 
significant signal gain or loss in any of the β₂ integrin subunits assessed (Figure 3.10, 
Figure 3.11). This means that the panel could potentially be used on any biobanked 
disease samples, making it possible to validate if effects are disease-specific or in the 
broader context of inflammation. The possibility of fixing samples without significant 
signal loss is similarly important, as it ensures that staining remains viable if the flow 
cytometer usually used has technical problems. While not feasible in the context of this 
project, it would also allow staining to be done freshly on samples remotely, before 
analysis of the fixed sample after transport back to appropriate facilities. This might be 




Furthermore, it could be demonstrated that no signal loss occurred in any of the 
subunits except CD18 total when using a tissue digestion protocol (Figure 3.9). This 
means that the panel can not only be used in PB, SF or cells isolated from other bodily 
fluids, but also on cells isolated from tissues. This could be especially interesting when 
investigating the effect of β₂ integrins on highly tissue-specific conditions, such as RA 
or celiac disease. As β₂ integrins might also have an important role in cancer 
(Bednarska et al., 2016), this also suggests that the panel could be used on tumour 
biopsies to compare to healthy tissue samples and assess β₂ integrin contribution to 
tumour maintenance. 
3.4.3 Differences between β₂ integrin subunits identified 
Several structural differences between β₂ integrin subunits became apparent during 
the staining optimisation process. Mostly these differences exist between CD11a and 
both CD11b and CD18, which seem to behave more similarly to each other. While 
CD11a was the only subunit where the active conformation was significantly decreased 
in low temperatures, this was due to a very small amount of signal lost, as visible in 
the overlay (Figure 3.1). On the other hand, both active CD11b and CD18 were not 
significantly lower at cold temperatures, but a much larger shift occurred between warm 
and cold staining temperature, with active CD18 being virtually undetectable at 5.6°C 
in all three experiments. While this effect might simply be due to individual protein 
structure generally being more or less vulnerable to changes in temperature, the 
difference between CD11a and the other β₂ integrin subunits could also signify a 
functional difference. Although this has not been demonstrated for β₂ integrins, a link 
between fever and integrin-mediated homing of immune cells has been recently 
identified (Lin et al., 2019), potentially suggesting that differential temperature control 
between integrin subunits has to be in place to control for this.  
While the effect of staining time on CD18 could not be assessed due to time 
constraints, differences occurred between CD11a and CD11b in regards to their 
staining time (Figure 3.2). Active CD11a was detected at high levels on the cell surface 
after only 5min, while active CD11b increased in signal brightness over time. One might 
argue that is merely due to more β₂ integrins becoming active, but this is unlikely as 
this occurs within very short time frames, so could easily be achieved in 5min of 
staining time. It is therefore more likely that this this effect is due to differences in β₂ 
integrin trafficking between cell surface and cytoplasm. Only 1% of CD11a molecules 




all cell surface molecules being endocytosed and returning to the cell surface every 
minute (Bretscher, 1992). This makes it likely that most CD11a subunits to be stained 
would be on the surface already when only stained for 5min, while the increased 
cycling speed of CD11b might lead to new receptors appearing on the cell surface 
throughout the 30min staining process. However, this also raises the question if the 
CD11b antibody would be internalised at higher rates due to the higher cycling speed 
of CD11b. While this is certainly a possibility, it seems unlikely that signal is lost due 
to internalisation as fast as signal is gained from more CD11b appearing on the cell 
surface, as we see an increase in signal over time. Another potential reason for this 
difference would be that CD11a and CD11b have different rates of cycling between 
active and inactive conformation on the cell surface, rather than cycling between 
cytoplasm and cell surface. However, by my knowledge this has not been shown in the 
published literature so far. 
The difference between CD11a on one hand and CD11b/CD18 on the other is revealed 
again in the effects of PMA activation. Clear shifts in subunit activation occurred in 
CD11b and CD18, but only a subtle shift occurred in CD11a (Figure 3.3) although none 
of these were significant when looking at only 3 samples, with some experiments 
showing loss of CD11a activation upon PMA stimulation (Figure 3.8). This is especially 
puzzling because CD11a was one of the first β₂ integrins identified to increase 
adhesive capabilities of cells upon PMA-stimulation (Patarroyo et al., 1985), posing the 
question how adhesion can be increased without visible activation. While the specific 
mechanism by which the protein kinase C activator, PMA, increases integrin-mediated 
adhesion is not fully elucidated, there is some evidence that it is due to downstream-
signalling events rather than a direct phosphorylation of the integrin subunit (Danilov 
and Juliano, 1989). One possibility is therefore that the increase in adhesion in 
response to PMA is due to receptor avidity rather than affinity. Supporting this, Kucik 
and colleagues showed that PMA increases non-directed CD11a mobility in 
lymphocytes, further suggesting that PMA releases cytoskeletal restraints on CD11a 
rather than acting on the integrin directly (Kucik et al., 1996). As active CD11a was 
detected on over 50% of cells, it is possible that levels of activation contribute less to 
adhesion than clustering behaviour of CD11a on the cell surface. Another possibility is 
that the mAb used to detect CD11a behaves differently compared to CD11b and CD18. 
While CBRM1/5, the antibody used to detect CD11b has been described to be a 




active CD11a is more complex. As well as binding to active CD11a, clone MEM-83 has 
also been shown to induce adhesion of T cells to ICAM-1, which led to the assumption 
that MEM-83 also actively contributes to inactive CD11a assuming its high affinity state 
(Binnerts et al., 1994; Hogg et al., 1993; Landis et al., 1993). It is therefore likely that 
instead of CD11a reacting differently to PMA compared to CD11b, that the antibody 
used to detect already increased levels of active CD11a to its maximum, leaving very 
little room for further increases. Indeed, if gating on all cells positive for total CD11a, 
close to 100% of them are positive for active CD11a, suggesting that MEM-83 indeed 
actively contributes to activation of CD11a.  
To conclude, several differences between CD11a and CD11b were detected during 
the panel optimisation process, which fit with published literature regarding differences 
in trafficking and avidity of these subunits. This is promising, as it further validates that 
we can effectively measure expression of total and active β₂ integrins, and that this 
measurement actually relates to their function. 
3.5 Conclusions 
I successfully developed a flow cytometry panel that allows me to quantify the total 
expression and activation-status of β₂ integrin subunits CD11a, CD11b and CD18. 
Furthermore, this panel can differentiate between a variety of APCs of interest, 
including cDC1 DCs, cDC2 DCs and pDCs, as well as CD14+ and CD16+ monocytes.  
After having established that total and active forms of an integrin can be stained in the 
same sample, the next step was to quantify the expression of total and active integrins 
in Mo-DCs and explore how their expression changes under conditions of activation 























  Characterisation and function of β₂ integrins on 





After having established that total and active β₂ integrins can be assessed on the 
same cells, I investigated expression and function of β₂ integrins in in vitro generated 
Mo-DCs. I hypothesised that β₂ integrins play an important role in mediating immune 
tolerance on DCs, which is however challenging to investigate in vitro. Therefore, I 
focused specifically on two Mo-DC culturing conditions that represent two extremes: 
mature Mo-DCs, which were found to elicit immune cell activation (Sallusto and 
Lanzavecchia, 1994; Zhou and Tedder, 1996), and tolerogenic Mo-DCs, which have 
tolerising and immunoregulatory roles (Anderson et al., 2008). While this does not 
mirror tolerance induction in DCs in vivo, mature and tolerogenic Mo-DCs still 
provided an excellent model system to investigate the roles of β₂ integrin expression 
and activation on DC-like cells between immune activation and tolerance.  
4.1.1 Mature and tolerogenic Mo-DCs 
Briefly, Mo-DCs were derived from human CD14+ monocytes isolated from healthy 
PB, that became DC-like after 7 days of culture in the presence of IL-4 and GM-CSF. 
Tolerogenic Mo-DCs received tolerising agents Dexamethasone as well as Vitamin 
D3, but both tolerogenic and mature Mo-DCs received stimulation with LPS on Day 6 
of culture. There are several reasons for choosing Mo-DCs to investigate potential 
immunoregulatory roles of β₂ integrins in DCs: 
First, they are an established in vitro model of DCs. While current literature suggests 
that most DCs present in PB in the steady state are myeloid- and not monocyte-
derived (Guilliams et al., 2014), studies also suggest that in vitro generated Mo-DCs 
and PB DCs share many common features. For example, Mo-DCs and CD11c+ PB 
DCs express similar levels of the antigen-presenting complex HLA-DR as well as 
costimulatory factors such as CD40, CD83 and CD86 (Osugi et al., 2002). 
Furthermore, Mo-DCs are able to present antigen and elicit T cell proliferation in an 
MLR (Sallusto and Lanzavecchia, 1994). With the knowledge that DCs only 
constitute 1% of PBMCs, culturing Mo-DCs from healthy blood monocytes therefore 
provides a viable option to generate stable DCs in sufficiently high numbers to test 
expression as well as functionality of β₂ integrins. 
Second, mature and tolerogenic Mo-DCs were selected because of their ability to 
activate and tolerise T cells, respectively, similar to cDCs. Tolerogenic Mo-DCs, 




anti-inflammatory cytokine profile, with higher expression of IL-10 and concurrent 
lower expression of IL-12p70, IL-6 and TNF-α when compared to mature Mo-DCs 
(Anderson et al., 2008). The same study also observed that mature Mo-DCs induced 
activation and proliferation of both naïve and memory T cells, while tolerogenic Mo-
DCs were significantly less capable to stimulate T cells. Lastly, naïve T cells that 
were primed by tolerogenic Mo-DCs produced more IL-10 upon restimulation with 
either mature Mo-DCs or anti-CD3/anti-CD28 while memory T cells were shown to be 
hyporesponsive to restimulation. Furthermore, tolerogenic Mo-DCs were found to 
control T cell activation by mature Mo-DCs in a co-culturing system where both 
mature and tolerogenic Mo-DCs were present (Harry et al., 2010). Comparing β₂ 
integrin expression and function between mature and tolerogenic Mo-DCs therefore 
provides the opportunity to investigate possible differences in a well-defined model 
system of immune stimulation (mature Mo-DCs) and regulation (tolerogenic Mo-
DCs). 
To conclude, respective phenotypes of both mature and tolerogenic Mo-DCs are 
well-described and large numbers of Mo-DCs can be generated in vitro relatively 
easily. Using mature and tolerogenic Mo-DCs therefore represent a useful tool to 
understand the role of β₂ integrins in immune activation and regulation. In addition, 
some properties of tolerogenic Mo-DCs described in the literature suggest a likely 
involvement of β₂ integrins in their function, which I will explore in the next section. 
4.1.2 The potential role of β₂ integrins on Mo-DCs  
After establishing that mature and tolerogenic Mo-DCs are a model system well-
suited to investigate the roles of β₂ integrins between immune activation and 
tolerance, it is important to discuss published literature that suggest differences in β₂ 
integrins between the two Mo-DC subtypes. 
Several studies have shown that genes encoding β₂ integrins are differentially 
expressed between CD14+ monocytes and Mo-DCs. For example, CD18 expression 
is increased in unstimulated (immature) Mo-DCs compared to monocytes (Angénieux 
et al., 2001). However, CD11a gene expression was downregulated in TNF-α 
stimulated Mo-DCs compared to monocytes, but did not differ between immature and 
mature Mo-DCs, alongside an upregulation of genes important for cell migration, 
such as macrophage capping protein and vimentin (Ivaska et al., 2007; Naour et al., 




measuring surface expression of β₂ integrins on mature Mo-DCs compared to CD14+ 
monocytes, which found higher expression of CD11c, CD11b and CD18, but lower 
expression of CD11a on Mo-DCs compared to monocytes (Ammon et al., 2000). 
Furthermore, previous experience in the Hilkens laboratory has shown that 
tolerogenic Mo-DCs adhere more tightly to plastic compared to mature Mo-DCs 
(unpublished observation). Keeping Mo-DCs for 60min on ice was therefore 
introduced into the protocol to enable sufficient harvesting of tolerogenic Mo-DCs. 
While plastic is obviously not a biological ligand for β₂ integrins, this suggests that 
adhesive capabilities are altered in tolerogenic Mo-DCs. This is further supported by 
the finding that mouse BMDCs with deficient β₂ integrin signalling show reduced 
adhesion to both ligands and plastic (Morrison et al., 2014). As adhesion is one 
function of β₂ integrins, it therefore seems likely that either expression or 
conformational state of the adhesion receptors differs between mature and 
tolerogenic Mo-DCs, thereby affecting Mo-DC adhesive capabilities.  
Another important function of β₂ integrins is cell migration. Migration of immune cells 
towards the LN and correct positioning in T cell zones is primarily mediated by the 
chemokine receptor CCR7 binding to CCL19 and CCL21 located in the LN. While 
tolerogenic Mo-DCs can migrate towards CCL19, they are reported to migrate with 
25-40% of the efficiency of mature Mo-DCs (Anderson et al., 2009, 2008), which was 
proposed to be due to the lower expression of CCR7 on tolerogenic compared to 
mature Mo-DCs. However, other studies suggest that β₂ integrins might also be 
involved. For example, in mouse, mature migratory DCs are shown to upregulate 
CCR7 while simultaneously downregulating β₂ integrins such as CD18 and CD11c 
(Morrison et al., 2014). Interestingly, the same study also showed that CCR7 is also 
upregulated in BMDCs when the kindlin-3 binding site of the β₂ integrin is mutated, 
reducing the integrins ability to form stable adhesions and making cells assume a 
mature migratory phenotype. Furthermore, both ligands of CCR7, namely CCL19 and 
CCL21, were shown to induce CD11a/CD18 activation on human Mo-DCs via inside-
out signalling (Eich et al., 2011; Quast et al., 2009). These seemingly conflicting 
reports suggest that β₂ integrins might be important to mediate migration of cells into 
the LN once they receive CCR7 stimulation. This is supported by the finding that 
TNF-α stimulated Mo-DCs from two patients with LAD-1, where CD18 expression is 
impaired, show decreased trans-endothelial migratory ability (Fiorini et al., 2002). 




tolerogenic compared to mature Mo-DCs might therefore go alongside as of yet 
undescribed differences in β₂ integrins, which are potentially regulated by CCR7 
signalling. When comparing different immunosuppressive agents (Vitamin D3, IL-10, 
Dexamethasone, TGF-β, rapamycin) meant to induce tolerogenicity in Mo-DCs, it 
was furthermore shown that agents eliciting little immunosuppression also show no 
reduction in migratory ability towards CCL19 and vice versa (Boks et al., 2012). In 
fact, the same study did not pursue Vitamin D3-treated tolerogenic Mo-DCs after 
finding that they showed lowest migratory ability of all agents tested. One could 
therefore hypothesise that gaining immunosuppressive and regulatory functions 
occurs simultaneously with loss of migratory capability, making a role for β₂ integrins 
in this context likely. This however also holds a caveat for future use of tolerogenic 
Mo-DCs as cell therapy, as low migratory ability might also impede their ability to 
travel to the draining LN and render T cells unresponsive. 
Lastly, β₂ integrins have also been described to play a role in DCs forming contacts 
with T cells through the immunological synapse. For example, ligation of CD11b on 
human Mo-DCs reduced both their expression of CD86 and their ability to stimulate T 
cells (Podgrabinska et al., 2009), which has also been found in murine BMDCs 
(Behrens et al., 2007). CD11b was also found to be involved in controlling peripheral 
tolerance by restricting Th17 cell differentiation (Ehirchiou et al., 2007). Furthermore, 
both the active conformation of CD11a and CD11b were found to restrict T cell 
activation (Balkow et al., 2010; Varga et al., 2007), suggesting an active role of β₂ 
integrins in mediating T cell contacts from the DC side. While tolerogenic Mo-DCs 
were shown to have reduced T cell stimulatory abilities (Anderson et al., 2008), β₂ 
integrin expression on their surface has not been assessed so far.  
To conclude, differences in adhesive and migratory capabilities between mature and 
tolerogenic Mo-DCs, as well as their respective ability to stimulate T cells, suggest 
that they differ in expression of total or active β₂ integrins. Identifying these 
differences and assessing their role for Mo-DC function could yield important insights 
into the immunoregulatory function of β₂ integrins on DCs. 
4.1.3 Aims 
The aims of this chapter are as follows: 





2) Define the adhesive and clustering capabilities of mature and tolerogenic Mo-
DCs.  
3) Investigate the functional impact of CD11b manipulation on Mo-DC phenotype 
and T cell priming ability. 
4.2 Results 
4.2.1 Generation and phenotypic analysis of mature and tolerogenic Mo-DC 
populations  
First, populations of mature and tolerogenic Mo-DCs were generated by in vitro 
culture and characterised phenotypically and functionally. This was to ensure that 
culturing of mature and tolerogenic Mo-DCs was successful and could be compared 
to published literature. Additionally, phenotyping of Mo-DCs ensured consistency 
between Mo-DCs cultured from different healthy donors or on different days. To this 
end, immature Mo-DCs, mature Mo-DCs (LPS) and tolerogenic Mo-DCs 
(Dexamethasone+Vitamin D3+LPS) were compared for expression of key cell surface 
markers. While immature Mo-DCs were included in all cultures as an internal control 
for phenotyping purposes, they were not of special interest to the understanding of 
the role of β₂ integrins in Mo-DC between activation and tolerance, so this group is 
included in figures only if they are of interest to the question at hand. 
First, expression of CD14 and CD1c were assessed. A hallmark of successful in vitro 
DC induction is the loss of the monocyte marker CD14, while expressing CD1c 
(Sallusto and Lanzavecchia, 1994). As the monocytes utilised for this culture are 
selected for their CD14-positivity, the loss of this marker signifies that monocytes 
have indeed been transformed due to the presence of IL-4 and GM-CSF. An 
example of CD14 and CD1c expression in immature, mature and tolerogenic Mo-DCs 







Figure 4.1 Expression of CD1c and CD14 on Mo-DCs  
Expression of CD1c and CD14 on immature, mature and tolerogenic Mo-DCs. A. Representative 
expression of CD1c and CD14 on immature, mature and tolerogenic Mo-DCs cultured from CD14+ 
monocytes of a healthy donor compared to an unstained sample. B. MFI of CD14 expression, 
comparing immature, mature and tolerogenic Mo-DCs. Dotted line represents median of unstained 
control. One-way ANOVA, n=13. C. MFI of CD1c expression, comparing immature, mature and 
tolerogenic Mo-DCs to an unstained sample. Dotted line represents median of unstained control. 




CD14+ staining was absent from both immature and mature Mo-DCs, with signal 
brightness being highly similar to an unstained control. However, tolerogenic Mo-DCs 
showed some CD14+staining, some of which was CD1c positive (3.18%), while the 
largest part was CD1c negative (10.8%). CD1c expression was not significantly 
different between immature, mature or tolerogenic Mo-DCs, but all three Mo-DC 
subtypes expressed levels of CD1c above a median unstained signal (Figure 4.1C). 
As visible from the representative sample, immature and mature Mo-DCs showed 
very low CD14 expression which was not significantly different from unstained 
controls in immature Mo-DCs and actually significantly lower on mature Mo-DCs. 
However, the mean difference was very small, underlining that CD14 expression was 
comprehensively absent from mature Mo-DCs at the end of the 7-day culture. 
Interestingly, CD14 expression on tolerogenic Mo-DCs was significantly higher 
compared to an unstained control, suggesting that addition of immunosuppressive 
drugs inhibited the complete loss of CD14 from the cell surface. This could suggest 
that some cells did not complete the monocyte to DC differentiation process under 
tolerogenic cell culture conditions. Other studies have however also shown that 
Vitamin D3 might induce expression of CD14 (Oberg et al., 1993), suggesting that the 
presence of this tolerogenic factor stimulates CD14 expression. Overall, CD14 was 
only expressed on around 14% of tolerogenic Mo-DCs, suggesting that only a small 
proportion of cells was affected by this and that the large majority of cells in 
tolerogenic cultures resembled Mo-DCs. To conclude, it can be assumed that 
immature and mature Mo-DCs harvested were Mo-DCs and not monocytes, and that 
at least 85% of tolerogenic Mo-DCs assumed a DC-like phenotype. CD1c expression 
compared to an unstained control is shown in Figure 4.1C, revealing that all Mo-DC 
subtypes express CD1c. Again, tolerogenic Mo-DCs differed from immature and 
mature Mo-DCs in that they expressed lower levels of CD1c, while this was not found 
to be significant, it suggests that addition of Dexamethasone and Vitamin D3 
inhibited full Mo-DC development.  
Immature Mo-DCs are known to increase in costimulatory markers such as CD83, 
CD86 and the antigen-presenting MHC HLA-DR upon LPS stimulation to yield 
mature Mo-DCs (Harry et al., 2010; Osugi et al., 2002). Tolerogenic Mo-DCs on the 
other hand were described to exhibit a semi-mature state, with significantly reduced 
expression levels of CD83 and CD86 and reduced expression of HLA-DR compared 




confirmed in Figure 4.2A, which shows a representative overlay of expression of 
CD83, CD86 and HLA-DR on immature (shown in green), mature (shown in red) and 
tolerogenic (shown in blue) viable Mo-DCs. Immature Mo-DCs were lowest in all 
markers, while mature Mo-DCs showed the highest expression. Tolerogenic Mo-DCs 
showed medium to low expression of CD83, medium expression of CD86 (both 
intermediate between immature and mature) but expressed HLA-DR in similarly high 
levels to mature Mo-DCs. Expression of these three costimulatory molecules was 
quantified (Figure 4.2B), which confirmed that mature Mo-DCs express significantly 
higher levels of CD83 and CD86 compared to both immature and tolerogenic Mo-
DCs, which were not shown to be significantly different from each other. However, 
while HLA-DR expression was significantly increased between immature and mature 
Mo-DCs, tolerogenic Mo-DCs were not shown to be significantly different from 
mature Mo-DCs. While representative histogram overlays showed that tolerogenic 
Mo-DCs were slightly higher in CD83 and CD86 when compared to immature Mo-
DCs, this effect was not found to be significant in the pooled data.  
 
 
Overall, this suggests that the Mo-DC culturing system yielded three distinct Mo-DCs 
subtypes, which show differential expression of CD83, CD86 and HLA-DR. Here, 
Figure 4.2 Expression of CD83, CD86 and HLA-DR on Mo-DCs  
Expression of costimulatory receptors CD83 and CD86, as well as MHC class II HLA-DR on 
immature, mature and tolerogenic Mo-DCs. A. Representative histogram overlay of expression of 
CD83, CD86 and HLA-DR by immature (green), mature (red) and tolerogenic (blue) Mo-DCs. B. MFI 
expression of CD83, CD86 and HLA-DR comparing immature (green), mature (red) and tolerogenic 




immature and mature Mo-DCs represented the low and high ends of costimulatory 
molecule expression, with tolerogenic Mo-DCs being more similar to immature Mo-
DCs in respect to expression of CD83 and CD86, while HLA-DR expression was 
closer to that of mature Mo-DCs. 
However, expression of MHC and costimulatory molecules alone are not sufficient to 
define DCs as either mature or tolerogenic. Distinct other markers are needed to 
distinguish tolerogenic from mature Mo-DCs. TLR2, a cell surface receptor that 
recognises bacterial lipoproteins and whose expression is induced by exposure to 
Dexamethasone , and the TGF-β receptor LAP have previously been described as 
markers of tolerogenic Mo-DCs (Harry et al., 2010; Shibata et al., 2009). Expression 
of TLR2 and LAP is shown using a multi-colour dot plot on immature, mature and 
tolerogenic Mo-DCs (Figure 4.3A). While immature and mature Mo-DCs showed 
some TLR2 expression, between 20-35% of Mo-DCs did not express TLR2. In 
contrast, tolerogenic Mo-DCs expressed much higher levels of TLR2 with only 2.2% 
of cells not expressing the marker. TLR2 signal was significantly brighter on 
tolerogenic Mo-DCs compared to both immature and mature Mo-DCs, and was also 
expressed on a larger percentage of tolerogenic Mo-DCs (Figure 4.3B). Interestingly, 
a significantly smaller percentage of mature Mo-DCs expressed TLR2 compared to 
the percentage of immature Mo-DCs. Furthermore, only 1-3% of immature and 
mature Mo-DCs showed expression of LAP, while up to 12% of tolerogenic Mo-DCs 
expressed LAP. Quantifying expression of LAP, no differences in MFI between the 
different Mo-DC subsets can be observed, although a significantly larger proportion 
of tolerogenic Mo-DCs expressed LAP when compared to mature Mo-DCs (Figure 
4.3).  
Overall, phenotyping of Mo-DC subtypes showed that culturing of the three different 
subtypes generated distinct populations that show significant differences in 
expression of key markers that matched their description in the literature. Mo-DCs 
lost CD14 expression but retained or in some cases gained CD1c expression as they 
differentiated into Mo-DCs. Addition of LPS caused a rapid increase in surface 
expression of CD83, CD86 and HLA-DR in mature DCs, but this was only the case 
for HLA-DR in tolerogenic Mo-DCs. Furthermore, tolerogenic Mo-DCs showed 
significantly increased surface expression of TLR2 compared to both immature and 
mature Mo-DCs, as well as an increased proportion of tolerogenic Mo-DCs 




mature and tolerogenic Mo-DCs reliably, which could therefore be used to study β₂ 







Figure 4.3 Expression of LAP and TLR2 on Mo-DCs  
Expression of LAP and TLR2 on immature, mature and tolerogenic Mo-DCs. A. Representative 
multi-colour dot plot of expression of LAP and TLR2 on immature, mature and tolerogenic Mo-
DCs. B. MFI expression of TLR2 (left) and LAP (right) on immature (green), mature (red) and 
tolerogenic Mo-DCs (blue). Both signal brightness (MFI, top) and %positive population (bottom) 




T cell stimulatory abilities of mature and tolerogenic Mo-DCs  
Mature Mo-DCs are described to induce higher levels of T cell proliferation and IFN-γ 
production compared to tolerogenic Mo-DCs in an MLR (Anderson et al., 2008). To 
test this, T cell proliferation in an MLR was tested using a cell proliferation dye (CTV, 
Figure 4.4A-B) and supernatants were tested for levels of IFN-γ (Figure 4.4C) and IL-
10 (Figure 4.4D) using an ELISA. However, no significant difference in T cell 
proliferation was observed, neither in the total amount of proliferation nor when 
comparing different levels of division (Figure 4.4B). In fact, around 90% of T cells co-
cultured with both mature and tolerogenic Mo-DCs were shown to have undergone 5-
7 cell divisions, with only a small percentage of cells in either cell type having 
undergone 1-2 divisions. This suggested that at Day 6, that mature and tolerogenic 
Mo-DCs drive the same level of T cell division. This could potentially be due to the 
fact that it is difficult to detect further divisions after seven, as the CTV gets too 
diluted for detection. Therefore, potentially an earlier time point would show 
differences between mature and tolerogenic Mo-DCs ability to stimulate T cell 
proliferation, as the maximal amount of proliferation has not been reached yet. 
Another option however is that mature and tolerogenic Mo-DCs drive different T cell 
phenotypes. This is especially possible as IFN-γ levels in mature Mo-DC 
supernatants were significantly higher compared to tolerogenic Mo-DC-co-cultures 
(Figure 4.4C), confirming that the mature and tolerogenic Mo-DC states result in 
altered T cell priming. ln addition to IFN-γ, I also measured levels of the anti-
inflammatory cytokine IL-10 in Mo-DC MLR supernatants to test if there was an 
increase in anti-inflammatory signalling in tolerogenic Mo-DC MLRs. No significant 
differences in IL-10 levels were found between MLRs using tolerogenic or mature 
Mo-DCs (Figure 4.4D). However, measuring IL-10 in MLRs had the inherent caveat 
that both T cells and Mo-DCs can produce it. This could mean that IL-10 production 
by either Mo-DC subset masked differences in IL-10 production by T cells that were 
present in the culture. Interestingly, the only donor that showed increased IFN-γ 
production in tolerogenic MLRs simultaneously also showed the only decrease in IL-
10 production in tolerogenic compared to mature MLRs. This could suggest that this 
specific culture was unusual, possibly due to donor to donor variation of both Mo-







conclude, I established that cultured mature and tolerogenic Mo-DCs are stable and 
 
 Figure 4.4 Effect of mature and tolerogenic Mo-DCs in an MLR 
Effect of mature and tolerogenic Mo-DCs on T cell proliferation, IFN-γ and IL-10 production in an 
MLR. A. Gating strategy to yield proliferated cells in percent (Proliferated) and cells that had 
undergone 1-2, 3-4 and 5-7 divisions respectively. Single live cells, CD11c-CD3+CD4+. B. Total T 
cell proliferation in percent of T cells that have diluted CTV staining after 6 days of co-culture (left) 
and percent that had undergone 1-2, 3-4 and 5-7 cell divisions, comparing mature and tolerogenic 
Mo-DCs. C. IFN-γ concentration detected in MLR supernatants by ELISA. D. IL-10 concentration 




comparable to Mo-DCs discussed in previously published literature in respect to both 
their phenotype and their ability to stimulate T cells. Shortly, mature Mo-DCs had not 
only the ability to induce T cell proliferation but also showed to induce high levels of 
IFN-γ production by T cells. In contrast, tolerogenic Mo-DCs could induce T cell 
proliferation similar to mature Mo-DCs, the T cells produced significantly lower 
amounts of IFN-γ. Phenotypic differences, as well as immunostimulatory versus 
immunoregulatory abilities, in the form of T cell stimulatory abilities, were shown to be 
different between mature and tolerogenic Mo-DCs. This underlined that mature and 
tolerogenic Mo-DCs cultured by me are indeed two distinct phenotypes to investigate 
further.  
4.2.2 Clustering abilities of Mo-DCs  
In addition to differences in cell surface marker expression in Mo-DC subtypes, it was 
also important to assess if Mo-DC subtypes differ in their functionality in respect to 
cell adhesive behaviour. This is because differences in adhesive capabilities have 
been observed but so far not quantified. To this end, clustering phenotype of mature 
and tolerogenic Mo-DCs was assessed.  
Clustering phenotypes of monocyte-derived dendritic cells 
Mature Mo-DCs have been described previously to show DC morphology, including 
dendrite-like extensions, as well as to form tight clusters with each other (Zhou and 
Tedder, 1996). Given reports of altered adhesion of Mo-DC subtypes (Hilkens et al, 
unpublished observations), I then looked at Mo-DC morphology and clustering by 
imaging. Therefore, immature, mature and tolerogenic Mo-DCs were incubated for 6h 
at 37°C on glass after all stimulants were washed off, imaged using a bright field 
microscope and cell clustering was quantified using a CellProfiler pipeline, whereby 
both clusters of cells and individual unclustered cells could be detected as objects, 
enabling measurements of various parameters, including object area.  
Immature (green), mature (red) and tolerogenic Mo-DCs (blue) were cultured on 
glass slides (representative images shown in Figure 4.5A). Differences in Mo-DC 
clustering was observed between conditions: immature Mo-DCs showed the least 
level of clustering, mature Mo-DCs showed few large clusters of cells and tolerogenic 
Mo-DCs showed a large number of smaller clusters. When quantifying the images 
using Cellprofiler, it was observed that clusters were significantly larger in mature Mo-




DCs in turn formed significantly larger clusters compared to immature Mo-DCs 
(Figure 4.5B, left). This result was furthermore supported when considering the 
median radius of clusters, which describes the median length of distance between 
any pixel within a cluster to the closest pixel outside of the cluster. Mature Mo-DC 
clusters are shown to have the largest median radius, with both tolerogenic and 
immature Mo-DC clusters having significantly lower median radius values (Figure 
4.5B, right). Furthermore, the number of both clusters (left) and single unclustered 
cells (right) was determined for each condition to determine clustering behaviours of 
different Mo-DC subtypes (Figure 4.5). Mature Mo-DCs showed a significantly lower 
number of clusters compared to both immature and tolerogenic Mo-DCs, which did 
not differ in their number of clusters. Furthermore, mature Mo-DCs showed 
significantly less single unclustered cells compared to immature Mo-DCs, underlining 
again that mature Mo-DCs show higher rates of clustering compared to especially 
immature Mo-DCs. Overall, this confirmed that mature Mo-DCs show the highest 
level of cell clustering of all three Mo-DC types as the form a smaller number of larger 
clusters, with significantly less cells remaining unclustered. Immature Mo-DCs on the 
other hand show the least amount of clustering, with the smallest area and median 
radius of clusters observed. Lastly tolerogenic Mo-DCs possess an intermediate 
phenotype, with clusters that are significantly larger than immature Mo-DC clusters, 
but significantly smaller compared to mature Mo-DCs. Clustering ability of mature 
and tolerogenic Mo-DCs on glass slides suggests that mature Mo-DCs are less 
adhesive and therefore able to move faster together to form large clusters, while 
tolerogenic Mo-DCs could be supposed to be more adhesive, thereby only being able 
to transverse shorter distances to form smaller clusters. Although this is adhesion to 
glass, one could speculate that increased adhesive capabilities of tolerogenic Mo-
DCs might alter their ability to migrate and affect how tightly they adhere to T cells, 









4.2.3 The role of CD11a in Mo-DCs  
As previously discussed in the introduction to this chapter, evidence supports an 
important role for β₂ integrins in mediating the functional differences between mature 
Figure 4.5 Cell clustering phenotype of Mo-DCs  
Cell clustering of immature, mature and tolerogenic Mo-DCs incubated for 6h at 37°C on glass slides. 
A. Representative bright field microscopy images of immature (green), mature (red) and tolerogenic 
Mo-DCs (blue) on glass slides. 10x magnification. B. Area in pixels of clusters identified by cellprofiler 
(left) as well as median radius in pixels per cluster (right). Area is defined as the number of pixels in 
the region of the cluster, while median radius is defined as the median distance of any pixel in a 
cluster to the closest pixel outside of the object. One-way ANOVA, immature n=2490, mature=1493, 
tolerogenic=2405 individual clusters. C. Number of clusters identified per image by Cellprofiler 
pipeline (left) and number of unclustered individual cells identified per image by Cellprofiler pipeline 
(right). One-way ANOVA, immature n=23, mature n=29, tolerogenic n=28 healthy control donors. 




and tolerogenic Mo-DCs. Indeed, the clustering data (Figure 4.5) indicate clear 
differences in adhesive properties between mature and tolerogenic Mo-DCs. 
However, very little is known about the expression and conformation of β₂ integrin 
subunits in Mo-DCs, and how integrin expression might influence Mo-DC function.  
To assess a potential role of CD11a in Mo-DCs, total and active CD11a expression 
was assessed. As double staining for total and active CD11a led to a significant 
signal loss of total CD11a, due to steric hindrance (Chapter 3, section 3.3.4, Figure 
3.4), total CD11a staining was assessed using both double stained (total and active 
CD11a mAbs)  and single stained (total CD11a mAbs only) cells. Double stained total 
CD11a (left) was found to be significantly lower on tolerogenic DCs compared to both 
immature and mature Mo-DCs (Figure 4.6A). However, when considering the staining 
of the same samples not affected by steric hindrance (single stained, right), no 
significant differences in total CD11a expression between Mo-DC subtypes were 
observed. This suggests that the level of steric hindrance differs between cell types. 
Investigating this further, the level of steric hindrance between Mo-DC subtypes, both 
as the difference between single stained and double stained MFI (left) and as 
percentage of signal lost (difference single-double stained as percentage of single 
stained, right) was plotted (Figure 4.6B). This showed that tolerogenic Mo-DC indeed 
lost significantly more total CD11a signal compared to immature and mature Mo-
DCs. This was the case both for total signal plotted as MFI, as well as percentage of 
signal loss, with immature Mo-DCs losing a mean of 13.9% of signal, mature Mo-DCs 
losing only a mean 0.7% of signal and tolerogenic Mo-DCs losing a mean of 34.7% 
of their total CD11a signal. Surprisingly, two out of 13 mature Mo-DCs actually 
gained signal when double stained. Furthermore, when excluding the three samples 
with the highest levels of steric hindrance shown from the double-stained data, no 
significant difference between expression of total CD11a was observed (Figure 
4.6C), confirming that steric hindrance was the cause for the significantly different 
expression of total CD11a in tolerogenic Mo-DCs. As total CD11a expression was 
not significantly different between mature and tolerogenic Mo-DCs, but steric 
hindrance was increased in tolerogenic Mo-DCs, one could hypothesise that 
tolerogenic Mo-DCs have increased levels of active CD11a. This would explain why 
more total CD11a signal was lost, as more binding of active CD11a might reduce 







Figure 4.6 Expression of total CD11a in Mo-DCs 
Expression of total CD11a in immature, mature and tolerogenic Mo-DCs. A. MFI of total CD11a, 
comparing double stain (left, total and active CD11a stained) and single stain (right, only total CD11a 
stained). B. Level of steric hindrance in immature, mature and tolerogenic Mo-DCs. Left shows the 
difference between single and double stain in MFI values (MFI lost to steric hindrance), right shows 
differences in steric hindrance as a percentage of single stain (% of signal lost to steric hindrance). 
C. MFI of total CD11a, double stain with three samples with highest levels of steric hindrance 
recoreded removed. Results shown are from single, live cultured cells. Matched one-way ANOVA, 





When considering active CD11a expression on tolerogenic Mo-DCs, this hypothesis 
was confirmed, as tolerogenic Mo-DCs expressed significantly more active CD11a 
compared to mature Mo-DCs (Figure 4.7). Expression of active CD11a was clearly 
higher in both a dot plot and a histogram overlay (Figure 4.7A). Interestingly, 
tolerogenic Mo-DCs did not differ significantly from immature Mo-DCs, which were 
also significantly higher in active CD11a expression compared to mature DCs. This 
was surprising, as one could therefore expect levels of steric hindrance due to higher 
active CD11a expression in immature Mo-DCs to be similar to tolerogenic Mo-DCs 
(Figure 4.7). However, this was not the case as there was significantly less steric 
hindrance in immature Mo-DCs compared to tolerogenic Mo-DCs (Figure 4.6B). This 
suggested that factors affecting steric hindrance of CD11a antibodies are potentially 




significantly increased expression of active CD11a in tolerogenic compared to mature 
 
 
Figure 4.7 Expression of active CD11a in Mo-DCs  
Expression of active CD11a in immature, mature and tolerogenic Mo-DCs. A. Representative dot 
plot and histogram overlay of active CD11a expression in mature (red) and tolerogenic Mo-DCs 
(blue). B. MFI expression of active CD11a in immature, mature and tolerogenic Mo-DCs (left, 
matched one-way ANOVA, n=13), or only comparing mature and tolerogenic Mo-DCs (right, paired 





Mo-DCs could suggest that β2 integrins are altered on DCs under different 
circumstances. However, it is difficult to make assumptions about the potential 
functional impact of these differences on tolerogenic function of Mo-DCs. First, 
therefore, it was important to test if the observed difference in active CD11a 
expression affected cell adhesion. To this end, adhesion of mature and tolerogenic 
Mo-DCs to varying concentrations of the β₂ integrin ligand ICAM-1, which is a known 
ligand of CD11a (Landis et al., 1994), was compared. Given the increase in active 
CD11a expression seen in tolerogenic compared to mature Mo-DCs, we would 
predict increased adhesion of tolerogenic Mo-DCs to ICAM-1. Adhesion of mature 
and tolerogenic Mo-DCs to 0.1µg/ml (Figure 4.8A), 1µg/ml (Figure 4.8B) and 10µg/ml 
ICAM-1 (Figure 4.8C) is presented in Figure 4.8. Interestingly, no significant increase 
in adhesion was observed to any of the three concentrations of ICAM-1. Adhesion to 
the highest concentration of ICAM-1 (Figure 4.8C) showed a consistent upwards 
trend in all but one sample, which almost reaches statistical significance at p=0.051. 
This would suggest that the increase in active CD11a expression on tolerogenic Mo-
DCs was not sufficient to increase adhesion to low and medium concentrations of 
ICAM-1, but that there might be a small but potentially important biological effect at 
high concentrations of ICAM-1. However, while ICAM-1 is described to be one of the 
main ligands for CD11a, both CD11b and CD11c can also bind ICAM-1 (Blackford et 
al., 1996; Diamond et al., 1990). This means that either one of the other β₂ integrin 
alpha subunits could potentially have compensated for the lower expression of active 
CD11a on mature Mo-DCs, making them equal to tolerogenic Mo-DCs. If given the 
ability to undertake further studies, β₂ integrin subunit specific blockade could be 
utilised to assess CD11a-mediated adhesion to ICAM-1 specifically.  
To conclude, while total CD11a expression of CD11a did not differ between Mo-DCs, 
there was significantly higher expression of active CD11a on tolerogenic Mo-DCs 
compared to mature Mo-DCs. This explains the significantly increased level of total 
CD11a signal loss due to steric hindrance in tolerogenic Mo-DCs, as total CD11a 
binding sites may be obstructed by active CD11a binding. While increased 
expression of active CD11a on tolerogenic Mo-DCs did not translate to increased 
adhesion to one of the CD11a ligands ICAM-1, this could be explained by both 
CD11b and CD11c also being able to utilise ICAM-1 as a ligand, which could 
potentially mask effects of active CD11a expression. However, the almost significant 




adhesion to especially T cells, which express ICAM-1 as part of stabilising the 
immunological synapse, might be altered as an effect of altered CD11a 
conformational state. It is also important to note that different β₂ integrin subunits 
might have distinct downstream-signalling pathways depending on ligand, thereby 
suggesting that even though CD11b or CD11c can maintain adhesion to ICAM-1 on 
mature Mo-DCs, downstream signalling might be altered due to the lower levels of 
CD11a binding ICAM-1. Because of the consistent and significant increase in active 
CD11a on tolerogenic Mo-DCs, one could hypothesise that active CD11a plays an 





4.2.4 The role of CD11b in Mo-DCs  
Having explored total and active CD11a expression on Mo-DCs, I found that active 
CD11a expression was significantly higher on tolerogenic compared to mature Mo-
DCs, but that the two Mo-DC subtypes did not differ significantly in their adhesion to 
ICAM-1. As CD11b, a different β₂ integrin alpha subunit, can also bind ICAM-1 and 
was hypothesised to be partially responsible for the similar adhesive capabilities of 
tolerogenic and mature Mo-DCs despite their differences in active CD11a, CD11b 
was also investigated. As no significant signal loss due to steric hindrance was 
observed between active and total CD11b (Chapter 3, section 3.3.4, Figure 3.4), only 
Figure 4.8 Adhesion of mature and tolerogenic Mo-DCs to ICAM-1 
Adhesion assays comparing adhesion of mature to tolerogenic Mo-DCs to three concentrations of 
ICAM-1. A. Adhesion to ICAM-1 at 0.1µg/ml. B. Adhesion to ICAM-1 at 1µg/ml. C. Adhesion to 




samples where both total and active CD11b antibodies were used simultaneously 
were considered.  
There were no significant differences in total CD11b expression between immature, 
mature and tolerogenic Mo-DCs, nor when comparing mature and tolerogenic Mo-
DCs specifically to each other (Figure 4.9A-B). Neither expression of total CD11a nor 





Levels of active CD11b were found to be lower on tolerogenic Mo-DCs when 
compared to mature Mo-DCs (Figure 4.10A-B), but only when comparing mature and 
tolerogenic Mo-DCs directly. When comparing immature, mature and tolerogenic Mo-
DCs, tolerogenic Mo-DCs are not shown to be significantly different from mature Mo-
DCs, but are significantly lower than immature Mo-DCs (Figure 4.10B, left). However, 
when only comparing mature and tolerogenic Mo-DCs, tolerogenic Mo-DCs were 
shown to have significantly lower expression of active CD11b. Interestingly, 
expression of active CD18, the shared β₂ integrin subunit of both CD11a and CD11b, 
was also significantly lower in tolerogenic Mo-DCs when compared only to mature 
Mo-DCs (Figure 4.11A-B). As active CD11a was found to be significantly increased in 
tolerogenic Mo-DCs, this could suggest that the lower active CD11b levels dominate 
over higher active CD11a levels on tolerogenic Mo-DCs, as active CD18 was also 
Figure 4.9 Expression of total CD11b on Mo-DCs  
Expression of total CD11b on immature, mature and tolerogenic Mo-DCs. A. Representative overlay 
of expression of total CD11b in mature (red) and tolerogenic Mo-DCs (blue). B. MFI of total CD11b 
comparing immature (green), mature (red) and tolerogenic Mo-DCs (blue). Matched one-way 




significantly affected. However, when comparing active CD18 expression of all three 
Mo-DC subtypes to each other, no significant differences were observed. This could 
suggest that this effect is potentially smaller and therefore more relevant when 
comparing mature and tolerogenic Mo-DCs directly.  
 
As active CD11b expression was significantly lower on tolerogenic compared to 
mature Mo-DCs, but active CD18 expression was similar, it was important to assess 
if different levels of active CD11b expression had functional consequences on Mo-
DC adhesion. Similar to assessing adhesion of Mo-DCs to ICAM-1, adhesion was 
assessed to a range of CD11b ligands, including complement proteins iC3b and C4b 
as well as the blood protein fibrinogen. Due to the reduced expression of active 
CD11b on tolerogenic Mo-DCs, it was hypothesised that tolerogenic Mo-DCs would 
adhere less to CD11b ligands compared to mature Mo-DCs. Adhesion of mature and 




Figure 4.10 Expression of active CD11b in Mo-DCs  
Expression of active CD11b in immature, mature and tolerogenic Mo-DCs. A. Representative dot 
plot and histogram overlay of active CD11b expression in mature (red) and tolerogenic Mo-DCs 
(blue). B. MFI of active CD11b expression in immature, mature and tolerogenic Mo-DCs (left, 
matched one-way ANOVA, n=13), or only comparing mature and tolerogenic Mo-DCs (right, paired 









As previously mentioned, iC3b (Figure 4.12A) was described to play an important 
role in the complement cascade and is produced when Complement Factor I cleaves 
C3b. Once it is cleaved, iC3b can act as an opsonin, enabling leukocytes to bind via 
CD11b/CD18 (Ross et al., 1985). Adhesion to iC3b was not found to be significantly 
different between mature and tolerogenic Mo-DCs in the lowest and highest ligand 
concentration, but adhesion to iC3b was significantly higher in tolerogenic Mo-DCs at 
3.33mg/ml. This is surprising, as lower levels of active CD11b expression on 
tolerogenic compared to mature Mo-DCs would suggest a reduced ability to adhere 
to iC3b. C4b, a different member of the complement system, is located upstream of 
iC3b acting in concert with C2a to cleave C3 into C3a and C3b. It has also been 
described to act as opsonin mediating phagocytosis of opsonised cells mediated via 
outside-in signalling after CD11b binds to it (Gresham et al., 1991). No differences in 
adhesion between mature and tolerogenic Mo-DCs were found in any of the three 
concentrations of C4b (Figure 4.12B). Lastly, fibrinogen, a member of the coagulation 
cascade also termed Factor I, is an important factor for blood clotting and a 
Figure 4.11 Expression of active CD18 in Mo-DCs  
Expression active CD18 in immature, mature and tolerogenic Mo-DCs. A. Representative 
dot plot and histogram overlay of active CD18 expression in mature (red) and tolerogenic 
Mo-DCs (blue). B. MFI of active CD18 expression in immature, mature and tolerogenic Mo-
DCs (left, matched one-way ANOVA, n=13), or only comparing mature and tolerogenic Mo-





commonly used ligand to test adhesive capabilities of CD11b (Sándor et al., 2016b). 
Here, the breadth of ligand concentration used was larger with an additional 
concentrations added due to the wide variation in adhesion to fibrinogen between 
Mo-DCs derived from different donors. No significant differences in adhesion to 
fibrinogen were found in the lower concentrations, but at the highest ligand 
concentration of 100µg/ml tolerogenic Mo-DCs were found to be significantly more 
adhesive compared to mature Mo-DCs. These data fit with the increased adhesion to 
iC3b but contradict the hypothesis that reduced active CD11b expression would 
result in reduced adhesion to CD11b ligands.  
The result that lower expression of active β₂ integrins resulted in increased adhesion 
to its ligand is puzzling and requires further discussion. There are several ways to 
interpret these results. First, while CD11b is lower on tolerogenic Mo-DCs, it could be 
more potent and therefore more likely to establish stable adhesion to a ligand that 
withstands washing steps of the adhesion assay protocol to a higher degree. This is 
however highly unlikely, as β₂ integrins in their active form have the highest affinity 
for ligand and integrin activation correlates well with adhesive capability (Coller, 
1985; Shattil et al., 1985). 
A more likely explanation is the ligand promiscuity of β₂ integrins, which was already 
discussed in the context of different β₂ integrin alpha-subunits binding to ICAM-1. Not 
only CD11b but also CD11c can bind both iC3b and fibrinogen (Loike et al., 1991; 
Malhotra et al., 1986; Myones et al., 1988), making it possible that CD11c 
compensates for reduced expression of active CD11b on tolerogenic Mo-DCs. While 
no difference in total CD11c expression on Mo-DCs was found (Figure 4.13), active 
CD11c expression was not measured. One could therefore hypothesise that active 
CD11c expression on tolerogenic Mo-DCs is increased, compensating for the 
reduction in active CD11b expression and leading to an overall increase in adhesion 








Figure 4.12 Adhesion of mature and tolerogenic Mo-DCs to iC3b, C4b and Fibrinogen 
Adhesion assays comparing adhesion of mature (red) to tolerogenic Mo-DCs (blue) to three 
concentrations of iC3b and C4b, and four concentrations of fibrinogen. A. Adhesion to iC3b at 
1µg/ml, 3.33µg/ml and 10µg/ml. Paired student’s t test, n=10. B. Adhesion to C4b at 1µg/ml, 
3.33µg/ml and 10µg/ml. Paired student’s t test, n=10. C. Adhesion to Fibrinogen at 0.1µg/ml (n=6), 





This explanation is supported further by the fact that C4b is not described to be a 
ligand for CD11c, and adhesion to this protein did not show a similar pattern to iC3b 
and fibrinogen, and adhesion did not differ between mature and tolerogenic Mo-DCs. 
This could suggest that respective binding of different β₂ integrin subunits to ligand 
might be regulated either by subunit conformational state or interplay between 
different subunits, such as CD11b and CD11c. 
In conclusion, active but not total CD11b expression was significantly lower on 
tolerogenic Mo-DCs when compared to mature Mo-DCs. Additionally, active CD18, 
the pairing β₂ integrin of both CD11a and CD11b, was also significantly lower in 
tolerogenic Mo-DCs. This suggests that the lower expression of active CD11b 
dominates over the higher expression of CD11a on tolerogenic Mo-DCs. The down-
regulation of active CD11b on tolerogenic Mo-DCs, compared to both mature and 
immature Mo-DCs could suggest that lowering CD11b activation plays a role in the 
distinct phenotype tolerogenic Mo-DCs show compared to mature Mo-DCs. However, 
adhesion to β₂ integrin ligands iC3b, C4b and fibrinogen was not negatively affected 
by the decrease in active CD11b expression, suggesting that surface expression and 
functionality are potentially not directly linked. Indeed, adhesion to iC3b and 
fibrinogen was actually higher in tolerogenic compared to mature Mo-DCs, an effect 
presumed to be mediated by an increase in active CD11c. On the other hand, 









To summarise my work up to this point, I found that mature and tolerogenic Mo-DCs 
differ in their active β₂ integrin expression, with tolerogenic Mo-DCs expressing more 
active CD11a and less active CD11b than mature Mo-DCs. I also found that 
adhesion to iC3b and fibrinogen, which have been reported to be ligands for both 
CD11b and CD11c, was significantly increased in tolerogenic Mo-DCs, while 
adhesion ICAM-1, bound by both CD11a and CD11b, was not significantly different 
between groups with the available sample size. Furthermore, tolerogenic Mo-DCs 
showed less clustering when adherent to glass. Together these data suggest that 
altered β₂ integrin conformational state on tolerogenic Mo-DCs contributes to altered 
adhesive and clustering behaviour. However, while tolerogenic Mo-DCs showed 
reduced T cell stimulatory abilities, it was important to investigate if this could also be 
due to altered β₂ integrins on tolerogenic Mo-DCs. To this end, I tested if altering 
availability of the active CD11b β₂ integrin subunit affected the T cell stimulatory 
abilities of mature and tolerogenic Mo-DCs. 
4.2.5 Functional significance of β₂ integrins on Mo-DCs  
To investigate the roles of β₂ integrins on Mo-DCs in mediating T cell proliferation 
and activation, both increasing β₂ integrin activation and blocking β₂ integrin 
adhesion were explored in MLRs. T cell proliferation was measured by CTV signal 
loss, and IFN-γ and IL-10 levels were quantified in MLR supernatants by ELISA.  
 
 Figure 4.13 Expression of total CD11c on Mo-DCs  
Expression of total CD11b on immature, mature and tolerogenic Mo-DCs. MFI of total 
CD11c comparing immature (green), mature (red) and tolerogenic Mo-DCs (blue). 





I decided to focus on CD11b for the manipulation studies. This decision had several 
reasons. First, while active CD11a expression was significantly increased in 
tolerogenic compared to mature Mo-DCs, the significantly lower active CD18 
expression on tolerogenic Mo-DCs suggested that CD11b might be a more dominant 
integrin. Second, manipulating either CD11a or CD18 in the context of an MLR held 
additional caveats: β₂ integrins not only play a role on DCs but are also important 
adhesion receptors on T cells. Indeed, investigation of total CD11a, CD11b, CD11c 
and CD18 expression on naïve CD45RO- T cells showed high levels of CD11a and 
CD18, and a low level of CD11c (Figure 4.14). On the other hand, naïve T cells 
showed no positive staining for CD11b, which is congruent with the published 
literature on β₂ integrins on T cells: In mice, absence of CD11b expression was 
shown to be one of the hallmarks of naïve CD4+ and CD8+ T cells (Christensen et 
al., 2001; Hataye et al., 2006; McFarland et al., 1992). This made manipulation of 
CD11b the best option, as any effects on T cell proliferation and differentiation in 
MLRs would be due to the DC-specific function of the β₂ integrin and not any T cell-










Effect of activating the Mo-DC integrin subunit CD11b on T cell priming 
Considering the significant decrease in active CD11b expression between mature 
and tolerogenic Mo-DCs, one could hypothesise that increasing active CD11b 
expression could enhance T cell proliferation and/or production of IFN-γ. This could 
be paired with a lower production of IL-10 in MLRs where CD11b activation was 
increased. Overall, I predict that increasing active CD11b on tolerogenic Mo-DCs 
might make them more similar to mature Mo-DCs in their ability to stimulate T cells. 
To investigate the role of CD11b on Mo-DCs in T cell proliferation, Mo-DCs were 
cultured as previously described, harvested and co-cultured with freshly isolated 
naïve T cells from healthy buffy coats. Proliferation and cytokine analysis from 
supernatants took place on Day 6 of culture. 
To this end, a small-molecule agonist of CD11b, Leukadherin-1 (LA-1) was utilised to 
induce CD11b activation in MLRs. Leukadherins were identified to increase CD11b-
Figure 4.14 CD45RO-CD4+ T cells express CD11a and CD18, but not CD11b 
CD45RO-CD4+ T cells isolated from healthy buffy coat for use in MLRs were stained for expression 
of total β₂ integrins CD11a, CD11b, CD11c and CD18. Multi-colour dot plots of stained single 
CD3+CD4+ T cells are shown above histogram overlays of unstained t cells (black), an FMO control 




mediated adhesion to fibrinogen using a high-throughput screening system (Park et 
al., 2007), and have since been found to be a promising therapeutic agent (Dickinson 
et al., 2018). LA-1 specifically has been used in a wide range of studies and is 
commercially available. However, preliminary results testing the effect of LA-1 on 
MLRs showed that 15µM of LA-1, a concentration previously used in the literature 
(Maiguel et al., 2011), was not feasible due to the DMSO content: T cell proliferation 
was almost completely inhibited in both mature and tolerogenic Mo-DC cultures when 
treated with either LA-1 or the DMSO control (Figure 4.15). These data indicate that it 




As per the recommendation of the supplier, LA-1 was dissolved in pure DMSO before 
being added to cells, which meant cells in Figure 4.15 were exposed to 1.5% of 
DMSO. As concentrations over 1% of DMSO have been described to be toxic in 
some cell lines (Galvao et al., 2013), it was decided to reduce the amount of DMSO 
added to MLRs. To this end, LA-1 concentration was titrated using concentrations 
between 0.5% and 0.1% DMSO per well, which is tolerated by T cells (Kloverpris et 
al., 2010). 
It was found that adding LA-1 at a concentration of 5µM, resulting in a final 
concentration of 0.5% of DMSO, caused no negative effects on T cell proliferation in 
mature Mo-DCs, with T cell proliferation being equivalent between untreated and 
Figure 4.15 High concentrations of LA-1 dissolved in DMSO inhibits T cell proliferation in 
MLRs 
Effect of 15µM LA-1 or equivalent volume of DMSO (1.5%) as a control in MLRs with either mature 
(left) or tolerogenic Mo-DCs (right), compared to an untreated culture. Matched one-way ANOVA, 




DMSO-treated cultures in a representative experiment, at 57.4 and 53.0%, 
respectively (Figure 4.16A), which was confirmed in DMSO treated cultures not being 
significantly different from untreated cultures (Figure 4.16B). LA-1 treatment of 
mature Mo-DC MLRs resulted in a broadly similar level of T cell proliferation (63.6%), 
again confirmed by LA-1 treated cultures being not significantly different from 
untreated MLRs (Figure 4.16A-B). Conversely, the tolerogenic Mo-DC MLR was 
visibly affected by even the reduced amount of DMSO, with T cell proliferation in the 
DMSO control being reduced to 4.03% compared to 70.2% in the untreated culture 
(Figure 4.16C). However, it was interesting to observe that treatment with 5µM LA-1 
partially rescued T cell proliferation, with approximately a third (33.5%) of T cells in 
the LA-1-treated tolerogenic Mo-DC cultures undergoing cell division (Figure 4.16C). 
However, quantification of tolerogenic MLR data showed that while both DMSO and 
LA-1 treated MLRs showed significantly lower T cell proliferation, no significant 
increase between DMSO and LA-1 could be observed. As active CD11b was higher 
in mature Mo-DCs (Figure 4.10), one could hypothesise that CD11b activation cannot 
be further increased as mature Mo-DCs already expressed the maximal amount 
possible. One the other hand, tolerogenic Mo-DCs did show significant loss of T cell 
proliferation in response to 0.5% DMSO, as well as 5µM of LA-1. This differential 
response to DMSO between mature and tolerogenic Mo-DCs was surprising, as it 
suggested either that T cells did not proliferate as effectively in the presence of 
DMSO or that tolerogenic Mo-DCs in turn show reduced ability to activate T cells due 
to DMSO exposure. However, LA-1-treated tolerogenic Mo-DC co-cultures had a 
trend for higher T cell proliferation than their DMSO control counterparts. When 
comparing DMSO control and LA-1 treatment directly to each other, however, the 
result was not significant. This would indicate that LA-1 cannot rescue the negative 
effect of DMSO on T cell proliferation and instead shows that CD11b activation in 
MLRs has no effect on T cell proliferation.  
This was an unexpected result, as I had hypothesised that increasing activation of 
CD11b on tolerogenic Mo-DCs especially, due to their low expression of active 
CD11b (Figure 4.10), would increase Mo-DC-mediated T cell proliferation. To test the 
efficacy of the CD11b activating drug, effect of LA-1 treatment on active CD11b 
expression was investigated on Mo-DCs exposed to either 5µM LA-1 or equivalent 
DMSO and compared to untreated cells (Figure 4.17). Interestingly, no consistent 




DCs from four donors. In fact, results seemed to differ widely between donors: While 
donor 1 (Figure 4.17A) and donor 4 (Figure 4.17D) showed no effect of LA-1 
treatment in either mature or tolerogenic Mo-DCs, donor 2 (Figure 4.17B) showed 
lower active CD11b expression on mature Mo-DCs exposed to DMSO, and with the 
LA-1 treated cells actually being lower in active CD11b in both mature and 
tolerogenic Mo-DCs, although this is likely to be due to the reduction in total CD11b 
expression observed in both Mo-DC subtypes. The only Mo-DC data-set where LA-1 
treatment caused a visible increase in active CD11b expression was donor 3 (Figure 
4.17C), but treatment with the equivalent percentage of DMSO increased active 
CD11b to a similar degree as LA-1 in both mature and tolerogenic Mo-DCs.  
Overall, these data showed that treatment with 5µM LA-1 did not reliably induce an 
increase of active CD11b expression. LA-1 was reported to allosterically activate 
CD11b and thereby cause increased adhesion to fibrinogen and increased binding of 
an activation-specific antibody targeted at its pairing subunit CD18 (Maiguel et al., 
2011). However, the same study also suggested that this was due to binding of LA-1 
to the αI domain, which thereby stabilised the active conformation of CD11b. 
Therefore, while LA-1 was found to locally stabilise CD11b in its extended 
conformation, a global increase in expression of active CD11b was not observed in 
some studies (Faridi et al., 2013). Furthermore, using atomic force microscopy to test 
strength of ligand-integrin interaction, it was shown that LA-1 increased adhesion to 
ICAM-1 by increasing formation of membrane tethers with CD11b subunits showing 
weaker cytoskeletal linkage bonds (Celik et al., 2013). In light of this, it is possible 
that LA-1 is functional but that I cannot observe its functionality either with activation-
specific antibodies, as it has not been reported to directly affect conformational state 
of CD11b, or in the more long-term culture conditions of an MLR, as it has been 







Figure 4.16 Effect of LA-1/DMSO on mature and tolerogenic Mo-DCs  
Representative effect of 5µM LA-1 or 0.5% DMSO equivalent control on T cell proliferation in mature 
(A) and tolerogenic (B) Mo-DC MLRs, compared to untreated co-cultures. Effect of 5µM LA-1 or 
0.5% DMSO equivalent control on mature and tolerogenic Mo-DC MLRs, compared to untreated co-
cultures. A. Representative effect of LA-1/DMSO on mature Mo-DC MLRs. B. Quantification of effect 
of LA-1/DMSO on mature Mo-DC MLRs. One-way ANOVA, Mo-DCs n=3, naïve T cells n=3.C. 
Representative effect of LA-1/DMSO on tolerogenic Mo-DC MLRs. D. Quantification of effect of LA-









Figure 4.17 Effect of CD11b agonist LA-1 on expression of active and total CD11b 
Effect of 5µM LA-1 or 0.5% DMSO control on expression of active and total CD11b in mature and 





Another option is that CD11b is already in its active conformation in donors A, B and 
D (Figure 4.17). This argument can be supported by Figure 4.18, which shows 
mature and tolerogenic Mo-DCs with the respective lowest and highest MFI value for 
active CD11b. Comparing the highest recorded expression of active CD11b in both 
mature and tolerogenic Mo-DCs to the untreated conditions in Figure 4.17, this 
strongly suggests that CD11b is already in a highly active conformation and can 
therefore potentially not be activated further by LA-1. 
 
 
Lastly, it was important to consider if the negative effect of the DMSO vehicle was 
due to Mo-DCs or T cells being affected. To this end, percentage of dead cells, both 
CD11c+ to gain information on any Mo-DCs remaining in culture, and CD11c-, to 
assess if DMSO was directly toxic to T cells was being compared between untreated 
and the DMSO control (Figure 4.19). However, cell death was not significantly 
different between untreated and MLRs exposed to DMSO, and it was furthermore 
very low. This suggests that the negative effect of DMSO on T cell proliferation was 
not mediated by toxicity mediating increased cell death. However, considering that 
DMSO was shown to increase expression of active CD11b in Donor C (Figure 
4.17C), which was the only donor shown to not have high expression of active 
CD11b regardless of treatment, it could suggested that DMSO might have a range of 
effects on both Mo-DCs and T cells that hinder effective proliferation. However, as 
three out of four donors showed high expression of active CD11b regardless of 
DMSO, it is unlikely that its effect is mediated via CD11b. 
To conclude, treatment of MLRs with LA-1 had no significant effect on T cell 
proliferation as active CD11b expression on Mo-DCs was not increased. There was 
Figure 4.18 Range of expression of active CD11b on mature and tolerogenic Mo-DCs  
Histogram overlay of mature (left) and tolerogenic Mo-DCs (right) with lowest (light coloured) and 




an unexpected negative influence of DMSO on tolerogenic Mo-DCs that was not 
observed to affect mature Mo-DCs. This suggests that the DMSO vehicle, that LA-1 
was dissolved in, inhibited either Mo-DCs, T cells or both in their ability to produce T 
cell proliferation to a similar level of the untreated control. As active CD11b was not 
consistently increased by LA-1 treatment independently of DMSO, it was decided to 
not pursue measurement of IFN-γ and IL-10 concentrations in culture supernatants 
or further LA-1 treatment studies. Further investigation, for example of other CD11b 




Effect of blocking the β₂ integrin subunit CD11b 
Due to the low expression of active CD11b on tolerogenic Mo-DCs and considering 
tolerogenic Mo-DCs reduced ability to stimulate IFN-γ production by T cells in an 
MLR, I hypothesised that downregulating active CD11b is an immunoregulatory 
process. Investigating this hypothesis, I predicted that blocking CD11b on Mo-DCs in 
an MLR would decrease T cell proliferation and IFN-γ production, while 
simultaneously increasing IL-10 production. To investigate the effect of blocking 
CD11b function, a CD11b-specific blocking antibody (clone M1/70) was compared to 
an isotype control which were added to the MLRs.  
Figure 4.19 Effect of DMSO treatment on cell death 
Assessing the percentage of cell death occurring in mature and tolerogenic Mo-DC MLRs in response 
to DMSO. Cells shown are single, positive for cell death marker and either CD11c- (T cells) or 




The effect of blocking CD11b on T cell proliferation is shown in Figure 4.20A. While 
tolerogenic Mo-DCs were not significantly affected in their ability to induce T cell 
proliferation with CD11b blocking, mature Mo-DCs induced significantly less 
proliferation of T cells when CD11b was blocked. In mature Mo-DC MLRs treated 
with a CD11b blocking antibody, significantly less T cells showed a high number of 
divisions (5-7), suggesting that blocking of CD11b caused T cells to either divide less 
quickly or stop dividing after less division cycles. As expression of active CD11b was 
already lower on tolerogenic compared to mature Mo-DCs, one could hypothesise 
that availability of active binding sites for ligand was already reduced. This would 
suggest that, even though tolerogenic Mo-DCs still expressed high levels of active 
CD11b, reduction of active CD11b might only be able to reduce T cell stimulatory 
capability to a certain degree, which was already reached in tolerogenic Mo-DCs. 
This would explain the absence of an effect in tolerogenic Mo-DC MLRs. One could 
therefore suggest that reducing CD11b activity on mature Mo-DC made them more 
tolerogenic Mo-DC-like. In support of this, there was a small but significant decrease 
in IFN-γ concentration measured in MLR supernatants in mature but not tolerogenic 
Mo-DC MLRs when CD11b was blocked (Figure 4.20B). This suggested that blocking 
CD11b did not only have an effect on T cell proliferation but also reduced the amount 
of pro-inflammatory cytokines produced by the T cells. On the other hand, no 
significant difference in IL-10 production was found with CD11b blocking of MLRs of 
either mature or tolerogenic Mo-DCs (Figure 4.20C). The absence of an effect of 
blocking CD11b on IL-10 production by T cells could be due to different reasons. As I 
am hypothesising CD11b to be more pro-inflammatory, it is possible that production 
of IL-10 was simply not affected by CD11b. As previously mentioned, T cells can also 
produce IL-10, which might render small differences due to treatment with the CD11b 








Figure 4.20 Effect of blocking CD11b on mature and tolerogenic Mo-DCs in MLRs 
Effect of blocking of CD11b using a mAb (clone M1/70) compared to an isotype control (Rat, 
IgG2b, κ) in mature (red) and tolerogenic Mo-DC (blue) MLRs. A. Effect on T cell proliferation in 
percentage of T cells that showed diluted CTV signal due to cell division, percentage of T cells that 
have undergone proliferation (top) and percentage of cells per division category (1-2, 3-4, 5-7) 
(bottom) are compared between isotype control (unfilled circle) and CD11b blocking antibody 
(filled circle). B. Concentration of IFN-γ in MLR supernatants on day 6 measured by ELISA. C. 
Concentration of IL-10 in MLR supernatants on day 6 measured by ELISA. Paired Student’s t test, 




To conclude, blocking CD11b significantly reduced the level of T cell proliferation and 
IFN-γ production elicited by mature Mo-DCs, but not tolerogenic Mo-DCs. One could 
therefore hypothesise that blocking CD11b on mature Mo-DCs made them more 
similar to tolerogenic Mo-DCs in terms of their T cell priming capacity.  
4.3 Discussion 
In this chapter, I investigated expression of both total and active CD11a and CD11b 
on mature and tolerogenic Mo-DCs, as well as their respective ability to adhere to a 
range of β₂ integrin ligands. There, I found that tolerogenic Mo-DCs express higher 
levels of active CD11a, but lower levels of active CD11b compared to mature Mo-
DCs, which suggested opposing roles between the two subunits. While tolerogenic 
Mo-DCs actually adhered significantly better to CD11b ligands iC3b and fibrinogen, 
only a trend towards increased adhesion to ICAM-1 could be found at its highest 
concentration. Lastly, findings of differences in β₂ integrin expression were taken 
forward to test the functional role of the β₂ integrin CD11b in MLRs, using activating 
and blocking agents. This showed that blocking CD11b on mature Mo-DCs reduced 
their ability to induce T cell proliferation and downregulated IFN-γ production by T 
cells, suggesting that CD11b has pro-inflammatory roles in Mo-DCs. To summarise, 
in vitro study of mature and tolerogenic Mo-DCs has highlighted potential opposing 
roles for β₂ integrin subunits: high expression of active CD11a in tolerogenic Mo-DCs 
suggests an immunoregulatory role; whilst expression and intervention data point to 
a pro-inflammatory role for CD11b. 
4.3.1 Opposing roles of CD11a and CD11b 
While expression of the β₂ integrin CD11a in its active conformation was increased, 
in tolerogenic Mo-DCs compared to mature Mo-DCs, expression of active CD11b 
was significantly decreased in tolerogenic Mo-DCs. One can therefore conclude that 
they have opposing functions. While total CD11a or CD11b expression was not 
altered between Mo-DC subtypes, tolerogenic Mo-DCs expressed significantly higher 
levels of active CD11a and significantly lower levels of active CD11b compared to 
mature Mo-DCs. Tolerogenic Mo-DCs show decreased ability to stimulate IFN-γ 
production by T cells in an MLR, which may suggest that altered β₂ integrin 
conformational states could contribute to their tolerogenic function. Therefore, I 
hypothesised that CD11a has more immunoregulatory functions, as it was increased, 
while CD11b has more pro-inflammatory functions, as it was downregulated on 




Evidence for immunoregulatory roles of CD11a  
In the case of CD11a, an immunoregulatory role is supported by data in published 
literature. For example, constitutive activation of CD11a on BMDCs through a gene 
targeting approach actually reduced the amount of T cell proliferation DCs were 
ability to induce both in vitro and in vivo (Balkow et al., 2010). This was especially 
surprising, as constitutively active CD11a on DCs also increase their adhesion to 
ICAM-1 and prolonged contact time with T cells, both of which would have been 
expected to increase BMDC-mediated T cell stimulation. Furthermore, this effect 
could be rescued by blocking CD11a function using blocking antibodies, again 
suggesting that inactive CD11a is needed for effective T cell stimulation. Controlling 
activation of CD11a could therefore be understood as a highly effective 
immunoregulatory tool. However, this finding is surprising when considering what is 
known about timing DC-T cell interactions correctly. A large number of studies have 
shown that prolonged contact between T cells and DCs is needed for CD4+ T cell 
priming and proliferation (Celli et al., 2007; Hugues et al., 2004; Obst et al., 2005; 
Stoll et al., 2002). Additionally, Hugues and colleagues also reported that continuous 
short-term DC-T cell interactions are required for tolerance induction, and another 
study showed that Tregs limited development of diabetes by limiting contact duration 
between DCs and CD4+ T cells (Tang et al., 2006). However, another study showed 
that within the first 8h of antigen presentation, T cells only interacted briefly with DCs, 
after which they showed reduced motility and increased expression of activation 
markers (Mempel et al., 2004). After this time period, T cells were reported to 
associate with DCs for over 1h, finally resulting in T cell activation. This could 
suggest that early tight adhesion to T cells because of increased active CD11a might 
result in failure of T cells to upregulate activation markers CD44 and CD69 as well as 
increase cell motility. Seeing this in the context of my findings, it is therefore possible 
that the increase in active CD11a expression in tolerogenic Mo-DCs controlled 
contact duration with T cells. However, there is very little available information on 
CD11a in DCs, with no other studies finding a similar immunoregulatory role of 
CD11a in DCs.  
It is also interesting that CCR7, which was found to be lower on tolerogenic Mo-DCs 
in previous studies (Anderson et al., 2009, 2008), usually mediates activation of 
CD11a (Kliche et al., 2012). One could have therefore expected expression of active 




However, as active CD11a expression was significantly increased in tolerogenic Mo-
DCs this could have two reasons. Although CCR7 expression was not measured 
directly here, having utilised exactly the same protocol for generation of Mo-DCs and 
characterised their phenotype as identical to previous studies (Anderson et al., 2009, 
2008; Harry et al., 2010), it is likely that CCR7 expression is similar to reported 
values in my cultures. It is therefore unlikely that expression of CCR7 on tolerogenic 
Mo-DCs was responsible for the increase in active CD11a. Another, more likely, 
possibility is that activation of CD11a in tolerogenic Mo-DCs is not mediated via 
inside-out signalling of CCR7. For example, Anderson and colleagues also found that 
expression of CCR1, CCR2 and CCR5 remained high in tolerogenic Mo-DCs even 
after stimulation with LPS (Anderson et al., 2009). This would suggest that higher 
expression of these cytokine receptors might mediate the higher expression of active 
CD11a instead. This is supported by studies finding that macrophages expressing 
CD11a were recruited at much lower levels to a site of nerve injury in a KO mouse 
model of CCR2 compared to CD11b positive macrophages (Siebert et al., 2000). 
Furthermore, CCL5, a ligand of CCR1, was shown to specifically mediate adhesion 
of T cells to ICAM-3 via CD11a, suggesting a role for especially CCR1 in mediating 
the increased expression of active CD11a (Szabo et al., 1997).  
As discussed previously, targeting CD11a in an MLR holds caveats, as T cells also 
express the β₂ integrin subunit (Figure 4.14). This poses a technical challenge, as 
interfering with CD11a function in any way would always affect T cells as well as 
DCs, thereby making results less conclusive. However, there could be other ways to 
investigate the potential immunoregulatory role of CD11a on DCs. For example, an 
RNA silencing approach could be used to silence CD11a specifically on DCs before 
putting them in co-culture with T cells. One could expect that absence of CD11a from 
DCs would increase DC-mediated T cell stimulation. However, as transfection with a 
silencing RNA takes up to a week in culture, this approach would be difficult to do 
with mature and tolerogenic Mo-DCs, as tolerogenic Mo-DCs might alter their 
phenotype during this time and transfection rates might not be consistent between 
mature and tolerogenic Mo-DCs, making comparisons difficult. Possibly, a murine 
DC-specific KO of CD11a would give yield more information on the potential 






Evidence for pro-inflammatory roles of CD11b 
In contrast, the hypothesis that CD11b is a pro-inflammatory mediator of DC function 
due to my finding that it is significantly lower in tolerogenic Mo-DCs cannot be aligned 
with the published literature in the same way. Interestingly, active CD11b on DCs, 
similarly to active CD11a, was found to decrease the cells ability to stimulate T cells 
(Varga et al., 2007), which would suggest the significant reduction in active CD11b 
expression seen in Figure 4.10 actually represents a pro-inflammatory stimulus able 
to enhance T cell proliferation. However, this is not congruent with findings from my 
functional work, where I demonstrated that blocking CD11b on mature but not 
tolerogenic Mo-DCs significantly reduced the level of T cell proliferation and IFN-γ 
production elicited by Mo-DCs (Figure 4.20). Other studies have furthermore shown 
immunoregulatory roles of CD11b, especially in preventing Th17 immune responses. 
CD11b KO mice were shown to be unable to induce oral tolerance in response to a 
repeated antigen challenge, which was suggested to be due to increased IL-6 
production of CD11b deficient APCs which in turn swayed T cell differentiation 
towards a Th17 phenotype (Ehirchiou et al., 2007). In addition, ligating CD11b on 
human Mo-DCs was found to efficiently restrict Th17 T cell expansion from memory T 
cells by reducing the production of cytokines such as IL-1β, IL-6 and IL-23 (Nowatzky 
et al., 2018a). However, as this study did not demonstrate a similar effect in naïve T 
cells, one could argue that this described immunoregulatory role of CD11b is not 
relevant in the experimental system utilised in this chapter whereby naïve T cell 
priming is quantified. Furthermore, ligation of CD11b was found to increase 
expression of MHC and costimulatory molecules on DCs, but restrict release of pro-
inflammatory cytokines, thereby suppressing their stimulatory ability (Behrens et al., 
2007), and CD11b was found to make DCs more tolerogenic (Škoberne et al., 2006). 
CD11b on DCs binding to ICAM-1 on inflamed endothelial cells similarly suppressed 
stimulatory function (Podgrabinska et al., 2009). Lastly, CD11b was found to be 
highly important in restricting TLR signalling on DCs (Han et al., 2010, p. 88; Yee and 
Hamerman, 2013), and was found to induce production of the anti-inflammatory 
cytokine IL-10 (Wang et al., 2010). 
However, while several studies mentioned above suggest that CD11b negatively 
regulates TLR signalling, one study reported that CD11b deficiency caused reduction 
in T cell activation due to DCs inability to endocytose TLR4 in response to LPS 




2014). Still, considering the overwhelming breadth of evidence of CD11b playing 
immunoregulatory roles, the results of this chapter suggesting the exact opposite of 
CD11b being more pro-inflammatory have to be scrutinised.  
One possibility is that the CD11b blocking antibody causes the downstream 
signalling associated with CD11b ligation, resulting in an immuno-regulatory effect in 
line with previous reports. While several studies have shown that blocking CD11b 
reduced CD11b-mediated adhesion (Altieri, 1991; Kusunoki et al., 1994), it is not 
well-described if binding of the blocking antibody could induce intracellular signalling 
despite blocking adhesion. Published evidence on this is conflicting. In monocytes for 
example, CD11b-dependent enhancement of TNF-α production in response to 
monocytes was reduced when confronted with a CD11b blocking antibody compared 
to ligation of CD11b (Fan and Edgington, 1993). This would suggest that blocking 
CD11b does not have the same effect as ligating it in terms of downstream cell 
signalling. However, another study reported that macrophages could produce Nitric 
oxide (NO) in a dose-dependent manner, when treated with different levels of CD11b 
blocking antibody in the presence of IFN-γ (Goodrum et al., 1994). Furthermore, 
ligation of CD11b with a different ligand did not have the same effect, suggesting that 
specifically M1/70, the CD11b blocking antibody used in this study, might have 
functional roles when binding to CD11b in addition to merely blocking access to other 
ligands. Thinking about this potential dual role of blocking CD11b and the wealth of 
literature describing anti-inflammatory roles of CD11b, this could imply that by 
blocking CD11b two distinct roles of the integrin subunits could be affected. First, its 
contribution to DC-T cell physical contacts via CD11b binding to its ligand ICAM-1 on 
T cells, which is a function that would be blocked. Second however, is the signalling 
role of ligated CD11b, which might have downstream effects on expression of co-
stimulatory receptors and cytokine production and might potentially be increased by 
providing the CD11b blocking antibody in culture. CD11b blocking antibody acting in 
a similar way to ligation of CD11b, which was reported to be immunoregulatory, 
would explain the reduction in IFN-γ production and T cell proliferation in mature Mo-
DCs treated with it (Figure 4.20). However, it does not explain why tolerogenic Mo-
DCs, which showed to induce significantly lower IFN-γ production by T cells 
compared to mature Mo-DCs, have comparatively lower expression of active CD11b 





Balance between β₂ integrin subunits  
Another possibility is that β₂ integrin subunits, such as CD11a and CD11b (and 
indeed CD11c and CD11d), act in careful balance with each other, which is an 
aspect that none of the CD11b-specific studies mentioned above took into 
consideration. For example, mutating CD11b could potentially alter the balance of 
other β₂ integrin subunits, such as CD11a and CD11c, in an attempt to compensate 
for the loss of CD11b. Rather than attributing results directly to CD11b, it is therefore 
possible that the balance between different β₂ integrin subunits contributes to their 
respective function. This is especially likely considering the inconclusive results 
gained from investigating adhesive ability of Mo-DCs to a variety of β₂ integrin 
ligands, where it was found that tolerogenic Mo-DCs were not significantly increased 
in their adhesion to ICAM-1, although close at the highest concentration of ligand, but 
surprisingly showed significantly higher adhesion to ligands iC3b and fibrinogen, but 
not C4b, which had been hypothesised to be reduced due to the significantly lower 
expression of active CD11b on tolerogenic Mo-DCs (Figure 4.8 and Figure 4.12, 
respectively). As discussed, even if other β₂ integrin subunits such as CD11c 
compensated for reduction in active CD11b to mediate increased adhesion, this does 
still not explain why adhesion to C4b was not altered. This could suggest that 
balance of different β₂ integrin subunits is important to mediate adhesion to ligand.  
Role of β₂ integrins on tolerogenic Mo-DCs  
An important point that has not been discussed yet is the question if differences in 
expression of CD11a and CD11b on tolerogenic compared to mature Mo-DCs are 
downstream or upstream of cells assuming a tolerogenic phenotype. So far, I have 
assumed that alteration in expression of active CD11a and CD11b part of the 
changes that infer tolerogenic Mo-DCs with immunoregulatory functions. However, it 
is also possible that tolerogenic phenotype in turn drives altered β₂ integrin 
conformation on tolerogenic Mo-DC surfaces, thereby implicating it as a potential 
biomarker for tolerogenicity of Mo-DCs. Considering that targeting CD11b using a 
CD11b blocking antibody caused a reduction in T cell proliferation and IFN-γ 
production elicited by mature Mo-DCs (Figure 4.20), it is likely that CD11b has a 
functional role, as well as the potential opportunity to use it as a biomarker for 
tolerogenic Mo-DCs. However, as manipulating CD11a was technically difficult, a 




could not be confirmed in this study. Keeping in mind that another study did find that 
increases presence of active CD11a reduced T stimulatory capability of DCs (Balkow 
et al., 2010), it is however likely that both CD11a and CD11b might play distinct 
functional roles as well as being downstream of other tolerogenic mediators 
important for tolerogenic Mo-DC function. 
While the proposed immunoregulatory role of active CD11a in Mo-DCs could not be 
proven functionally, it has been previously shown in the published literature. In 
contrast, the hypothesised pro-inflammatory role of active CD11b finds no relevant 
support in the very limited literature, and is actually found to be similarly 
immunosuppressive to active CD11a. However, when blocking CD11b on mature 
Mo-DCs I found T cell proliferation and IFN-γ production to be significantly lower, 
again supporting a pro-inflammatory role for CD11b. To conclude, CD11b might have 
pro-inflammatory roles on DCs that have not been extensively described so far and 
remit further investigation. Especially as CD11b seems to have both pro-inflammatory 
and immunoregulatory roles depending on context, involvement of other β₂ integrin 
subunits will have to be considered.  
4.3.2 Possibility of modulating β₂ integrins to improve tolerogenic cell 
therapies for RA 
As mentioned in Chapter 1, tolerogenic Mo-DCs tolerised with a patient-specific 
antigen contributing to RA disease in this individual is currently being explored as a 
promising cellular therapy for RA. In theory, a cell-based tolerogenic therapy would 
not only decrease immune activation short-term but also educate the immune system 
to re-establish tolerance to self that is lost in RA. While the phase I clinical trial 
established that tolerogenic Mo-DCs injected into the joint are safe and the highest 
dose was reported to have positive effects in some study participants (Bell et al., 
2016), there are still some issues to resolve before this treatment can become 
available. Some of these issues, such as identifying a suitable antigen that is relevant 
for the immune response causing joint inflammation in a specific patient (Jansen et 
al., 2018), do not fall within β₂ integrin function. However, other aspects, such as the 
low migratory ability of tolerogenic Mo-DCs, could be partially explained and even 
potentially rectified by altered β₂ integrin function on tolerogenic Mo-DCs.  
While earlier studies found that tolerogenic Mo-DCs express low levels of CCR7 and 




compared to mature Mo-DCs (Anderson et al., 2009, 2008), it remains unclear if 
tolerogenic Mo-DCs can migrate out of the joint to the LN and whether such 
migration to the LN is required for the induction of tolerance (Bell et al., 2016). As 
ability to present auto-antigen as well as migratory ability have been described as the 
hallmarks of yielding systemic tolerising effects (Hilkens et al., 2010), it is likely that 
tolerogenic Mo-DCs will need to reach the LN to interact with T cells and induce 
systemic tolerance. As the migratory ability of tolerogenic Mo-DCs using currently 
established protocols is poor, culturing methods may need to be adapted to ensure 
migratory ability of tolerogenic Mo-DCs is sufficient. In the following paragraphs, I will 
therefore briefly discuss the potential effects of β₂ integrin expression on the 
tolerogenic Mo-DCs ability to migrate and the possibility to alter their β₂ integrin 
functionality to improve migratory abilities. 
Considering merely β₂ integrin expression on tolerogenic Mo-DCs, one cannot make 
assumptions about their ability to migrate. In mice, migration of cells from tissue to 
LN as found to occur independently of all β₂ integrins when in an inflammatory 
(Lämmermann et al., 2008; Morrison et al., 2014), which suggests that migration of 
Mo-DCs might occur independently of β₂ integrins in the inflammatory context of RA. 
However, the increased adhesion of tolerogenic Mo-DCs to plastic (observation in 
both Hilkens and Morrison labs), glass (Figure 4.5), as well as to iC3b and fibrinogen 
(Figure 4.12), suggests that altered composition of active β₂ integrin expression 
overall increases adhesion to various ligands, although adhesion to both plastic and 
glass could also be mediated by different adhesion receptors not considered in this 
study. This, in turn, might retain tolerogenic cells at the injection site, instead of being 
able to migrate to the draining LN.  
Overall, testing migratory ability of tolerogenic Mo-DCs could not be attained due to 
limited time. However, migration towards LNs was shown to be independent of β₂ 
integrins in an inflammatory context (Lämmermann et al., 2008; Morrison et al., 2014) 
and blocking CD11b on tolerogenic Mo-DCs had no significant effects on T cell 
proliferation (Figure 4.20). In murine studies however, integrin-deficient DCs were 
shown to migrate to LN in larger numbers in steady state, which was hypothesised to 
be due to decreased tissue retention (Morrison et al., 2014). Keeping in mind that 
reduced expression of active CD11b also yielded more tolerogenic cells, blocking 
CD11b on tolerogenic Mo-DCs might potentially make them more tolerogenic and 




changes in tolerogenic Mo-DC stimulatory capability when blocking CD11b (Figure 
4.20). Furthermore, as tolerogenic Mo-DCs have been described to only express low 
levels of CCR7, blocking β₂ integrins might not improve exit from tissues and 
migration to LNs to a similar level as shown by Morrison and colleagues. Further 
work on this topic should therefore assess migratory ability in response to blocking β₂ 
integrin subunits alongside T cell stimulatory ability. However, instead of blocking 
CD11b, which was found to decrease T cell proliferation in mature Mo-DCs (Figure 
4.20), it might be more interesting to block CD11a or CD11c to distinguish which 
subunit mediates the increase in adhesion to β₂ integrin ligands, which might impede 
migratory abilities. 
When considering manipulation of β₂ integrins to improve tolerogenic Mo-DC 
therapy, any strategies will likely have spatially or temporally separate or multi-modal 
in nature. This is because of the range of functions β₂ integrins can be involved in, 
and they possibility that different subunits are playing potentially opposing roles in 
tolerogenic function. For example, if we assume that expression of integrins retains 
Mo-DCs in the joint after injection, it would be most feasible to block integrins to 
enable Mo-DCs to exit the joint and migrate towards LNs more effectively. However, 
considering β₂ integrins potential role in DC-T cell interactions, it is possible that 
balance of subunit conformation could contribute to tolerising T cells. Therefore, 
targeting β₂ integrins to enable migratory abilities of tolerogenic Mo-DCs might impair 
their ability to induce tolerance and vice versa. To add a further layer of complexity to 
this, β₂ integrins also have a potential role in inducing downstream signalling that 
alters expression of costimulatory molecules and production of pro- or anti-
inflammatory cytokines. For example, a blocking antibody meant to increase 
migration out of the injection site could simultaneously increase pro-inflammatory 
signals produced by tolerogenic Mo-DCs by acting as a ligand for CD11b. Targeting 
β₂ integrins will therefore have to be carefully tested to reduce unwanted off-target 
effects, due to the distinct roles of β₂ integrins in tolerogenic Mo-DC function. 
To conclude, there are still severe gaps in current knowledge on the effect of β₂ 
integrins on Mo-DCs migratory ability. However, as these gaps are filled and 
available β₂ integrin targeting therapeutics advance, targeting β₂ integrins on 





In this chapter, I identified potentially opposing roles of the β₂ integrin α-subunits 
CD11a and CD11b utilising mature and tolerogenic Mo-DCs as a model system for 
immune activation and tolerance in DCs. My findings suggest that active CD11a is 
more immunoregulatory, due to the increased expression of its active form on 
tolerogenic Mo-DCs. On the other hand, active CD11b was downregulated on 
tolerogenic compared to mature Mo-DCs and blocking CD11b on mature Mo-DCs in 
an MLR reduced their ability to stimulate proliferation of and IFN-γ production by T 
cells. Despite adhesion assays showing that tolerogenic Mo-DCs showed higher 
adhesion to iC3b and C4b and a range of literature suggesting the opposite, this is 




































 Opposing roles of β₂ integrins on antigen-presenting 





In an in vitro setting, I hypothesised that CD11b has more pro-inflammatory roles, 
while CD11a is potentially more immunoregulatory. This was based on my findings 
that active CD11b expression was reduced on tolerogenic Mo-DCs, while active 
CD11a expression was increased compared to mature Mo-DCs. This was further 
backed by the result that blocking CD11b on mature Mo-DCs reduced the amount of 
T cell proliferation they were able to induce in an MLR, as well as the amount of IFN-
γ present in supernatants. Continuing this work, it was important to test if this finding 
could find support in an ex vivo setting. Specifically, in PB of healthy controls 
compared to patients with RA, a condition marked by a dysregulated immune 
system. The autoimmune condition RA was chosen as it represents a state of the 
immune system where tolerance to self is lost, which causes joint-specific as well as 
systemic pathology. Comparing healthy controls to patients who have active disease 
or are in remission therefore allows insights into how expression of β₂ integrins might 
potentially be altered in the context of loss of tolerance to self. As discussed 
previously, understanding both stimulatory and regulatory effects of β₂ integrins in 
DCs on immune function could make them more viable therapeutic targets for 
conditions such as RA, where immune regulation is lost, in the future. 
5.1.1 Role of antigen-presenting cells in Rheumatoid Arthritis 
While presentation of an auto-antigen to aberrant T and B cells is hypothesised to be 
the initiating event of RA pathogenesis, the role of APCs in RA pathogenesis as well 
as progression is not fully elucidated.  
In mouse models of articular initiation of RA, conventional DCs were reported to have 
a critical role in T cell activation and concurrent joint inflammation (Benson et al., 
2010), while pDCs were found to have more immunoregulatory roles in the murine 
joint (Jongbloed et al., 2009). However, the significance of DCs for RA progression is 
not well understood. Certain HLA-DR alleles, notably DR1 and DR4, are associated 
with more severe or more progressive disease, suggesting an important role for 
continuous T cell activation by DCs in RA (Weyand et al., 1992; Zeben et al., 1991). 
DCs were found to be present in higher numbers in synovial fluid of patients with 
established RA when compared to the less overtly inflammatory joint disease 
osteoarthritis (Harding and Knight, 1986), suggesting that there is an on-going role 
for DCs in maintaining joint inflammation. Circulating numbers of DCs in RA are a 




RA (Cooles et al., 2018; Jongbloed et al., 2005), while others suggest DC numbers 
were actually higher (Estrada-Capetillo et al., 2013). This conflict in findings could be 
due to DCs becoming sequestrated in inflamed joint tissues at certain disease 
stages, removing cells from the circulating pool. However, it is established that Mo-
DCs derived from RA patient blood monocytes are more pro-inflammatory than their 
healthy counterparts, characterised by increased IL-6 and IL-23 production and 
ability to induce Th17 cells (Estrada-Capetillo et al., 2013). Similarly, high numbers of 
DCs can be isolated from synovial fluid and were found to stimulate T cells better 
than cells isolated from peripheral blood (Zvaifler et al., 1985). Generally, as self-
reactive T cells should be deleted in the thymus, it is hypothesised that DCs present 
self-protein that has been altered due to citrullination or other factors to T cells and 
provide sufficient pro-inflammatory cytokines and costimulatory factors to activate T 
cells, which are unable to recognise the altered self-protein (McInnes and Schett, 
2011; Yu and Langridge, 2017). DCs therefore play important roles both in disease 
initiation as well as progression. 
Monocytes are widely described to be more active in the context of RA, marked by 
increased expression of CD14 (Shinohara et al., 1992), a receptor for complexes of 
LPS and LPS binding protein (LBP) which can mediate immune sensitivity in 
response to infection (Wright et al., 1990). Interestingly, a range of β₂ integrins, 
including CD11a, CD11b and CD18 were also shown to be increased (Lioté et al., 
1996; Torsteinsdóttir et al., 1999). While these changes are potentially due to the fact 
that monocytes are exposed to the inflammatory cytokine environment present in the 
systemic disease RA, evidence is accumulating that monocytes can also play an 
active role in creating the afore-mentioned pro-inflammatory environment. In vivo 
stimulated CD14+ monocytes from inflamed joints of RA patients were found to 
promote specifically Th17 responses when compared to resting CD14+ monocytes 
from PB (H. G. Evans et al., 2009), suggesting that monocytes have distinct pro-
inflammatory roles in the joint that are independent of systemic cytokines. This is 
especially important, as Th17 T cells are considered a potent contributor to joint 
destruction in RA (van den Berg and Miossec, 2009). Another study found that 
CXCL16 expression, which was found to be a driver of immune cell recruitment to the 
joint as well as disease pathogenesis (Nanki et al., 2005; Voort et al., 2005), was not 
altered between monocytes from healthy donors and patients with RA. However, 




than an increased influx of monocytes to the joint could in turn recruit other cells to 
the joint (Lieshout et al., 2009). 
To conclude, it can therefore be said that both DCs and monocytes are thought to 
contribute to both initiation of RA as well as disease progression. Exploring the role 
of β₂ integrins on DCs and monocytes specifically could therefore be of special 
interest to understand how β₂ integrins might potentially contribute to these different 
functions. 
5.1.2 Potential role of β₂ integrins in Rheumatoid Arthritis 
There is a limited amount of published literature on the role of β₂ integrins in RA, but 
it is striking that β₂ integrin subunits CD11a and CD11b seem to have different 
reported functions in the context of RA (Schittenhelm et al., 2017). 
In animal studies, CD11a was found to be important for the induction of RA disease 
models. Absence of CD11a in a KB x N serum transfer model of arthritis yielded mice 
resistant to disease induction (Watts et al., 2005). Supporting this, blocking all β₂ 
integrins in a rabbit model of RA caused a reduction of inflammation, suggesting that 
leukocytes could not be recruited to the joint in sufficient numbers to give rise to the 
full extent of the disease model (Jasin et al., 1992). Blocking CD11a, either using an 
anti-CD11a antibody (Kakimoto et al., 1992) or a small-molecule CD11a antagonist 
(Suchard et al., 2010), caused an improvement in clinical scores and reduced the 
amount of pro-inflammatory cytokine mRNA levels within the murine joint. Lastly, 
mice carrying a mutation in β₂ integrin ligand ICAM-1 similarly showed a reduction in 
susceptibility to the collagen-induced arthritis (CIA) model (Bullard et al., 1996). All of 
this suggests a pro-inflammatory role of CD11a in mice, specifically in leukocyte 
recruitment to the joint. In humans, however, the emerging role of CD11a seems to 
be more complex. CD11a expression was found to be increased in inflamed synovial 
tissue lymphocytes (Cush and Lipsky, 1988), but as the β₂ integrin subunit also plays 
an important role in lymphocyte migration, cause and effect are difficult to tease 
apart. On the other hand, blocking CD11a in vitro on healthy PB non-classical CD16+ 
monocytes was found to increase induction of Th17 T cells in response to treatment 
with a superantigen and a TLR2/NOD receptor agonist, suggesting an 
immunoregulatory role of CD11a on CD16+ monocytes but not CD14+ monocytes 




When considering the β₂ integrin subunit CD11b on the other hand, animal studies 
have shown that knocking out CD11b causes exacerbated joint pathology in a KB x 
N serum transfer model of arthritis (Watts et al., 2005). This result was repeated in a 
study utilising the CIA model, which also found that the observed increase in IL-6 
production and Th17 priming could be reversed when introducing a DC cell line 
expressing CD11b (Stevanin et al., 2017), suggesting that CD11b plays 
immunoregulatory roles on DCs in RA. Surprisingly, a different study using both the 
CIA model and serum transfer model, found that blocking CD11b immediately before 
onset of symptoms could ameliorate symptoms and render serum unable to induce 
arthritis in SCID mice (Taylor et al., 1996), potentially suggesting that CD11b might 
also contribute to cell recruitment to the joint. When FcγRIIB-deficient mice, which 
spontaneously develop arthritis, were treated with a CD11b monoclonal antibody, 
symptoms were improved. This occurred in tandem with a reduction in migration of 
inflammatory cells to the synovium (Ohtsuji et al., 2018). Despite these promising 
animal studies, a functional polymorphism of ITGAM (CD11b), was found to be 
significantly associated with SLE, but not with RA (Lee and Bae, 2015). While the 
polymorphism, coding for a single amino acid substitution at position 77 of the 
extracellular domain of CD11b, remains able to undergo conformational changes, it 
shows impaired ability to adhere to CD11b ligands and mediate phagocytosis 
(MacPherson et al., 2011; Rhodes et al., 2012). However, CD11b was also found to 
be increased in peripheral CD14+ monocytes of RA patients (Lioté et al., 1996).  
Consulting the published literature on a potential role of β₂ integrins in RA, it 
becomes apparent that several different aspects influencing β₂ integrin expression 
might occur simultaneously and might also differ between different cell types. First of 
all, there are systemic effects apparent in circulating cells as well as more local 
changes present in an inflamed joint. It is furthermore clear that β₂ integrins play a 
role in recruiting APCs to the joint, but other potentially more immunoregulatory roles 
in T cell activation are less well understood. Overall it is therefore possible that any 
additional roles carried out by β₂ integrins may be either subunit-specific, as 
suggested in the opposing roles of CD11a and CD11b observed in Chapter 4, or cell 
type specific, as suggested in studies finding differences in CD11b immunoregulatory 





This chapter aims to assess expression and conformation of β₂ integrin subunits in 
APCs from RA patients and compare them to healthy controls. The aims of this 
chapter therefore were to:  
1. Devise data analysis strategy that yields information on expression of both 
total and active β₂ integrins as well as how one relates to the other.  
2. Quantify β₂ integrin expression and conformation on APC populations in PB 
from healthy controls  
3. Compare expression and conformation of β₂ integrin α-subunits CD11a and 
CD11b specifically between PB of RA patients with active disease and in 
remission to healthy controls. Furthermore, compare expression and 
conformation of β₂ integrins in PB to SF of RA patients 
4. Investigate if in vitro stimulation of PBMCs with various pro- and anti-
inflammatory stimuli or RA SF can mimic the joint environment in respect to β₂ 
integrin expression and conformation 
5. Test the ability of PB cDC2 DCs to stimulate T cell proliferation in an MLR in 
the presence of CD11b antagonism or agonism.  
5.3 Results 
5.3.1 Analysis and quantification of clinical data 
β₂ integrin expression was to be assessed on clinical samples acquired over a period 
of 1-2 years. As expression level (MFI or brightness of signal) was one of the major 
read-outs anticipated, standardising flow cytometry data over time was necessary. 
This was because flow cytometer lasers undergo shifts over time, which could render 
samples collected at the beginning of the recruitment period more different from 
samples recruited towards the end than from a sample from a different group 
(Schwartz et al., 1998; Watson, 1987). For this, BD application settings were utilised, 
which were applied to Fortessa X20 baseline throughout the recruitment period. 
Application settings rely on recording standardised reference beads upon which 
photomultiplier (PMT) voltages can be adjusted to (Gratama et al., 1998).  
Quantifying expression levels of both total and active β₂ integrins simultaneously had 
the potential to yield a wide breadth of novel information. This was particularly the 
case because there is no available literature on the relationship between total 




the same time therefore provides unique insights into the role of β₂ integrin 
expression as well as conformational changes in different cell functions. To maximise 
information gained from this approach, a variety of analysis values were obtained for 
each sample. A detailed graphic representation of the different values obtained can 
be found in Figure 5.1.  
For total expression of β₂ integrins, three values were obtained, including the MFI of 
the total population (1), the % of cells positive for the total marker in question (2) and 
the MFI of the cells that were positive for that specific marker (3) (Figure 5.1A). This 
is because different cell populations might have different proportions of cells positive 
for a marker. If, for example, the total β₂ integrin in question is only expressed on a 
small proportion of cells, the large negative population present will dominate the total 
MFI (1). In this case, %MFI (3) gives more accurate information on how much of that 
specific marker is present on the cells that express it. This also leads immediately 
into why it is important to consider both MFI (1 and 3) and %Positive (2). While MFI 
yields information on how bright the marker is in this cell population, suggesting more 
or less surface expression, percentage of cell positive for a specific marker gives 
important information on how widely the marker is expressed in a specific cell type.  
For expression of active β₂ integrins, a total of five values were obtained. The first 
three values mirror what was obtained for the total expression of the subunit, with (4), 
(5) and (6) corresponding to MFI, %positive and %MFI respectively (Figure 5.1B). 
However, additionally to these values, two further measurements were taken into 
account to yield information on how total and active expression of a specific β₂ 
integrin subunit relate to one another (Figure 5.1C). To gather information on how 
many cells expressing the total β₂ integrin subunit also express the corresponding 
active subunit, the % of total-expressing cells positive for the active marker were 
recorded (T%) (7).  
As this analysis was done for total and active β₂ integrin subunits CD11a, CD11b and 
CD18 on five APC subtypes, not all values acquired for each sample were possible 
to show in the following chapter. Instead, all data was considered and the value best 






Effect of PMA activation on β₂ integrins 
While the use of PMA as a positive control was validated in Chapter 3, the desired 
effect of increasing active β₂ integrins was not significant, as it was only tested on 
three healthy samples. Additionally, the effect of PMA on CD11b and CD18 seemed 
to differ from the effect on CD11a, with the latter seemingly less responsive to 
stimulation. Therefore, it was decided to investigate the effect of PMA activation on 
CD11a with a larger sample size of healthy controls, as well as any differences 
between APC types reacting to stimulation with PMA. Additionally, the effect of 
stimulation on total β₂ integrins was assessed. For this, only double stained CD11a 
Figure 5.1 β₂ Quantification of β₂ integrin subunit expression 
Graphical description of data analysis strategy used for each cell type and β₂ integrin subunit 
considered (CD11a, CD11b or CD18). A. Data analysis strategy for total β₂ integrins, yielding 
measurements 1, 2 and 3. B. Data analysis strategy for active β₂ integrins, yielding measurements 4, 
5 and 6. C. Data analysis strategy to connect total β₂ integrin expression to active β₂ integrin 




total (when co-stained with active CD11a, affected by steric hindrance) was analysed 
due to limited cell number.  
PBMCs were gated in accordance with the gating strategy presented in Chapter 3, 
section 3.3.6, Figure 3.7. This yielded classical (CD14+) as well as non-classical 
monocytes (CD16+), as well as three DC subtypes, cDC1 DCs (CD141+), cDC2 DCs 
(CD1c+) and pDCs (CD11cneg). Expression of active CD11a, CD11b and CD18 on 
unstimulated (-PMA) and stimulated (+PMA) APC populations is compared in Figure 
5.2. Active CD11a was not significantly altered by PMA stimulation in CD14+ 
monocytes or cDC2 DCs. Interestingly, however, active CD11a was significantly 
different in all other APC types, but instead of increasing the amount of active CD11a 
on the cell surface, PMA stimulation resulted in lower expression of active CD11a. 
Active CD11b was significantly increased upon PMA-stimulation in all APC types 
except pDCs. Lastly, active CD18 was significantly increased upon PMA stimulation 
in CD14+ monocytes and CD16+ monocytes, but none of the DC populations. 
This reduction in active CD11a upon PMA stimulation could be due to increased 
endocytosis from the cell surface upon activation. However, this would suggest that 
active CD11a is endocytosed from the cell surface much quicker than active CD11b 
or CD18, where an increase in active β₂ integrin upon PMA stimulation can be 
observed. While this is possible considering my findings in Chapter 3 showing that 
sufficient CD11a staining can be achieved after 5min, while both CD11b and CD18 
need to be stained for 30min to achieve sufficient signal (Chapter 3, 3.3.2, Figure 
3.2), it still seems unlikely. Another possibility is that PMA acts differently on CD11a 
than it acts on CD11b and CD18. The fact that CD18 reacted to PMA differently on 
different cell types again suggests that there is APC-type specific regulation of β₂ 
integrin activation. This is especially the case for CD18, as an increase in active 
CD18 likely also caused associated α-subunits to become activated. The fact that 
this was not the case for CD11a, and furthermore not shown in DC populations 
suggests that different cell types regulate β₂ integrin subunits differentially to yield 
migration or adhesion results necessary in the biological context of the cell. This was 
supported by findings in the literature, showing that if CD11a is transfected into a 
non-hematopoietic cell line remains constitutively active and is not affected by a 
protein kinase C inhibitor reported to reduce expression of active CD11a (Dustin and 




have different pathways to modulate β₂ integrin expression via intracellular domains 
(Ginsberg et al., 1992). 
Next, the effect of PMA stimulation on total β₂ integrin expression was analysed 
(Figure 5.3). There was no significant effect of PMA stimulation on total CD11a 
expression except in pDCs, where total CD11a expression was significantly lower in 
the stimulated sample. Interestingly, total CD11b was significantly higher in all APC 
types except pDCs upon PMA stimulation. This suggests that PMA not only 
increased the amount of CD11b subunits assuming their high-affinity form, but also 
the amount of total CD11b on the cell surface.  
This could mean that CD11b trafficking, which occurs at a faster rate than CD11a 
(Bretscher, 1992), is further increased when cells are stimulated with PMA. Total 
CD18 was also significantly increased in PMA-stimulated CD14+ monocytes, cDC2 
DCs and cDC1 DCs, but not CD16+ monocytes or pDCs. Considering the results of 
both CD11a and CD11b, it is possible that CD11a is more dominant on CD16+ 
monocytes and pDCs, resulting in no significant difference in CD18, while the 
significant effect on total CD11b expression is more dominant on CD14+ monocytes, 
cDC2 DCs and cDC1 DCs. Furthermore, it is important to keep in mind that CD11c, 
which is highly expressed on all APC types but pDCs due to the utilised gating 
strategy, can also pair with CD18 and might thereby affect expression of total or 
active CD18 in response to PMA stimulation.  
In summary, PMA stimulation caused an increase in expression of active CD11b in 
all cell types but pDCs and CD18 in both classical and non-classical monocytes. 
Surprisingly, expression of active CD11a was significantly lower after stimulation in 
CD16+ monocytes, cDC1 and pDCs, suggesting that the different β₂ integrin subunits 
react differently to PMA exposure. Furthermore, when testing the effect of PMA on 
total β₂ integrin expression, it was found that expression of total CD11b and CD18 is 
also significantly increased in several APC types after stimulation, potentially 
suggesting a role of PMA in β₂ integrin cycling. Expression of total CD11a was 
significantly reduced in pDCs but otherwise remained unaffected by PMA stimulation, 
again underlining that CD11a reacts to PMA in a fundamentally different way from 











Figure 5.2 Effect of PMA on active β₂ integrin expression 
Expression (MFI) of active CD11a, CD11b and CD18 was compared between unstimulated (black 








5.3.2 β₂ integrin expression on APCs in health 
While there is evidence of different APC types expressing different levels of β₂ 
integrins, there is, to my knowledge, no information in the published literature on how 
this relates to β₂ integrin activation status (conformation). It was therefore of 
importance to assess a healthy control data set in respect to their total and active β₂ 
integrins on monocytes and DCs isolated from peripheral blood. To this end, 29 
healthy controls were assessed using the active integrin panel described in Chapter 
3 to quantify the expression of total and active integrin subunits on APCs.  
Figure 5.3 Effect of PMA on total β₂ integrin expression 
Total expression (MFI) of CD11a, CD11b and CD18 was compared between unstimulated (black 





Total β₂ integrins in healthy control APCs 
Signal brightness of cells expressing the marker (MFI) for total CD11a, CD11b, CD18 
and CD11c (MFI) for each of the APC types of interest is shown in Figure 5.4 (left). 
Additionally, the % of cells expressing the marker in question for CD11a, CD11b and 
CD18 was shown, as well as the MFI exclusively of cells expressing the marker 
(%MFI). Lastly, an overlay histogram of respective expression of total β₂ integrins on 
the five different APC subtypes was presented. As CD11c was used as a marker to 
delineate all APCs except for pDCs, % of cells expressing the marker is not shown as 
it would be 100% for all cell populations considered, except for pDCs. As discussed 
in Chapter 3, there is significant loss of CD11a total signal due to steric hindrance 
when staining for both active and total antibodies together. Total and active CD11a 
stained together (“double stain”), will therefore not only be shown in Figure 5.4A but 
will also be compared to the total CD11a single stain in Figure 5.5, allowing for 
validation of the double stained result. According to the double stain samples, CD11a 
expression is highest on cDC1 DCs, while expression on classical (CD14+) and non-
classical (CD16+) monocytes is similar to CD11a expression on cDC2 DCs. Lastly, 
pDCs are shown to have the lowest amount of CD11a expression on their surface, 
significantly lower even than cDC2 DCs. The differences in CD11a expression are 
shown to be indeed due to differing amounts of CD11a total on the cell surface of the 
APCs, as the % of cells positive for the CD11a total marker is close to 100% for all 
samples in CD14+ and CD16+ monocytes, as well as cDC1 and cDC2 DCs. pDCs are 
the only cell types that do not express CD11a on all the cells in the population in 
some healthy donors, but this difference is not significant. Importantly, when 
comparing these results to the single stained CD11a (Figure 5.5), results are largely 
the same. The only exception is that both CD14+ and CD16+ monocytes show 
significantly higher CD11a expression compared to cDC2 DCs, a result which is not 
visible in the double stained samples. This strongly suggests that steric hindrance 
occurring largely does not differ between cell types but is mostly consistent, enabling 
direct comparison of double stained samples. It can therefore be concluded that 
assessment of total expression of CD11a is not hindered by the presence of steric 
hindrance in the used experimental systems, as relative differences between cells 
persist regardless of its presence. 
CD11b expression shows a markedly different expression profile from CD11a in 




low expression on CD16+ monocytes, cDC2, cDC1 and pDCs, which were all 
significantly lower than CD14+ monocytes. Interestingly, CD11b expression showed 
more variation in % expression between cell populations. While almost 100% of 
CD14+ monocytes expressed CD11b on their surface, this was not the case for the 
other cell types. CD11b was only expressed on around 60% of CD16+ monocytes 
and cDC2 DCs, and 30% of cDC1. pDCs had the lowest %positive value, with only 
20% of cells in the population expressing CD11b total (Figure 5.4B).  
CD18 expression was highest on CD14+ monocytes and lowest on pDCs, with 
expression being significantly lower on cDC2s compared to CD16+ monocytes 
(Figure 5.4C). Similarly, to CD11a total, CD18 was expressed on almost 100% of the 
cell populations considered, meaning that graphs plotting MFI and %MFI look 
virtually the same, with the difference in signal brightness being due to the amount of 
CD18 expressed on the cell surface and not to the amount of cells expressing it.  
Lastly CD11c was highest in CD14+ monocytes and cDC2 DCs, and significantly 
lower CD16+ monocytes and cDC1 DCs Figure 5.4D). As the absence of CD11c in 
the presence of HLA-DR was used to delineate pDCs it is not surprising that the 
marker was absent from this population. However, it is important to note that none of 
the β₂ integrins considered were highly expressed on pDCs, which always showed 
















 Figure 5.4 Total β₂ integrins in healthy 
controls 
Total expression of CD11a, CD11b, CD18 
and CD11c in five APC subtypes of 
interest, CD14+ monocytes+, CD16+ 
Monocytes, cDC2 and cDC1 DCs, as well 
as pDCs. Measurements shown are %MFI 
and %Positive cells, except for CD11c 
where only MFI was available. Repeated 





To summarise, total CD11a and CD18 were expressed on virtually all cells of any 
given population. This is maybe not surprising, as both are needed for homeostatic 
monocyte migration (Henderson et al., 2003), a role which could also be true for 
circulating DCs. CD11b on the other hand was present on nearly all CD14+ 
monocytes, but percentage of cells stained positive for the marker was significantly 
lower in CD16+ monocytes and cDC2 DCs, significantly lower again in cDC1 DCs 
and lowest values were recorded in pDCs. Considering brightness of signal only in 
cells positive for the total integrin, CD11a had a markedly different pattern from all 
other total β₂ integrin subunits considered. Total CD18, CD11b and CD11c were 
 
 Figure 5.5 Effect of steric hindrance on total CD11a in healthy controls 
Double stain of total and active CD11a affected by signal loss due to steric hindrance (left) 
compared to single stain of total CD11a unaffected by signal loss due to steric hindrance 
(right). %MFI and %Positive for total CD11a expression are shown. Repeated measures one-




highest expressed on CD14+ monocytes, with significantly lower levels in CD16+ 
monocytes, cDC2 and cDC1 DCs, and significantly lower levels again in pDCs. Total 
CD11a on the other hand was highest expressed on cDC1 DCs, with medium 
expression in CD14+ and CD16+ monocytes, as well as cDC2 DCs. What all β₂ 
integrins shared however, is their low expression on pDCs, which were significantly 
lower in all integrin subunits.  
Considering how this compares to previously published date on β₂ integrin 
expression in human DCs and monocytes (Chapter 1, section 1.4.2, Table 1.1), this 
data set confirmed several previously published results, including that cDC2 DCs 
were significantly higher in CD11c compared to cDC1 DCs (Haniffa et al., 2012; 
Robbins et al., 2008), that pDCs expressed CD11a (Rosa et al., 2003) but almost no 
CD11b (Haniffa et al., 2012; Li et al., 2011; Rieckmann et al., 2017) and that 
circulating monocytes expressed CD11a, CD11b and CD11c. However, this data set 
did not confirm the findings that CD11b expression is higher in cDC2 DCs than in 
cDC1 DCs (Haniffa et al., 2012; Robbins et al., 2008), but rather shows that less 
cDC1 DCs are positive for the marker. Instead, the data in Figure Figure 5.4 indicate 
that CD11b expression was equivalent in these DC populations.  
To summarise, I have found that different APC types differ not only in their respective 
expression of β₂ integrins, but also in the amount of cells expressing the β₂ integrin 
subunit. While all APC types were found to express CD11a and CD18 on their 
surface, expression of CD11b was more varied between cell types. Furthermore, I 
showed that the amount of signal lost due to steric hindrance when staining both total 
and active CD11a together is consistent in all APC types. This importantly means 
that total CD11a expression can be compared between APC types using double-
stained samples affected by steric hindrance.  
Active β₂ integrins in healthy control APCs  
Having found high expression of β₂ integrin subunits in cDCs and monocytes, but not 
pDCs, I went on to assess the expression of the active β₂ integrins forms in these 
APCs. When investigating active β₂ integrin subunits, only CD11a, CD11b and C18 
could be considered, as active CD11c was not included due to limitations of the 
panel design. Total MFI (left, all cells expressing the active β₂ integrin in question), as 
well as the percentage of cells expressing both total and active β₂ integrins (T 




express the active β₂ integrin in question), the MFI of cells positive for the active 
conformation of the respective β₂ integrin (%MFI, middle right, MFI of active β₂ 
integrin on cells that also express its total form) and a histogram overlay of 
expression in all five APC types is shown in Figure 5.6. This allowed for both 
comparing the amount of positive staining between populations (MFI, %MFI, 
histogram overlay), as well as showing how many cells of a population express the 
respective active integrin subunit (T %Positive).  
Similar to total CD11a (Figure 5.4,Figure 5.5), active CD11a was expressed on 
almost 100% of cells, that also expressed total CD11a, of all APC populations 
analysed. Again, pDCs had a lower percentage of cells positive for active CD11a in 
some samples, but this was not significant. Highest levels of active CD11a were 
measured on CD14+ monocytes and cDC1 DCs, and significantly lower on CD16+ 
monocytes. Expression of active CD11a was further reduced in cDC2 DCs, and 
significantly lower again in pDCs. It is interesting to note that expression of active 
CD11a on the cell surface was similar between CD14+ monocytes and cDC1 DCs, 
even though cDC1 DCs express much higher levels of total CD11a (Figure 5.4). This 
suggests that CD11a activation on cDC1 DC surfaces is tightly controlled, as it did 
not directly correlate with the amount of total CD11a expression. The fact that 
different cell types showed significantly different amounts of active CD11a staining, 
with highest signal recorded in CD14+ monocytes and cDC1 DCs, thereby implies 
that conformation of CD11a is cell type specific. This suggests two things: the first is 
that different cell types have different ‘optimum’ levels of active CD11a at steady-
state. As an example, different APC populations might require different levels of 
active CD11a to adhere to endothelium and extravasate into tissue depending on cell 
size or density. However, the data did not fit this hypothesis, as active CD11a was 
found in lower levels on cDC2s compared to cDC1 DCs, even though cDC2 DCs are 
closer in cell size and granularity to cDC1 DCs than to CD14+ monocytes. The other, 
more likely option, is that there are differences in CD11a expression and 
conformation between different APC subtypes, which might impact on the respective 









Figure 5.6 Active β₂ integrins in 
healthy control APCs 
Active expression of CD11a, CD11b, 
CD18 in five APC subtypes of interest, 
CD14+ monocytes, CD16+ Monocytes, 
cDC2 and cDC1 DCs, as well as pDCs. 
Measurements shown are MFI, T 
%Positive cells and %MFI. Repeated 





The highest expression of active CD11b was found in CD14+ monocytes, with close 
to 100% of this population expressing the total marker also expressing the active 
marker (Figure 5.6B). This was significantly different from only 40-50% of total 
CD11b+ CD16+ monocytes and cDC2 DCs expressing active CD11b. A mean of 30% 
of total CD11b+ cDC1 DCs expressed active CD11b, but the spread between donor 
samples was very wide, with some donors having up to 90% of total CD11b+ cDC1 
DCs expressing active CD11b. Thus, active CD11b expression was not significantly 
different from CD16+ monocytes and cDC2 DCs. Lastly, active CD11b was only 
expressed on around 20% of total CD11b+ pDCs, which was significantly lower 
compared to all other APC populations except cDC1 DCs. MFI of the cells that did 
express active CD11b is much more uniform. CD14+ monocytes expressed by far the 
greatest levels of active CD11b, while all other APC populations were quite similar to 
each other. However, the 20% of total CD11b+ pDCs that expressed active CD11b 
on their cell surface did express significantly less than CD16+ monocytes, but not any 
of the other APC types. It is striking that CD14+ monocytes were found to have such 
high expression of active CD11b. Especially as published literature suggested β₂ 
integrins are largely inactive on cells in circulation (Li et al., 2017), this could again 
suggest that CD14+ monocytes have a lower threshold for CD11b activation 
compared to other APC types.  
Lastly, active CD18 showed a similar expression pattern to active CD11b. CD14+ 
monocytes expressed significantly more active CD18 than all other APC types 
considered (Figure 5.6C). They were also close to 100% positive for active CD18, 
which was significantly different from only 25-35% of total CD18+ CD16+ monocytes, 
cDC1 DCs and cDC2 DCs. pDCs showed the lowest expression of active CD18+ 
cells, with only 10% of total CD18+ cells positive.  
To summarise, CD11a has different expression and activation patterns across APC 
populations compared to the other β₂ integrin subunits. Importantly, cDC1 DCs 
expressed higher levels of both the total and the active forms of CD11a compared to 
cDC2 DCs. Total CD11b expression was lower in cDC1 compared to cDC2 DCs, 
although expression of active CD11b was equivalent. These differences between 
CD11a and CD11b in cDCs were especially interesting as it mirrored observations 
made during the active integrin panel optimisation process in Chapter 3, where 
CD11a showed different properties in regard to steric hindrance, staining duration 




CD11a and CD11b have overlapping functions, they are not interchangeable and 
show differences in which cell types they have which roles on.  
The effect of age on β₂ integrin expression and conformation 
After providing a thorough analysis of β₂ integrin subunit expression and 
conformation in APC populations in healthy control individuals, I now go on to assess 
the effect of an individual’s age on expression and conformation of β₂ integrins. 
Assessing the effect of age on β₂ integrins is especially interesting in respect to a 
potential immunoregulatory role β₂ integrins might play, as senescent DCs were 
shown to be less able to stimulate T cells (Gardner et al., 2017) and that monocytes 
from individuals over the age of 65 are functionally and transcriptionally distinct upon 
activation from monocytes derived from younger donors (Metcalf et al., 2017). 
Testing the effect of age on β₂ integrin expression is therefore valuable not only to 
ensure age differences between healthy controls do not affect the results, but also to 
reveal potential differences in their function with age. As there is no published 
information on how β₂ integrins might differ with age of the individual, correlation 
between age of the donor and the signal of total and active β₂ integrins is shown in 
Figure 5.7.  
Neither total nor active CD11a showed any significant correlation with age in any of 
the cell types. A similar picture emerges for total and active CD11b, suggesting that 
neither CD11a nor CD11b are in any way affected by age. Active CD18 is 
significantly correlated with age in CD14+ monocytes and cDC1 DCs, while total 
CD18 is significantly correlated with age in cDC1 DCs and pDCs. However, when 
considering the R2 values for the linear regression calculated for each correlation, 
they are very low, ranging from 0.139 to 0.258. This suggests that the correlation is 
not very strong and that the statistically significant result could arise due to a Type II 
statistical error. However, as the possibility remains that CD18 is correlated with the 
age of the donor, this needs to be considered later when comparing healthy controls 
to RA patients: the analysis will include age as a covariate to ensure that any effects 









Effect of gender on total β₂ integrin expression  
Similarly to age, it is not known if gender has any effect on β₂ integrin expression. 
However, several studies have highlighted differences in immune system function 
 
 Figure 5.7 Correlation of total and active β₂ integrin expression with age in healthy controls. 
Age in years was correlated to total and active CD11a (left), CD11b (middle) and CD18 (right) for 
APC subtypes of interest. Total β₂ integrins are shown in black, active β₂ integrins are shown in 
green, with respective R2 values and significance noted above each plot. Linear regression with 




depending on gender (Klein and Flanagan, 2016; Whitacre, 2001), making it 
important to investigate β₂ integrins in this context. Figure 5.8 shows total CD11a, 
CD11b and CD18 expression for healthy APCs from females and males, which 
shows that total CD11a is significantly higher in female than in male healthy controls. 
RA occurs in women at twice the rate than it occurs in men (Alamanos and Drosos, 
2005). Due to the higher number of females, healthy controls could not be age-
matched exactly, although 9 of 10 male healthy controls could have been matched to 
9 female healthy controls. However, as the mean age of female healthy controls was 
46.30 and the mean age of male participants was 43.78, the difference in ages was 
not considered to have significant impact. As this healthy control data set was 
collected to eventually be compared to RA patient samples, healthy female and male 
samples were collected in proportion to reflect this observed 2:1 ratio. CD11a 
expression is significantly lower in males, which is true for all APC types analysed. 
Note that this difference was apparent when plotting either single or double stained 
CD11a total (data not shown). On the other hand, total CD11b and CD18 expression 
show no significant increase or decrease associated with gender. As the effect of 
higher CD11a expression on APCs from female participants was so striking, it was 
next considered if this was due to total CD11a being expressed on a lower 
percentage of cells in male participants. However, when looking at the percentage of 
cells positive for total CD11a in different APC populations (Figure 5.9), both male and 
female study participants showed close to 100% of cells expressing total CD11a in all 








Figure 5.8 Effect of gender on total β₂ integrin expression in healthy controls 
Total CD11a, CD11b and CD18 expression was compared between female (n=20, red circles) and 







This suggests that women have higher total CD11a expression on APCs rather than 
increased proportion of APCs expressing total CD11a. However, when analysing 
active β₂ integrins on APCs from female and male participants (Figure 5.10), active 
CD11a does not show the same difference between genders, suggesting again that 
active β₂ integrins do not directly correlate to the level of total integrin expression. 
Active CD11b and CD18 are also not significantly different between genders. 
In summary, gender of the study participant does not have any effect on 
conformation of β₂ integrins, but females express significantly more CD11a across 
APC types compared to males. This is an interesting finding that will be discussed in 
more detail in the discussion of this chapter. 
Figure 5.9 Percentage of male and female APCs expressing total CD11a 
Percentage of APC population expressing total CD11a (% Positive) was compared between 











Figure 5.10 Effect of gender on active β₂ integrin expression 
Expression of active CD11a, CD11b and CD18 was compared between female (n=20, red circles) 





5.3.3 β₂ integrin expression in APCs in Rheumatoid Arthritis 
As discussed in the introduction to this chapter, there is a potential role for β₂ 
integrins in RA initiation or progression. However, due to range of β₂ integrin 
functions between migration and adhesion and the complexity of RA, it is difficult to 
draw clear conclusions from previously published literature. To gain more knowledge 
of the potential immunoregulatory roles of β₂ integrins, I aimed to identify any 
changes in expression and conformation of β₂ integrins in the inflammatory setting of 
the autoimmune disease RA. To investigate β₂ integrin expression on APCs in 
patients with RA, RA patients were recruited in a local clinic and processed 
immediately. Samples were categorised into active (DAS28>3.2) and remission 
(DAS28<2.6) groups according to 2010 EULAR RA classification criteria (Aletaha et 
al., 2010). Healthy controls showed no signs of joint pain and had not been 
diagnosed with a disease or disorder affecting the joints.  
Power calculations for RA patient sample size 
As there was no published information to the effect size that could be expected, 
power calculations were expected to be adjusted during the sample acquisition 
process (Jones et al., 2003). As discussed in the methods (Chapter 2, section 2.9, 
Table 2.4 and Table 2.5), a priori power calculations assuming a power of 0.95 
showed that 34 samples per group would be sufficient to detect a large effect size 
after Cohen’s d (Cohen, 1992). Assuming only 80% (0.8) probability that significant 
results were indeed correct lowered the amount of samples per group to 13 to effect 
large effect sizes, or to 31 samples per group to detect medium effect sizes. It was 
therefore decided to collect 10 samples in each group and repeat power calculations 
once effect sizes specific to total and active β₂ integrin expression in APCs could be 
attained (Lakens, 2013). Effect sizes were calculated using the mean squared 
residual (MSresidual), a value that describes the difference between the sample 
mean and the individual observed values, which derived from a one-way ANOVA and 
g*power. Effect sizes varied widely between β₂ integrin cell type combinations, with 
active CD18 expression needing 1344 samples per group to correctly detect a 
significant difference at 95% probability. Considering that small effect sizes between 
10 samples per group in certain β₂ integrin APC types combinations (6 total and 
active β₂ integrin subunits x 5 APC types) signified that there was no significant 
difference to be detected, it was decided to only consider combinations where 




Calculating this, it was found that 32 samples per group yielded 12 of 30 β₂ integrin 
APC combinations to be correctly powered at 0.8 or above. These 12 correctly 
powered comparisons consisted out of five total CD11a comparisons (all APC types), 
four total CD11b comparisons (all APC types except pDCs), two active CD11a 
comparisons (CD14+ and CD16+ monocytes) and one active CD11b comparison 
(CD14+ monocytes). The sample number needed to achieve the next tier of correctly 
powered comparisons per group, was not considered to be achievable. It was 
therefore decided to aim to recruit at least 32 samples per group.  
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N/A 4.48 (±1.03) 1.73 (±0.67) 
Table 5.1 Recruitment details of healthy controls and patients with RA 
The final number recruited for each group, as well as their median age, gender ratio 
and mean DAS28 is shown in Table 5.1. A total of 29 healthy controls, 31 active RA 
and 24 RA patients in remission were recruited for this study. The largest number of 
samples had to be excluded in remission patients, where more than 10 patients were 
diagnosed by their healthcare professional to be likely in remission but whose DAS28 
was equal or higher than 2.6. Interestingly, 2 patients that were identified to be likely 
in remission in the clinic turned out to have a DAS28 over 3.2, which is why they 
were included in the active RA cohort. Differences in ‘clinical remission’ (no tender or 
swollen joints) and remission defined by DAS28 cut-off points have been observed in 
the past, with the criticism being raised that DAS28 might be an imperfect tool to 
assess remission (Mäkinen et al., 2005). However, while CRP-DAS28 was found to 




2014), which was used throughout this study, as CRP-DAS28 could not be obtained 
for all patients. It was, however, also found that patients’ perception of disease 
activity, which is a composite part of the DAS28 value, is dependent on the difference 
between disease activity at the beginning of treatment compared to a later time point 
(ALETAHA et al., 2009; Felson et al., 2011). This could be one reason why clinical 
perception of disease activity and DAS28 did not match.  
Healthy controls were recruited to match age and gender ratio of RA patients as 
closely as possible. However, age-matching was found to be difficult. This was due to 
the fact that healthy donors were still largely in the work force, while recruitment of 
established RA patients included many who were of retirement age. While the oldest 
healthy donor was 71 years old, oldest donors in both active and remission RA were 
10-15 years older, being 87 and 81 respectively. However, age-spread between 
healthy controls and RA patient samples was similar. Considering this, the age-gap 
of 10 years between the median healthy control and the median RA patient was 
thought to be acceptable. As studies have shown that RA occurs in twice as many 
women as men, healthy controls were recruited accordingly. However, this data set 
shows a much higher number of women in active RA with a ratio of 1:5, while the 
ratio in remission is closer to 1:1.4. Considering the differences in total CD11a 
between female and male healthy controls (Figure 5.8), the effect of gender on total 
CD11a expression will have to be considered in all further analysis. The mean 
DAS28 confirms that samples collected show high and low disease activity according 
to their group.  
Disease status and medication in RA patient samples 
Disease status as well as the drugs study participants were prescribed are shown in 
Table 5.2. Both active and remission groups had disease for 10-13 years. 
Participants with active RA were more likely to be RF+, while CCP+ status was 
similar between groups. In terms of medication, more patients in remission were on 
MTX (70.8%) compared to people with active disease (54.8%). This could potentially 
be explained by adverse reactions to MTX, which in turn could negatively affect 
disease activity. Alternatively, there is a higher likelihood that the first-line treatment 
MTX had not controlled disease in the past so had been discontinued in these 
patients with active disease. Approximately half of both groups were on various 
DMARDs, with HCQ being the most commonly prescribed drug in both groups. It is 




to the successful treatment with one of the first-line DMARDs. Lastly, approximately 
10% less patients in remission were on biologics (20.8%), while 32.3% of patients 
























RA disease status 
 
Active Remission 
Mean Disease duration (±SD) 12.73 (±8.68) 10.83 (±7.11) 















No medication 3 patients  
(2 <6months after 
diagnosis) 
1 patient 
Methotrexate (MTX) 51.51% (17/31) (6 
take no other drugs) 
70.8% (17/24) (7 take 
no other drugs) 
Disease-modifying anti-





Leflunomide (LEF)                       
Azathriopine (AZA) 






































The comparably smaller number of people prescribed Biologics is easily explained by 
the high cost of the medication, which usually makes it a last effort to reduce disease 
activity if other drugs have failed. 
Even though sufficient numbers of samples could only be attained in the active RA 
cohort with 31 samples, patient recruitment can still be considered a tentative 
success. Comparisons of expression are still highly powered in 8 of the assumed 12 
comparisons, including both total CD11a and CD11b in cDC1 and cDC2 DCs, which 
are the main cells of interest to understand the role of β₂ integrins in DCs. 
Furthermore, three comparisons are still correctly powered to compare active RA to 
healthy controls (CD11a active and CD11b active in CD14+ monocytes, CD11a total 
in CD16+ monocytes), with the only comparison that is not correctly powered due to 
the lower amount of healthy controls and remission samples recruited being CD11b 
total in CD14+ monocytes. While having to exclude a large part of remission samples 
was unfortunate, this seems to be common in clinical research pertaining remission, 
but did not largely affect the comparisons made. The differences in age (Figure 5.7) 
and gender ratio (Figure 5.8) between different groups have to be considered. To 
further ensure age was not a significant factor, it was used as a covariate when 
differences between different patient groups were assessed. Furthermore, gender 
ratios between healthy controls and RA patients’ groups were different, an aspect 
which might influence expression of especially total CD11a. This will be discussed in 
more detail in the discussion at the end of this chapter. Considering the RA patient 
groups, they compare well to published literature in terms of medication and disease 
status (“Guidelines for the management of rheumatoid arthritis,” 2002; Song and 
Kang, 2010). It can therefore be concluded that the group of RA patients recruited 
into the study are representative of the wider patient community and can be 
compared to published studies.  
5.3.4 The β₂ integrin CD11a in APCs from RA patients 
First, it was assessed if expression of CD11a is altered in RA. For this, the data set 
discussed above was interrogated in terms of total and active CD11a expression. 
Expression of total CD11a on different APC types between patients who have high 
disease activity or who are in remission is shown in Figure 5.11. No significant 
differences between RA patient groups were found, suggesting that CD11a 




or controlling remission. When comparing healthy controls to both RA patient groups 
(Figure 5.12), representative histogram overlays show that expression of total CD11a 
is slightly lower on CD14+ monocytes from patients in remission and also on cDC2 
DCs from RA patients in general (Figure 5.12A). However, Figure 5.12B shows that 
total CD11a is significantly lower in cDC2s from patients with both active disease and 
remission, when compared to healthy controls. However, the fold difference between 
active RA and healthy controls is quite small at 1.42, and the fold difference between 
remission and healthy controls is 1.63 in cDC2 DCs, which is similarly low. 
Interestingly, this trend is mirrored in CD14+ monocytes, cDC1 and pDCs, where only 
patients with low disease activity show significantly lower CD11a expression than 
healthy controls. This suggests that expression of total CD11a is altered, particularly 
on cDC2 DCs, in the inflammatory context of RA, but regardless of disease activity. 
Considering the higher expression of active CD11a on tolerogenic DCs compared to 
mature DCs shown in Chapter 4, one could hypothesise that the immunoregulatory 
function of CD11a is lost in RA, contributing to an altered immune phenotype that 




 As mentioned previously, total CD11a shows significant signal loss due to steric 
hindrance when stained together with active CD11a. To confirm the result of reduced 
Figure 5.11 Total CD11a expression in RA 
Total expression of CD11a (MFI) compared between active RA (orange squares, n=31) and 
disease in remission (blue triangles, n=24) on five APC types of interest isolated from PB. Unpaired 




total CD11a in cDC2s isolated from RA patients compared to healthy controls, single 
stained total CD11a was plotted (Figure 5.13A, right). Surprisingly, no significant 
difference between RA patient samples and healthy controls was found in the single 
stained total CD11a samples. Looking further into this, it can be observed that rather 
than CD11a being lower in cDC2s from RA patients, it is the amount of steric 
hindrance that is increased in both active and remission RA groups. This was 
confirmed by considering both the difference in MFI (Figure 5.13B, left), showing 
significantly increased MFI between double and single stain, as well as the % of 
steric hindrance (Figure 5.13B, right), showing that a significantly greater percentage 





 Figure 5.12 Total CD11a expression in healthy controls compared to RA patients 
Expression of total CD11a comparing RA patient groups (active and remission) to healthy controls. A.  
Histogram overlays of representative total CD11a expression of each of the groups in each of the 
APC types. Representative samples were chosen as close to median of patient group as possible. B. 
Total CD11a expression (MFI) between healthy controls and RA patients. One way ANOVA, n=29 for 







Healthy control cDC2s lost a mean of 30% of total CD11a signal by staining 
alongside active CD11a, while a mean of 45% and 50% were lost respectively by 
patients with high and low disease activity. The fact that more total CD11a signal is 
lost in RA samples suggests that there is more active CD11a on RA patient cDC2s, 
which in turn cause an increase in steric hindrance. However, when looking at active 
CD11a expression, this was not the case. While there is a small but significant 
decrease in active CD11a expression between active RA and remission in cDC1 and 
Figure 5.13 Effect of steric hindrance on total CD11a in RA 
Total CD11a expression on cDC2 DCs compared between healthy controls (black circles, n=29) 
and patients with either active RA (orange squares, n=31) or in RA remission (blue triangles, n=24). 
A. Total CD11a expression on cDC2s in Double stain (shown before in Figure 5.12, and here left) 
and total CD11a single stain (right). B. Amount of steric hindrance on cDC2 DCs between healthy 
controls and RA patients. Left shows the difference between single and double stain in MFI values 
(MFI amount lost to steric hindrance), right shows differences in steric hindrance as a percentage of 
single stain (% of signal lost to steric hindrance). Unmatched one way ANOVA, n=29 for healthy 




cDC2 DCs (Figure 5.14), there are no significant differences between healthy 
controls and RA patients (Figure 5.15). This result is supported by the representative 
overlays of the three groups considered, which show no increase in active CD11a 
expression in RA samples (Figure 5.15). This result is particularly puzzling, as it 
suggests that the increase in steric hindrance is not caused by an increase in active 
CD11a expression. 
 
Exploring if the increase in steric hindrance could be due to the prescribed 
therapeutics, total CD11a was assessed between patient groups taking different 
classes of anti-rheumatic drugs (Figure 5.16). For this, total CD11a expression 
determined by double staining (total and active CD11a together) was plotted. This is 




Figure 5.14 Active CD11a expression in RA 
Expression of active CD11a (MFI) compared between active RA (orange squares, n=31) and 








Figure 5.15 Active CD11a expression in healthy controls compared to RA patients 
Expression of active CD11a comparing RA patient groups (active RA, remission) to healthy controls. 
A. Histogram overlays of representative total CD11a expression of each group in each APC type. 
Representative samples were chosen as close to median of patient group as possible. B. Total 
CD11a expression (MFI) between healthy controls and RA patients. One way ANOVA, n=29 for 








Figure 5.16 Effect of RA therapeutics on total CD11a expression in RA samples 
Expression of total CD11a determined by double staining (affected by steric hindrance, MFI) on five 
APC subsets of interest, comparing between drug-naïve and drug exposed individuals both with 
active disease (orange) and in remission (blue). Specific therapeutics considered include 
Methotrexate (left, No MTX, n=21, MTX, n=34) and broader groups of therapeutics considered 
include other DMARDs (middle, No DMARDs, n=25, DMARDs, n=30) and Biologics (right, No 




Discussing patients in such broad treatment groups (e.g. no biologics vs. biologics) 
has its caveats, as different drugs of the same group might have differing effects on 
the amount of steric hindrance. Furthermore, many study participants are on 
combinational therapy, which is highly individualised. Both issues make it difficult to 
collate groups of patients on the exact same therapy that are larger than 2-4 
samples. This makes it impossible to make statistically sound observations. Keeping 
the comparably small size of this data set in mind, broad grouping of patient samples 
by therapeutics is, while not perfect, the best available option.  
It was found that neither taking MTX, DMARDs nor Biologics had any significant 
effect on total CD11a expression on any type of APC (Figure 5.16). As seen in Figure 
5.11, there was no significant difference in total CD11a expression between active 
RA and patients in remission, with no clustering of either disease group occurring in 
any of the cell types or therapeutics taken. While there was no significant difference 
in total CD11a expression due to Biologics, this result could be complicated by the 
much lower number of patients on Biologics, making the group size uneven. Despite 
this, there was no significant effect of drugs on total CD11a that would explain the 
increase in steric hindrance observed in cDC2 DCs (Figure 5.16).  
Having found no effect of drugs on CD11a steric hindrance, the influence of other 
disease factors was analysed. To this end, the effect of DAS28, disease duration and 
Rheumatoid factor (RF) positive or Anti-citrullinated protein (CCP) positive status of 
RA patients was considered in Figure 5.17. However, no significant relationship 
between total CD11a expression and any of the clinical information available was 
found. The reason for the increase in steric hindrance in RA samples can therefore 
not be fully elucidated using the information available from this current data set.  
To summarise, RA patients with active disease or in remission show increased signal 
loss due to steric hindrance, which caused the observed reduction in total CD11a 
expression (Figure 5.12). Surprisingly, there is no equivalent increase in active 
CD11a expression in RA samples that would account for this observed increase. 
Further analysis did not associate any disease parameters available to me (DAS28, 
disease duration, RF or CCP status) with the increased steric hindrance. Therefore, it 
is likely that another factor, common to active and remission groups but not healthy 
controls, is responsible. Potential causes for this difference will be discussed in more 




to why this increase in steric hindrance could occur will therefore be discussed in 





 Figure 5.17 Effect of DAS28, disease duration and disease status on total CD11a expression. 
Expression of total CD11a affected by steric hindrance (MFI, double stained) was investigated in terms of the effect of various RA patient variables. Both active 
RA (n=31, orange squares) and remission (n=24, blue triangles) were considered. A. Correlation between DAS28 and expression of total CD11a. Linear 
regression with fitted line. B. Correlation of disease duration in years with expression of total CD11a. Linear regression with fitted line. C. Comparing RF-




CD11a in RA synovial fluid 
While considering total and active CD11a in PB is important, RA is an autoimmune 
disease primarily affecting the joints. To test if expression of the β₂ integrin subunit 
CD11a is different between the periphery and the site of inflammation, total and 
active CD11a expression was compared on different APCs between SF and PB from 
the same patient (Figure 5.18). Interestingly, both total and active CD11a expression 
were significantly decreased in SF in almost all cell types. The only exception were 
cDC1 DCs, which show no significant increase or decrease in total or active CD11a 
in SF compared to PB. However, as cDC1 DCs only make up around 0.1% of all 
PBMCs, their low number in PB might contribute to this finding. Considering the 
overlays of cells from SF (shown in blue) and PB (shown in red) (Figure 5.18, left), it 
is clear that the decrease in MFI was due to the larger spread of the population, and 
not due to the complete loss of total or active CD11a-high cells. 
The result that total and active CD11a were lower on APCs found in SF compared to 
PB has several implications. First, considering the hypothesised immunoregulatory 
role of CD11a, this finding implies that immune regulation is either lost or actively 
downregulated in the inflammatory joint environment. To explain the difference, 
immunoregulatory and pro-inflammatory mechanisms have to be finely balanced to 
achieve a sufficient protective immune response, while simultaneously preventing 
immune-mediated tissue destruction. As the microenvironment of a swollen joint in 
RA is starkly pro-inflammatory, with the presence of high levels of cytokines such as 
IL-1β, IL-6, TGF-β and IFN-γ (Schlaak et al., 1996), CD11a could actively be 
downregulated to remove the influence of CD11a-mediate immune regulation and 
achieve a sufficient immune response in response to the loss of tolerance to self-
antigen. On the other hand, it is also possible that the loss of total or active CD11a 
on all APCs except cDC1 DCs, is part of the immune dysregulation occurring as a 
result of, and potentially contributing to, the pathogenesis and maintenance of RA.  
To summarise, while neither expression nor conformation of CD11a were found to be 
different between healthy controls and RA patients, expression of both total and 
active CD11a was significantly lower in almost all APC types found in SF when 
compared to PB of RA patients. This suggests that CD11a might play a different role 









 Figure 5.18 Total and active CD11a expression in RA PB and SF 
Comparing expression of total and active CD11a in PB (red, circles, n=5) and matched SF (blue, 
squares, n=5) in five APC types of interest. Dot plot overlay of total and active CD11a expression in 
PB and SF (left), as well as total CD11a expression (middle, paired Student’s t test, MFI of single-





5.3.5 The β₂ integrin CD11b in Rheumatoid Arthritis 
Having investigated the β₂ integrin subunit CD11a in the context of RA, I next 
analysed the role of CD11b. As previously mentioned, comparing CD11a and CD11b 
is of special interest, as the two subunits seem to have distinct functions in DCs. 
Furthermore, I hypothesised that CD11b has pro-inflammatory roles in DCs based on 
findings in Chapter 4 that blocking it on DCs was able to decrease T cell stimulatory 
capacity. Therefore, investigating CD11b in PB of RA could provide insight into 
whether this subunit is dysregulated in RA, due to either contributing to the disease 
or being affected by the presence of inflammation.  
Total expression of CD11b in active RA and patients in remission is shown in Figure 
5.19. No significant differences between RA patient groups were observed in any of 
the APC types, suggesting that total CD11b does not have a role in contributing to 
active disease or maintaining remission in PB and is not altered by the inflammatory 
environment in RA PB. Similarly, when comparing the two RA patient groups to 
healthy controls, there are no significant differences in total CD11b expression in any 
APC type (Figure 5.20). This finding is confirmed when looking at the representative 
histogram overlays (Figure 5.20A), which show high overlap. 
 
 Figure 5.19 Total CD11b expression in RA 
Expression of total CD11a (MFI) compared between active RA (orange squares, n=31) and 






 Figure 5.20 Total CD11b expression in healthy controls compared to RA patients 
Expression of total CD11b comparing RA patient groups (active RA, remission) to healthy controls. 
A. Histogram overlays of representative expression of total CD11b of each group in each of the APC 
types. Representative samples were chosen as close to median of patient group as possible. B. 
Expression of total CD11b (MFI) between healthy controls and RA patients. One way ANOVA, n=29 





While active RA and remission had indeed slightly higher means compared to 
healthy controls, this difference was not found to be significant.  
Figure 5.21 shows that there are no significant differences in active CD11b 
expression between patients with active disease and in remission. Furthermore, 
when comparing healthy controls to RA samples (Figure 5.22), active CD11b 
expression is equivalent. Of note, active CD11b expression in remission sample 
cDC2 DCs had a slightly lower mean MFI compared to active disease and healthy 
controls (Figure 5.22A), but this was not significant.  
In summary, total and active CD11b expression is not significantly different in PB 







 Figure 5.21 Active CD11b expression in RA 
Expression of active CD11b (MFI) compared between active RA (orange squares, n=31) and 










Figure 5.22 Active CD11b expression in healthy controls compared to RA patients 
Expression of active CD11b comparing RA patient groups (active RA, remission) to healthy controls. 
A. Histogram overlays of representative active CD11b expression of each group in each APC type. 
Representative samples were chosen as close to median of patient group as possible. B. Expression 
of active CD11b (MFI) between healthy controls and RA patients. One way ANOVA, n=29 for healthy 





CD11b and CD18 in synovial fluid  
While neither expression nor conformation of CD11b was altered in RA when 
compared to healthy controls, next CD11b expression was assessed on APCs in SF. 
This was done to gain further insights into the differences between the site of active 
inflammation and circulating cells.  
Expression of total and active CD11b in RA PB compared to SF is shown in Figure 
5.23. Total CD11b was found to be significantly higher in SF compared to PB in 
CD16+ monocytes, cDC2 DCs and pDCs, but not CD14+ monocytes and cDC1 DCs. 
On the other hand, active CD11b expression was significantly elevated only in cDC2 
DCs and pDCs in SF compared to PB. This was reiterated by the overlays of cells 
from PB and SF (Figure 5.23, left), where SF cells showed a much larger spread of 
CD11b expression in CD16+ monocytes, cDC2 and pDCs, while CD14+ monocytes 
largely overlapped between SF and PB. While CD11b expression in cDC1 DCs was 
not significantly different between PB and SF, this could partially be due to the low 
numbers of cDC1 DCs present in PB. 
As investigating β₂ integrins on mo-DCs in vitro suggested that CD11b is a pro-
inflammatory molecule (Chapter 4), the increased expression of both total and active 
CD11b on cDC2 DCs and pDCs in the joint environment could suggest that CD11b is 
part of an increase in pro-inflammatory mechanisms being employed. Its increased 
expression in the joint might contribute to APC recruitment to and retention in the 
joint due to increased adhesive forces as well as increase interaction between T cells 
and DCs. The question of cause and effect is again difficult to tease apart. Is CD11b 
upregulated in response to pro-inflammatory stimuli in the joint, which then in turn 
contributes to maintaining the immune response? Or is it in fact part of the 
dysregulation that contributes to RA pathology? Overall, it is interesting that CD11b 
expression was shown to be increased in the same cells where CD11a expression 
was decreased, when comparing SF to PB. Both total and active CD11b therefore 
showed a completely reverse trend to CD11a in many APCs, with CD11b being 
significantly higher in synovial fluid than in PB, while CD11a was significantly lower. 
Together with the findings that CD11a was upregulated while CD11b was 
downregulated in tolerogenic Mo-DCs (Chapter 4), this strongly suggests that CD11a 
and CD11b might have opposing roles in APCs. This interesting finding will be 








Figure 5.23 Total and active CD11b expression in RA PB and SF 
Comparing expression of total and active CD11b in PB (red, circles, n=5) and matched SF (blue, 
squares, n=5) from the same RA patient in five APC types. Dot plot overlay of total and active CD11b 
expression in PB and SF (left), as well as total CD11b expression (middle, paired Student’s t test, 





However, CD11a expression was lower in cells isolated from SF more globally, 
affecting all cell types except cDC1 DCs. On the other hand, total CD11b was 
significantly increased only in SF CD16+ monocytes, cDC2 and pDCs, and active 
CD11b was only significantly increased in cDC2 and pDCs. This suggests that 
downregulation of CD11a has a more global role in the joint, while CD11b regulation 
is more cell-type specific. 
It is surprising that the effect was so stark in pDCs, as they were shown to express 
the lowest levels of both total and active CD11b of all cell types considered (Figure 
5.4,Figure 5.6). Consulting the literature on this topic, synovial pDCs from RA 
patients were found to be less mature compared to pDCs from PB, expressing lower 
amounts of CD40, CD83 and CD86 (Lande et al., 2004; Van Krinks et al., 2004). This 
could suggest that the increase in CD11b expression contributes to their immature 
state, meaning that the increase in CD11b is associated with less pDC activation. 
This has not been confirmed directly as our study did not segregate between 
immature and mature DCs. However, considering the inflammatory nature of the RA 
joint, it seems unlikely that the SF DCs are immature. Other studies have shown that 
SF pDCs are able to induce T cell proliferation and production of levels of IFN-γ, IL-
10 and TNF-α that were comparable to SF myeloid DCs (Cavanagh et al., 2005). The 
role of synovial pDCs in RA and how β₂ integrin expression relates to maturity 
therefore has to be explored in more depth.  
Expression of CD18, the pairing β-subunit of both CD11a and CD11b, was not shown 
in PB of RA patients, as no significant differences in either CD11a or CD11b were 
found. Here, however, it was important to include CD18 as it can give valuable 
information about the importance of either the significant decrease in CD11a or the 
significant increase in CD11b. Total and active CD18 staining in the five APC types is 
presented in Figure 5.24, showing that total CD18 was significantly higher in SF 
compared to PB in CD14+ and CD16+ monocytes, as well as cDC2s and pDCs. This 
suggests that the increase in CD11b dominated over the decrease of CD11a in SF, 
as CD18 expression was shown to increase. However, this effect was not replicated 
in active CD18, which was not significantly different in any of the cell types 
considered when comparing expression in SF to PB. All APC types except cDC1 
DCs were significantly lower in active CD11a in SF, but only cDC2 and pDCs were 









Figure 5.24 Total and active CD18 expression in RA PB and SF 
Comparing expression of total and active CD18 in PB (red, circles, n=5) and matched SF (blue, 
squares, n=5) from the same RA patient in five APC types. Dot plot overlay of total and active CD18 
expression in PB and SF (left), as well as total CD18 expression (middle, paired Student’s t test, 





This, therefore, suggests that while total CD11b could determine total CD18 
expression, this was not the case for active CD18, where the increase in active 
CD11b and decrease in active CD11a seem to balance each other out. However, as 
neither active CD11c nor active CD11d were considered in this panel, they would 
have influenced the expression of active CD18. 
In summary, both expression of total CD11b and CD18 were found to be significantly 
increased in CD16+ monocytes, cDC2 DCs and pDCs. But while expression of active 
CD11b was also significantly increased in cDC2 DCs and pDCs, no significant 
changes in expression of active CD18 were observed in any of the APC types when 
comparing PB to SF. Together with the finding that expression of total and active 
CD11a were increased on various APC types, this suggests that CD11b is playing an 
opposing role to CD11a. 
5.3.6 Exploring functional roles of CD11a and CD11b ex vivo 
Having investigated expression of total and active CD11a and CD11b in the context 
of RA, the data strengthens my result from Chapter 4, which suggested that the two 
β₂ integrin α-subunits have opposing functions, with CD11a being more regulatory 
while CD11b has more inflammatory roles. This role seems to be negligible in PB, 
where no significant differences between RA patients and healthy controls were 
found in either CD11a or CD11b expression. Comparing SF of RA patients to 
matched PB revealed total and active CD11a to be significantly reduced in SF 
(Figure 5.18), while total and active CD11b was increased on APCs in SF (Figure 
5.23).  
To investigate this result further, two questions were considered to explore the 
functional roles of CD11a and CD11b ex vivo. First, the effect of SF and various pro- 
and anti-inflammatory cytokines on total and active β₂ integrin expression was 
investigated. This was to test the hypothesis that β₂ integrins on synovial APCs 
respond to their pro-inflammatory environment, which would explain the stark 
differences seen between SF and PB. Second, following on from suppression of T 
cell proliferation after blockage of CD11b in Chapter 4, the effect of CD11b blocking 
on cDC2s sorted from peripheral blood was investigated.  
5.3.7 Mimicking the synovial environment in vitro 
Due to the wide-spread significant decrease in total and active CD11a expression 




concluded that β₂ integrins have opposing function. It was considered that a more 
immunoregulatory role of CD11a was lost in RA, while the pro-inflammatory roles of 
CD11b found in Chapter 4 were further enhanced by the high concentration of pro-
inflammatory cytokines present in an acutely inflamed joint. To test this hypothesis, 
healthy PBMCs were exposed to pro-inflammatory (+IL-1/TNFα, +LPS) or anti-
inflammatory stimuli (+IL-10/TGFβ) for 18h and total and active β₂ integrins were 
measured on APCs. Importantly, IL-1 and TNFα, as well as IL-10 and TGFβ have 
been reported to be present in SF (Lettesjö et al., 1998; Schlaak et al., 1996). 
Additionally, PBMCs were exposed to thawed cell-free SF samples from three donors 
to determine if SF components could elicit a decrease in CD11a expression with a 
concomitant increase in CD11b. It was hypothesised that pro-inflammatory IL-1/TNFα 
and LPS stimulation would increase total CD11b expression and reduce total and 
active CD11a expression, while IL-10/TGFβ would increase CD11a expression and 
reduce total expression of CD11b by APCs. 
CD11a expression in stimulated APCs  
Total and active CD11a expression on APCs in the different conditions described 
above is shown in Figure 5.25. In CD14+ monocytes, a significant decrease in total 
CD11a was seen in two conditions compared to untreated; however, it was lower in 
both LPS and IL-10/TGFβ treatment groups. This is surprising, as total CD11a 
expression in IL-1/TNFα treated cells was not significantly different from untreated. 
Counterintuitively, expression of total CD11a on CD14+ monocytes was not affected 
by addition of any of the SF samples. Expression of active CD11a was globally 
significantly reduced when comparing any treatment to untreated cells. However, 
there are subtle differences between different treatment groups worth exploring. 
Considering the SF treatment conditions, more heterogeneity between the different 
donors is revealed. SF1 showed the lowest active CD11a expression of all 
conditions, while both other SF samples, SF2 and SF3 treatments both caused more 
expression of active CD11a. These differences were however not significant. This 
suggests that our hypothesis is not correct in the case of CD14+ monocytes. While 
pro-inflammatory LPS treatment reduced the expression of total CD11a, it is not likely 
that this is what happens in the joint as the effect was not seen using IL-1/TNFα. 
Interestingly, SF did not affect expression of total CD11a. This could be explained by 
the fact that there was not sufficient biobanked synovial fluid available to test levels 




not clear how much of each cytokine is present. Simply put, cytokine concentrations 
could have been too low to elicit significant effects on total CD11a expression in 
CD14+ monocytes. Another potential reason is that β₂ integrin expression and 
conformation are regulated by cell-cell contacts within the joint, which cannot be 
mimicked by adding cell-free SF. The global downregulation of active CD11a in all 
conditions is puzzling, as all cytokines were highly diluted in culture medium before 
being added to the well and compared to untreated, which only received medium.  
CD16+ Monocytes showed a different pattern of total CD11a expression to CD14+ 
monocytes upon stimulation (Figure 5.25, top right). All pro- and anti-inflammatory 
stimuli significantly reduce the amount of total CD11a expression. The only exception 
is treatment with SF2, which caused no significant increase or decrease in total 
expression of CD11a total. The data. show again that while pro-inflammatory 
cytokines reduce total CD11a as hypothesised, the same can be said for treatment 
with the anti-inflammatory combination IL-10/TGFβ. Considering the absence of an 
effect of SF on total CD11a expression in CD14+ monocytes, it could be 
hypothesised that SF samples from different donors have varying contents. Similarly, 
to CD14+ monocytes, the CD16+ monocytes data does not support my hypothesis. 
However, differences in expression of total and active CD11a suggest that β₂ 
integrins are differently controlled on the closely related monocyte types.  
Looking at total CD11a expression on cDC2 DCs, total CD11a expression is 
significantly decreased in IL-1/TNFα and LPS treatment groups, while IL-10/TGFβ 
treatment does not significantly alter total CD11a expression compared to untreated 
cells. SF treated cells again show high heterogeneity between donors, with SF3 
causing significant decrease in expression of total CD11a, while neither treatment 
with SF1 nor SF2 show any effect. There is no significant difference in active CD11a 
expression following any treatment condition. Similarly, to the results in CD14+ and 
CD16+ monocytes, cDC2 DCs reduce their total CD11a expression upon 
encountering pro-inflammatory stimuli. In contrast to both monocyte populations 
however, anti-inflammatory IL-10/TGFβ does not cause a decrease in total CD11a, 
instead maintaining it at a normal level.  
Similar to cDC2 DCs, expression of total CD11a is significantly lower in cDC1 DCs 
when treated with IL-1/TNFα or LPS, but not with IL-10/TGFβ. Total CD11a is also 
lower on cDC1 DCs treated with SF3, but neither of the other SF samples. There are 




conditions. Both expression of total and active CD11a is significantly lower on pDCs 
treated with SF3, but none of the other treatments affect expression of CD11a.  
Due to limited knowledge of the extent of steric hindrance affecting CD11a double 
staining at the time of experiment design, a single stained control for total CD11a 
was not included for all treatment groups. However, considering that difference in 
total CD11a between PB and SF became more and not less significant when plotting 
total CD11a not affected by steric hindrance, it was assumed that any effects seen 
would be due to a change in expression and not in steric hindrance. However, it 
cannot be assessed if pro- or anti-inflammatory cytokines could indeed affect steric 
hindrance, which is a caveat of this experiment.  
In summary, pro-inflammatory stimuli (IL-1/TNFα, LPS), as well as treatment with 
SF3, caused a reduction in total CD11a expression on both cDC2 and cDC1 DCs, 
while conformation status was not affected. This supports the hypothesis of a 
immunoregulatory role of CD11a on DCs, as it was downregulated in response to 
pro-inflammatory stimuli. Considering differences in CD11a expression described 
between monocyte and DC types, one could furthermore hypothesise that expression 
is differentially regulated between monocytes on one side and DCs on the other side.  
CD11b expression in stimulated APCs 
The effect of different stimuli on total and active CD11b expression in different APC 
types is presented in Figure 5.26. In CD14+ monocytes, total CD11b expression was 
significantly lower in all conditions when compared to untreated, including all SF 
samples. This was similar to the active CD11a results in CD14+ monocytes (Figure 
5.25). Despite reduced total CD11b, active CD11b was only significantly reduced 
when treated with LPS. As the PB-matched SF data (Figure 5.23) showed no 
significant increase in either total or active CD11b in synovial fluid, this result would 
fit the hypothesis that while CD11b might be pro-inflammatory on DCs, it might have 
opposite effects on monocytes.  
In CD16+ monocytes, neither expression of total nor active CD11b was significantly 
affected by any treatment condition. Also, the global downregulation of CD11b 
observed in CD14+ monocytes upon addition of any kind of stimulus was not seen in 
CD16+ monocytes. Considering that total CD11b was significantly increased in SF 




suggests that we cannot mimic the effects seen in SF cells in this in vitro stimulation 
system.  
Expression of CD11b in cDC2 DCs was similarly unaffected by stimuli. The untreated 
samples showed a large data spread in both total and active CD11b, which did not 
appear to be typical for other APCs observed. No other significant differences in 
either total or active CD11b expression were observed.  
cDC1 DCs showed a significant reduction in total CD11b in LPS, IL-10/TGFβ and 
SF2 conditions compared to untreated, but no significant differences in active 
CD11b. Similarly to CD14+ monocytes, lower CD11b expression was apparent in all 
treatment conditions, but is not as strong as in the monocytes.  
Lastly, pDCs showed no significant differences in stimulated compared to untreated 
cells in either total or active CD11b expression, but heterogeneity of SF samples was 
shown again.  
Overall, data showing expression of total and active CD11b in response to various 
stimuli did not support the hypothesis that increased CD11b expression in SF is due 
to the pro-inflammatory cytokines present in the joint environment. However, several 
considerations have to be kept in mind when putting this result into context. First, it 
was not possible to use cells isolated from PB or SF of RA patients for these 
experiments. While no differences in total or active CD11b expression between 
healthy controls and RA patients could be found, it could still be possible that β₂ 
integrins of RA patients react differently to stimuli that those of healthy controls. This 
is likely as myeloid DCs from RA SF were found to express greater levels of 
costimulatory factors compared to PB DCs and were far more proficient at inducing T 
cell proliferation (Moret et al., 2013). This suggests that DCs are likely to be 
functionally altered in the inflammatory joint environment of RA. Another 
consideration is that the increased total and active CD11b expression in CD16+ 
monocytes, cDC2 and pDCs may be due to chronic rather than short-term exposure 
to cytokines. As healthy PBMCs were only stimulated for 18h, it is possible that either 
chronic joint inflammation or the event of a flare on the background of a dysregulated 






CD18 expression by stimulated APCs 
Levels of total and active CD18 expression in APCs in response to overnight 
exposure to various stimuli are shown in Figure 5.27.  
As both total CD11a and total CD11b were reduced on CD14+ monocytes when 
exposed to any of the stimuli, it is unsurprising that a similar pattern emerges with 
total CD18 expression. Expression of total CD18 in the untreated condition was 
significantly higher than with IL-1/TNFα, LPS or SF2 stimulation, but not than any of 
the other conditions. Considering the different SF samples, it appears that total CD18 
expression following SF1 and SF3 treatment was similar, in contrast to the 
significantly lower expression of total CD18 in SF2 treatment. Expression of active 
CD18 was significantly reduced in LPS treatment, but not in any of the other 
treatment conditions, suggesting again that active CD18 expression was not 
immediately dependent on total expression.  
Considering CD18 on CD16+ monocytes, no significant differences in active CD18 
were observed with stimulation. However, total CD18 expression was significantly 
lower in cells treated with SF1 compared to untreated cells, suggesting that SF1 
might contain either higher concentrations or different cytokines that cause total 
CD18 reduction.  
Total CD18 expression in cDC2 DCs was more similar in pattern to total CD11b 
expression, although here no significant differences were observed between 
treatment groups. Similarly, active CD18 expression was not significantly different in 
cDC2 DCs in any treatment group.  
In cDC1 DCs, untreated cells had significantly greater levels of total CD18 compared 
to LPS, IL-10/TGFβ and SF2, while no significant differences in active CD18 were 
observed.  
Lastly, total CD18 expression in pDCs was reduced with SF3 treatment but with no 
other stimuli. No significant differences in active CD18 expression in pDCs between 







Figure 5.25 CD11a on 18h stimulated APCs 
PBMCs were isolated from healthy controls and either left untreated or 
stimulated with IL1/TNFα (10ng/ml each), LPS (100ng/ml), IL10/TGFβ 
(10ng/ml each) or one of three thawed cell-free SF samples (SF1-3, 25 
diluted in RF10). Different APC types were assessed in terms of total and 
active CD11a expression using the active integrin panel. Repeated measures 






Figure 5.26 CD11b on 18h stimulated APCs 
PBMCs were isolated from healthy controls and either left untreated or 
stimulated with IL1/TNFα (10ng/ml each), LPS (100ng/ml), IL10/TGFβ 
(10ng/ml each) or one of three thawed cell-free SF samples (SF1-3, 25 
diluted in RF10). Different APC types were assessed in terms of total and 
active CD11b expression using the active integrin panel. Repeated measures 






Figure 5.27 CD18 on 18h stimulated APCs 
PBMCs were isolated from healthy controls and either left untreated or 
stimulated with IL1/TNFα (10ng/ml each), LPS (100ng/ml), IL10/TGFβ 
(10ng/ml each) or one of three thawed cell-free SF samples (SF1-3, 25 
diluted in RF10). Different APC types were assessed in terms of total and 
active CD18 expression using the active integrin panel. Repeated measures 




In summary, expression or conformation of CD18 is not altered in cDC2s, but total 
expression is reduced in cDC1 and pDCs in response to both pro- and anti-
inflammatory stimuli or SF. Total and active CD18 expression in different APC types 
therefore does not clearly follow either CD11a or CD11b expression patterns, 
suggesting that the other pairing subunits CD11c and CD11d may react to the 
various stimuli and influence these results. 
5.3.8 Effect of blocking CD11b on cDC2 stimulatory ability 
First, it was assessed if cDC2s sorted from peripheral blood were impeded in their 
ability to stimulate T cell proliferation when the CD11a/CD11b ratio was shifted by 
blocking CD11b. This question was based on a series of observations from both in 
vitro and ex vivo experiments utilising Mo-DCs (Chapter 4). There I found that 
expression of active CD11a is increased, while active CD11b was decreased, on 
tolerogenic compared to mature Mo-DCs, and that blocking CD11b on mature Mo-
DCs made them less efficient at stimulating T cells. From this I hypothesised that 
CD11b is a pro-inflammatory mediator in DCs. Therefore, I wanted to test if blocking 
CD11b on PB cDC2 DCs had the same effects. However, one caveat of this 
experiment was that cDC2s in PB are likely to be immature. Furthermore, considering 
the hypothesis that the increase in synovial CD11b is linked to its increased pro-
inflammatory roles in the joint environment of RA, this is also an opportunity to 
question if expression links up with function. It was therefore hypothesised that 
blocking CD11b would result in reduced T cell proliferation and IFN-γ production, 
while potentially increasing IL-10 production by both DCs and T cells. Conversely, it 
is predicted that activating CD11b will enhance its inflammatory ability, thus 
increasing T cell proliferation and IFNγ production.  
To test these hypotheses, cDC2 DCs were sorted from PB of three healthy donors 
and co-cultured with naïve CD4 T cells for 6 days, either untreated or in the presence 
of CD11b antagonism (M1/70 or isotype control mAbs, Figure 5.28A) or CD11b 
agonism (LA-1 or control DMSO, Figure 5.28B). As naïve CD4 T cells express 
CD11a as well as CD18, only CD11b could be targeted specifically on DCs in an 
MLR (Chapter 4, section 4.2.5, Figure 4.14). No significant difference in percentage 
of proliferated T cells between untreated MLRs and CD11b blocking by M1/70 
treatment was found (Figure 5.28B). There was also no significant difference in either 
IFN-γ or IL-10 levels measured in MLR supernatants. However, it is important to note 




donors with a simultaneous increase in IL-10 levels visible in all three donors, though 
not significant. This could suggest that while there was little effect of CD11b blocking 
on T cell proliferation, production of pro- and anti-inflammatory cytokines might be 
impacted by the blockage of CD11b. Ideally, additional samples would be analysed 




On the other hand, LA-1 treated MLRs showed a significant decrease in T cell 
proliferation compared to untreated. However, the same was true for DMSO treated 
cells, suggesting that the negative effect of DMSO on cell proliferation is to blame for 
the significant decrease in T cell proliferation observed in the LA-1 culture. As 
upregulation of active (or indeed total) CD11b using LA-1 could not reliably be 
achieved in vitro (Chapter 4, section 4.2.5, Figure 4.17), it is likely that the DMSO 
rather than LA-1 is responsible for the loss of T cell proliferation. Indeed, DMSO has 
previously been reported to block T cell proliferation (Vanherwegen et al., 2019). 
Neither IFN-γ nor IL-10 production was significantly affected by treatment with LA-1, 
Figure 5.28 Effect of CD11b in FACS -sorted cDC2 MLRs 
cDC2s were sorted from three healthy donors and co-cultured with naïve T cells for 6 days, in the 
presence of either CD11b blocking antibody (M1/70, control: Isotype control) or a small-molecule 
CD11b agonist (LA-1, control: DMSO). Shown are T cell proliferation in % of single live CD11c-
CD3+CD4+ cells which had lost a proportion of their CTV staining (left), as well as the concentration 
of IFNγ (middle) and IL-10 (right) in the co-culture supernatants. Matched one-way ANOVA, n= 3 





but it seems as if IFN-γ production followed the pattern of T cell proliferation, with 
almost no IFN-γ being produced in LA-1 or DMSO controls (Figure 5.28). 
To conclude, blocking CD11b on sorted PB cDC2s from healthy donors did not 
reduce T cell proliferation. However, one could hypothesise that no effect can be 
seen because of the immaturity of cDC2s circulating in PB. It could therefore be 
possible that investigating this further using a larger sample number or a longer co-
culture might reveal differences that cannot be observed in this culturing system. 
Furthermore, it might be necessary to induce DC maturation before any effects of 
CD11b blocking can be observed.  
5.4 Discussion 
The aims of this chapter were to investigate the roles of total and active β₂ integrins 
in RA patient PB and SF samples compared to healthy controls in order to identify 
potential differences. In this chapter, I have devised a way to ensure data acquired 
over time is consistent and comparable, and developed a data analysis strategy that 
fully utilises the breadth of information captured by the integrin panel. Furthermore, I 
have characterised active and total β₂ integrin expression levels on APCs in detail in 
healthy samples, creating a valuable baseline of expression and activation status in a 
healthy context. There, I found that total CD11a expression is significantly higher in 
females than in males. I then compared the properties of β₂ integrin α-subunits 
CD11a and CD11b in the autoimmune context of RA, comparing both PB and SF to 
this healthy baseline. While no differences between healthy controls and RA patients 
were found in PB, comparing PB with matched SF of active RA patients again 
suggested opposing roles of β₂ integrins. While both total and active CD11a were 
downregulated in SF cells, total and active CD11b were upregulated particularly on 
DC populations. Lastly, I investigated how expression of active and total β₂ integrin 
subunits related to function, utilising different methods of in vitro manipulation of β₂ 
integrins (agonism and antagonism). There, I found that total expression of CD11a is 
downregulated in response to pro-inflammatory but not immunoregulatory stimuli in 
cDC1 and cDC2 DCs, further supporting the hypothesis that it has immunoregulatory 
roles. In contrast, neither total nor active CD11b were affected by either pro-
inflammatory or immunoregulatory stimuli in cDC2 or pDCs, but were decreased in 
cDC1 DCs, not supporting my hypothesis of CD11b as a pro-inflammatory modulator. 
This chapter poses several interesting questions on the significance of these 




5.4.1 Gender differences in β₂ integrins 
Considering the gender differences observed in total CD11a expression (Figure 5.8), 
with female study participants showing higher CD11a expression in all APC types 
analysed, it is important to interrogate this effect in more detail. 
There is no prior evidence in the literature for this phenomenon, which is potentially 
unsurprising considering the previously acknowledged lack of cell-specific 
information on β₂ integrins. Furthermore, the field of immunology is potentially prone 
to under-reporting gender differences as less than 10% of published articles in the 
field analyse at least part of their data by gender (Beery and Zucker, 2011). This is 
surprising, as there are several established differences in immune responses 
between male and female study participants, including larger T cell numbers, 
antibody responses to infection and Type I interferon responses in human females 
(Klein and Flanagan, 2016). 
In mice, it was observed that APCs from female mice are more efficient at presenting 
antigen either to female or male T cells, suggesting that the difference between 
genders lies on the APC rather than the T cell side (Weinstein et al., 1984). Putting 
this into context with the increased CD11a expression in female study participants 
(Figure 5.8), it is possible that the increased surface expression of total CD11a also 
improves formation of the immune synapse, in turn increasing the efficiency of T cell 
activation. This hypothesis would also fit with the absence of significant differences in 
active CD11a between genders (Figure 5.10), as shifting the balance towards more 
active CD11a was found to actually decrease the amount of T cell activation (Balkow 
et al., 2010).  
Another potential reason for the increase in total CD11a in females is the role the 
hormone oestrogen plays in the female immune system. For example, pDCs from 
both female humanised mice and human female adults were found to become more 
activated and increase TLR7 and TLR9 signalling in response to oestrogen (Seillet et 
al., 2012). On the other hand, absence of all β₂ integrins caused an increase in TLR-
mediated signalling (Yee and Hamerman, 2013), suggesting that β₂ integrins play an 
important role in dampening down TLR-signalling. It could therefore be suggested 
that CD11a is upregulated in female study participants to counteract the comparably 
larger TLR-mediated signalling caused by the presence of oestrogen in the system. 




found no significant negative correlation of total CD11a expression with age, refuting 
this theory.  
Interestingly, no differences in total CD11a expression between male and female 
study participants who had RA were found (data shown in appendix). This suggests 
that comparably lower total CD11a expression in APCs of female study participants 
may contribute to RA pathology. This is interesting as women are more susceptible 
to many autoimmune disorders (Whitacre, 2001). Therefore, the role of gender in β₂ 
integrin expression, particularly in CD11a expression, should be investigated in more 
detail.  
To conclude, gender differences in total CD11a expression in APCs have not been 
described in the published literature to my knowledge. While it could not be identified 
why female healthy controls express significantly higher levels of total CD11a 
compared to males, one could hypothesise that the higher expression of total CD11a 
on female APCs is connected to the immune functions in females, including their 
increased ability to present antigen and the potential dampening of increased TLR-
responses caused by oestrogen. Future studies on β₂ integrins should therefore 
ensure that any gender differences are sufficiently reported on and studied in more 
detail. With differing gender ratios, 1:2.1 in healthy controls and 1:5 in active RA 
patients, one could have assumed that patients with active RA express higher levels 
of total CD11a due to the larger numbers of females. This is however not the case, 
as there were no differences in total CD11a when steric hindrance did not influence 
the results. Furthermore, differences in expression of total CD11a between female 
and male participants with RA could not be found. The increased expression of total 
CD11a in female healthy controls therefore does not affect any conclusions drawn 
from comparing the RA data set to healthy controls.  
5.4.2 Increase of steric hindrance in RA samples  
As mentioned previously, I observed significantly reduced expression of total CD11a 
in cDC2 DCs in RA patients compared to healthy controls (Figure 5.12). Further 
analysis revealed that expression was not reduced in the single stained condition and 
that the effect was caused by an increase in steric hindrance (Figure 5.13). This 
result is puzzling as the increase in steric hindrance was not accompanied by an 




source of the steric hindrance (Chapter 4, section 4.2.3, Figure 4.6). Considering the 
highly significant differences, this effect has to be explored in more depth. 
First, one explanation is that total CD11a staining is lost due to its close proximity to 
the non-covalently associated β subunit, CD18. As steric hindrance was only tested 
between total and active antibodies of each β₂ integrin subunit in isolation, it would 
be possible that total or active CD18 might interfere with binding of the antibody 
raised against total CD11a. However, neither total nor active CD18 were shown to be 
significantly increased in any of the APC types in RA samples to explain this increase 
in steric hindrance (data shown in appendix). The only exception was pDCs, where a 
significantly smaller percentage of pDCs expressed total CD18 in remission samples. 
However, the percentage of pDCs expressing active CD18 was lower and not higher 
than in healthy controls, and this effect could not be observed in any of the other 
APC types. It is, therefore, considered unlikely that the increase in steric hindrance in 
RA samples is due to increased binding of active or total CD18 antibodies. 
A second option to consider is that the increase in steric hindrance is due to an 
increase in avidity of CD11a/CD18. As β₂ integrin avidity is potentially more important 
than affinity in the context of inside-out signalling (Bazzoni and Hemler, 1998), this 
could potentially point to a difference in CD11a signalling in RA. To explain, 
increased clustering of CD11a might result in an increased likelihood of close 
proximity of total CD11a binding sites to each other and therefore a loss of total 
CD11a antibody access. This would explain the increase in steric hindrance, not only 
would signal be lost due to steric hindrance between active and total CD11a mAbs, 
but also between total mAbs binding to epitopes that have brought closer together 
due to increase β₂ integrin clustering. While this is possible, it does however not 
explain why there is no significant signal loss of total CD11a in the RA samples 
where no steric hindrance to active CD11a occurred. RA single stained total CD11a 
should at least show 15-20% less signal compared to the healthy controls, if this 
hypothesis was valid, as this is the increased amount of signal lost in active RA 
samples. Furthermore, it seems unlikely that steric hindrance would occur between 
different CD11a subunits, but not within the same CD11a protein. It is therefore 
unlikely that increased avidity of CD11a in RA samples is the cause for the significant 




A third possibility is that the active CD11a antibody binds to an intermediate state of 
the β₂ integrin, where total and active antibody binding sites are positioned in closer 
proximity to another and steric hindrance increases. Inactive and active forms of β₂ 
integrins are extreme situations and a variety of intermediate states have been 
described in the literature (Carman and Springer, 2003). However, this would also 
imply that either intermediate CD11a states occur more frequently or intermediate 
CD11a activation states are recognised at significantly higher rates in the context of 
either active RA or remission. Additionally, affinity of the active CD11a antibody for its 
target was proposed to be quite promiscuous, demonstrated by its ability to bind its 
target even in cold temperatures (Chapter 3, section 3.3.1, Figure 3.1). The group 
first identifying MEM-83, the clone used to detect active CD11a, reported that it binds 
in I domain of the alpha-subunit (Landis et al., 1994), which is located immediately in 
the active binding site between the β-propeller of CD11a and the I-like domain of 
CD18. While this would suggest that MEM-83 binds exclusively when CD11a is in its 
fully extended conformation, Landis and colleagues actually found that the antibody 
increased adhesion of T cells to ICAM-1 and bound regardless of cation availability. 
This would not only explain why no further increase in active CD11a expression 
could be elicited by PMA, it also strongly suggests that MEM-83 binds to the 
intermediate affinity states of CD11a and activates them. It is therefore a real 
possibility that significantly increased levels of steric hindrance in RA signal 
increased levels of β₂ integrins in their intermediate state. This increased readiness 
for activation might contribute or be elicited by the pro-inflammatory environment in 
RA. 
While it is likely that binding to intermediate affinity β₂ integrin states contribute to the 
increase in steric hindrance, the idea that binding sites of total and active CD11a are 
somehow closer together in RA patients could reveal a further possibility. X-ray 
crystallography studies on the structure of CD11a revealed a 5-stranded parallel β-
sheet surrounded by 7 α-helices on both sides (Binnerts and van Kooyk, 1999; Qu 
and Leahy, 1995), which was hypothesised to be the active conformation of CD11a 
as it was shown to be bound to Mn2+, a potent cation activator if β₂ integrins. Keeping 
in mind that β₂ integrin conformation can be altered by cation concentrations in the 
surroundings (Zhang and Chen, 2012), it is possible that an altered cation balance in 
PB of RA patients might contribute to the increase in intermediate CD11a that in turn 




reduced in the PB of RA patients (Scott et al., 1981). Considering that Ca2+ was 
found to be one of the main cations inhibiting β₂ integrin activation in PB (Dransfield 
et al., 1992), it is somewhat surprising that the potentially lower Ca2+ levels of the RA 
data set would not in turn increase the levels of active CD11a expressed by APCs. 
One could therefore tentatively hypothesise that CD11a is structurally altered in 
response to the state of chronic inflammation present in RA, which is accompanied 
by low Ca2+ expression. This would explain both the increase in steric hindrance, as 
well as the absence of increased active CD11a in response to low Ca2+. However, 
there are still caveats to this hypothesis, as it does not sufficiently explain why neither 
active CD11b nor CD18 are similarly altered in response to low Ca2+ levels. However, 
keeping previous observations of the different properties of CD11a compared to 
CD11b/CD18 in mind (Chapter 3), one could propose that CD11b and CD18 might 
react to the pro-inflammatory environment with different modifications that would not 
affect steric hindrance. 
To conclude, the specific reason why CD11a mAb steric hindrance is significantly 
increased in APCs from RA patient samples could not be elucidated and further tests 
on the subject were not within the time limits of this project. However, considering all 
possible options, one could propose that CD11a structure or avidity is consistently 
altered in RA patients in a way that total and activation-specific binding sites move 
closer together, causing an increase in β₂ integrins in their intermediate state which 
in turn causes a loss of signal due to steric hindrance. Future studies should explore 
this link in more detail. 
5.4.3 Opposing functions of CD11a and CD11b 
My findings from Chapter 4 suggest that β₂ integrin pairing subunits CD11a and 
CD11b have opposing functions in Mo-DCs, with CD11a being more 
immunoregulatory, while CD11b has more pro-inflammatory roles. I will now explore 
this conclusion in the context of the knowledge on β₂ integrins in APCs in a human ex 
vivo setting gained in this chapter.  
There were no differences in expression of total or active CD11a and CD11b in APCs 
isolated from PB of RA patients compared to healthy controls, suggesting that 
function of β₂ integrins in PB is not altered in RA. However, the striking increase in 




healthy controls (Figure 5.13) suggests that the two β₂ integrin subunits might react 
differently to the changed environment in RA PB. 
However, when considering CD11a and CD11b expression in RA SF, evidence of 
opposing functions clearly emerges. While total and active CD11a are significantly 
lower in SF APCs compared to PB (Figure 5.18), total and active CD11b are 
significantly higher in SF (Figure 5.23). These results are partially supported by other 
studies reporting large amounts of ‘shed’ CD11a in SF effusions (Evans et al., 2006), 
suggesting that CD11a is actively lost from cell surfaces rather than internalised. This 
finding would support my conclusion from Chapter 4, that CD11a is 
immunoregulatory in DCs and is actively downregulated to maintain joint 
inflammation. To achieve the inflammation present in an RA joint during flare, it 
would make sense that immunoregulatory mediators, such as CD11a, are 
downregulated. Shedding of CD11a is one way to achieve this. On the other hand, 
pro-inflammatory mediators, as I suggested CD11b to be, would increase to enable 
and perpetuate this pro-inflammatory local microenvironment, as I have shown to be 
the case in SF APCs.  
Following this finding further, I exposed healthy PBMCs to various pro- and anti-
inflammatory stimuli to investigate if both CD11a and CD11b could be manipulated 
by mimicking the potential factors present in SF. However, the data from short-term 
in vitro stimulation of APCs did not show the same effects of integrin subunit 
expression as we see in SF. cDC1 and cDC2 DCs indeed decrease total CD11a 
expression upon stimulation with pro-inflammatory mediators IL-1/TNFα or LPS and 
are not affected by immunoregulatory stimuli, supporting my conclusion. In contrast, 
neither expression of total nor active CD11b was affected by stimulation, and cDC1 
DCs confusingly expressed significantly less total CD11b after both stimulation with 
LPS (pro-inflammatory stimuli) and IL-10/TGFβ (anti-inflammatory stimuli).  
To summarise, while the ex vivo PB versus SF data is striking, I have not been able 
to completely replicate this result with short-term stimulation in vitro. It is therefore 
likely that this effect is dependent on either a state of chronic inflammation or on 
other environmental aspects, that cannot be replicated in vitro. One example of such 
an environmental factor would be the presence of multiple other cell types in the 
inflamed joint. However, as the failure of β₂ integrin-targeted therapeutics is largely 




understanding of the specific properties and functions could improve future 
therapeutic interventions. 
5.5 Conclusion 
In this chapter, I successfully characterised, in detail, total and active β₂ integrin 
expression in healthy study participants, finding that different APC types have distinct 
expression of both total and active β₂ integrins. In addition, total expression of CD11a 
is significantly higher in females compared to males. Furthermore, I investigated if β₂ 
integrins were in any way altered in the context of the autoimmune disorder RA PB and 
SF. While no differences were found in PB between healthy controls and RA patients, 
comparing RA PB to SF yielded striking results, with expression of total and active 
CD11a being decreased and expression of total and active CD11b being increased in 
SF. Lastly, the reaction of β₂ integrins to outside stimuli as well as their functional role 
was tested to gain further insight into β₂ integrin functionality. Here, I found that neither 
blocking nor stimulating CD11b had any significant effect on T cell stimulatory 
capacities of PB cDC2 DCs, although this is likely due to their immature state. 
Furthermore, I found that pro-inflammatory stimuli decrease expression of total CD11a 
in DCs, but not monocytes. In contrast, expression of conformation of CD11b was not 
altered in DCs by stimuli, except in cDC1 DCs, where pro-inflammatory stimuli caused 
a decrease in total CD11b.  
The most striking result of this chapter is the opposite relationship between CD11a and 
CD11b demonstrated in the RA PB to SF comparison, finding that CD11a is 
downregulated in the joint, while CD11b is upregulated. This mirrors my findings in 
Chapter 4, which leads me to conclude that CD11a and CD11b have opposing roles 
in DCs. In my final discussion, I will therefore explore the respective significance of 
























The role of β₂ integrins in the immune systems is multifactorial. While the 
heterodimeric adhesion receptors were primarily associated with playing pro-
inflammatory roles due to their roles in migration, cell signalling and maintaining the 
immunological synapse, more recent work has also highlighted their potential 
immunoregulatory roles on macrophages and, of special interest in this thesis, on 
DCs. This thesis therefore investigated the hypothesis that dysregulation of β₂ 
integrins on DC surfaces might contribute to aberrant inflammatory responses and 
autoimmunity. To this end, expression and conformation of β₂ integrin subunits 
CD11a, CD11b and CD18 were assessed simultaneously in human Mo-DCs, as a 
model of immune tolerance versus activation (mature and tolerogenic Mo-DCs) and a 
dysregulated immune system where tolerance to self has been lost and is causing 
pathology (RA patient samples). Furthermore, the impact of activating or blocking 
specific integrin subunits in DCs on subsequent T cell priming was defined. In the 
following discussion, I will discuss the challenges in detecting and targeting β₂ 
integrins encountered during this thesis, before delving into my findings that β₂ 
integrins are dysregulated in RA. Furthermore, I will discuss my findings that CD11a 
and CD11b play opposing roles on DCs and comment on how this would impact 
targeting β₂ integrins therapeutically. Lastly, I will explore further work that arises 
from the findings presented in this thesis.  
6.1 Challenges in targeting β₂ integrins for research and therapeutic reasons 
The question if a β₂ integrin-targeted antibody is blocking adhesion, mediating 
outside-in signalling or both arose predominantly when targeting CD11b on DCs in 
MLRs. As discussed in Chapter 4 (section 4.3.1), there is a wide range of published 
evidence for an immunoregulatory role of CD11b on DCs (Nowatzky et al., 2018b; 
Varga et al., 2007; Yee and Hamerman, 2013). This made my finding that T cell 
proliferation and production of IFN-γ was reduced in a mature Mo-DC MLR when 
adding a CD11b-specific antibody surprising, as it suggested pro-inflammatory roles 
for CD11b. 
The antibody clone used in this thesis to block CD11b, M1/70, has been well 
established to block CD11b-mediated functions in multiple species. For example, 
M1/70 strongly inhibited resetting of erythrocytes in response to stimulation with 
complement (Springer et al., 1982) and reduced adhesive ability to fibrinogen in a 
dose-dependent manner (Rogers et al., 1998). The same study also reported that 




to the site of artery injury. In a rabbit model of muscle injury, M1/70 blocked 
neutrophil-mediated oxidative burst and limited the severity of injury (Brickson et al., 
2003). Interestingly, this study also observed that treatment with M1/70 actually 
reduced CD11b receptor density on neutrophils, suggesting that the blocking effect of 
M1/70 was not exclusively mediated by reducing CD11b binding to its endogenous 
ligands. Potentially, binding of M1/70 to CD11b caused increased internalisation of 
the receptor, therefore reducing its presence on the cell surface.  
However, in murine DCs, M1/70 was found to reduce CpG-mediated production of IL-
6 (Stevanin et al., 2017), which led the authors to propose that the relative resistance 
of CD11b+ C57BL/6 to CIA compared to CD11b KO mice is mediated via tight control 
of IL-6 production by CD11b. Furthermore, both murine and human macrophages 
were shown to increase production of tissue factor (TF), an important initiating factor 
in the coagulation cascade, two to eight-fold when treated with M1/70 (Fan and 
Edgington, 1991). This suggested that M1/70 is not merely functioning as a blocking 
antibody, it is also able to induce functional outside-in signalling when binding to 
CD11b and therefore act as ligand in its own right. However, it is puzzling how M1/70 
could induce downstream signalling without also inducing the active conformation of 
CD11b, as the essential signalling molecules talin and kindlin are only recruited after 
integrin activation. One would therefore have to assume that M1/70 binding activates 
CD11b but simultaneously blocks integrin-mediated adhesion and binding by other 
ligands to explain its effects on cell function.  
Considering the evidence suggesting that M1/70 can both act as a blocking agent 
and a functional ligand, one could assume that this is an isolated phenomenon, 
potentially only true for the binding site of M1/70. However, clone ICRF44 (or clone 
44), which binds total CD11b and was used in this study for flow cytometry purposes, 
has been used to block or bind CD11b in a similar fashion to M1/70, suggesting that 
clear boundaries between ‘blocking’ and ‘ligating’ are difficult to assess when 
targeting β₂ integrins. Similar to M1/70, clone ICRF44 has been described to block a 
variety of CD11b-mediated functions. For example, it was shown to block adhesion to 
iC3b, as well as chemotactic abilities and cell spreading when seeded on plastic 
coverslips (Dana et al., 1986). Another study showed that clone ICRF44 treatment of 
COS cells, exclusively expressing CD11b, CD11c and CD18, but not CD11a, 
reduced IL-23 mediated release of pro-inflammatory cytokines (Lecoanet-Henchoz et 




adhesion in the presence of hydrogen peroxide (H2O2) (Blouin et al., 1999), as well 
as CD86-mediated adhesion of monocytes to fibrinogen (Sitrin et al., 1996).  
While this would suggest that usage of clone ICRF44 is suitable for blocking CD11b-
mediated adhesion, several studies have also reported that it has functional effects 
on cells. For example, in vitro treatment of neutrophils with clone ICRF44 caused 
rapid release of neutrophil gelatinase B (MMP-9), which was proposed to contribute 
to their transmigration into sites of inflammation (Wize et al., 1998). Furthermore, the 
antibody was found to induce translocation of NF-κB from the cytoplasm to the 
nucleus and subsequently mediate production of macrophage inflammatory protein 
1α (MIP-1α) and MIP-1β by primary human monocytes (Rezzonico et al., 2001). This, 
again, suggested that clone ICRF44 actively mediated cell function via outside-in 
signalling. Lastly, treatment of human Mo-DCs with clone ICRF44 was previously 
shown to reduce Mo-DC-mediated T cell proliferation and IFN-γ production, although 
CD11b-mediated inhibition could be overturned when Mo-DCs were simultaneously 
infected with Listeria monocytogenes (Škoberne et al., 2006). Indeed, a follow-up 
study reported that ligating CD11b on human Mo-DCs using clone ICRF44 efficiently 
restricted memory T cell development into Th17 T cells, by skewing cytokine 
production by Mo-DCs (Nowatzky et al., 2018b). However, while both studies 
observed that DC function was more tolerogenic after treatment with clone ICRF44, 
neither assessed signalling occurring after binding of the CD11b-specific antibody 
directly. Together, this suggests that while clone ICRF44 might block CD11b-
mediated adhesion, there is a wide range of evidence supporting that it induces 
functional differences in cells by ligating CD11b. 
So how does the potential dual role of CD11b targeting antibodies in blocking and 
ligation affect interpretation of my results? I used M1/70 to block CD11b in MLRs and 
found it to reduce T cell priming by mature Mo-DCs (Chapter 4, section 4.2.5, Figure 
4.20). Considering that treatment of human Mo-DCs with CD11b-specific antibody 
clone ICRF44 caused similar reduction in their ability to induce proliferation and IFN-γ 
production by T cells (Škoberne et al., 2006), it is possible that this result could be 
similarly explained by ligating effects of M1/70 on CD11b. To clearly distinguish 
between ligation and blocking action of M1/70, further tests on mature Mo-DCs in the 
presence of antibody would have to be made to detect if outside-in signalling 
molecules are phosphorylated after exposure to M1/70. While treatment with the 




was potentially due to its solving agent DMSO, which had unforeseen negative 
effects. Ligating CD11b would therefore be testing if a functioning agonist of CD11b 
has the same effect on T cell proliferation and IFN-γ production. However, the 
suggestion that immunoregulatory functions are induced by ligation rather than 
blocking of CD11b does not make sense when considering my finding that active 
CD11b is significantly lower on tolerogenic Mo-DCs. It is therefore likely that M1/70 
did act as a blocking antibody in the context of an MLR, as mature Mo-DCs became 
more tolerogenic Mo-DC-like, which expressed lower levels of active CD11b. 
Furthermore, the ICRF44 CD11b antibody was used when staining for 30min at 37°C 
for flow cytometry to detect total CD11b expression. Despite the evidence that this 
antibody can also elicit downstream signalling, it is unlikely that this aspect altered 
staining results, as CD11b could still be activated further by PMA, thereby suggesting 
that ICRF44 did not cause activation of all CD11b subunits it bound to.  
In summary, both M1/70 and clone ICRF44 have been classically described as 
‘blocking’ antibodies, largely due to their ability to reduce CD11b-mediated adhesion. 
However, taking all evidence into account, this is not factually correct, as both 
antibodies mediate a range of cellular functions, including production of both pro- and 
anti-inflammatory mediators (Nowatzky et al., 2018b; Rezzonico et al., 2001). It is, 
therefore, likely that interpretation of the effects of CD11b-targeting antibodies in the 
literature has so far primarily been based on testing a narrow range of functions in 
each paper, resulting in the term ‘blocking’ if a functional aspect was reduced or 
‘ligating’ if a functional aspect was induced. While this is reasonable due to limited 
space for publication and the need for a coherent story, it makes interpretation of 
published data and its potential therapeutic impact highly complex, as exact functions 
of mAbs currently used in basic research could be multifactorial and potentially 
dependent on cell-type and environment. Future studies should acknowledge the 
potential dichotomy of mAbs or other therapeutic targets blocking some functions but 
activating others, thereby potentially impacting interpretation of results. Furthermore, 
it would be important to test if downstream outside-in signalling actually occurs as a 
direct result of individual antibodies binding, as this is not known so far.  
An important question that arises from the difficulty to correctly distinguish between 
effects mediated by ‘blocking’ and ‘ligation’ of a β₂ integrin subunit is what this means 
for the targeting β₂ integrins therapeutically in the future. Currently, the most 




leukadherins (Faridi et al., 2013; Panni et al., 2019). One possibility is that these 
therapeutic agents are not only promising because they reduced inflammation in 
animal models (see Chapter 1, Section 1.4.5) (Faridi et al., 2013; Park et al., 2007), 
but because of their defined function on integrins: they increase adherence of the β₂ 
integrin to its ligand. It is therefore possible that failure of other CD11b-targeting 
therapies to outperform placebo in human (see Chapter 1, Section 1.4.5) (Dove, 
2000; Harlan and Winn, 2002) was partially due to not fully understanding their 
functionality and thereby affecting β₂ integrins and in turn cell properties in 
unforeseen ways.  
6.2 Evidence of dysregulation of β₂ integrins in RA 
As the main aim of my thesis was to define the roles of β₂ integrins on DC in 
tolerogenic and autoimmune environments, I will first explore which of my findings 
support my original hypothesis that integrin expression and/or conformation may be 
dysregulated in RA.  
First, no differences in the expression of total or active β₂ integrin subunits were 
observed in any of the DC subtypes or monocytes isolated from PB between healthy 
controls and RA patients (Chapter 5, sections 5.3.4 & 5.3.5, Figure 5.12, Figure 5.15, 
Figure 5.20, Figure 5.22). This suggested that, in PB, β₂ integrin expression or 
conformational regulation were neither actively contributing to pathology nor altered 
in response to the presence of inflammation due to established autoimmunity.  
However, while this result does not support a role of β₂ integrins in systemic immune 
dysregulation, several other results presented in this thesis do support the hypothesis 
that β₂ integrins are dysregulated in autoimmunity. CD11a, in particular, was found to 
have different properties when comparing healthy controls and RA patients. For 
example, total CD11a expression was significantly lower in healthy male controls 
compared to healthy females. However, when comparing total CD11a expression 
between male and female RA patients, no significant differences between genders 
was observed (Appendix, Figure 7.1). Considering the fact that women are twice as 
likely to suffer from RA and other autoimmune disorders compared to men (Whitacre, 
2001), this could suggest that dysregulation of CD11a expression leading to a 
change in immune cell communication could contribute to RA pathology. This is 
further supported by evidence that APCs derived from healthy female mice showed 




male (Weinstein et al., 1984). The authors suggested that the higher reactivity of 
APCs from female mice might contribute to an increased likelihood to breach self-
tolerance. Finally, the female hormone oestrogen has been found to increase TLR-
signalling (Seillet et al., 2012), while β₂ integrins have been described to dampen and 
control TLR signalling (Yee and Hamerman, 2013). As no difference in CD11a 
expression between male and female RA patients was found, one could therefore 
suppose that decreased CD11a on female RA patients fails to regulate the TLR 
signalling mediated by oestrogen. This would further support the theory that the loss 
of difference in total CD11a expression between male and female RA patients could 
contribute to disease pathology in women. To conclude, this data therefore suggests 
that β₂ integrins, especially loss of CD11a, might play a role in mediating 
autoimmune diseases such as RA in women. It is here also important to state that, to 
my knowledge, no other differences in integrin expression or function have been 
reported to be different between genders. 
Another difference between healthy controls and RA patients concerning CD11a was 
observed in the significantly increased steric hindrance between total and activation-
specific antibodies in both active and remission RA samples compared to healthy 
control samples (Chapter 5, section 5.3.4, Figure 5.13). By elimination of other 
possibilities, I concluded that this was likely to be due to a consistent alteration in 
either molecular structure, such as an increase in the intermediate activation state, or 
avidity (clustering) of CD11a, that resulted in total and active binding sites moving 
closer together, therefore increasing loss of total CD11a signal due to steric 
hindrance. While exploring this altered state was not within the remit of this thesis, 
this finding suggested that the β₂ integrin subunit CD11a is consistently altered in 
RA. These alterations in CD11a expression and molecular properties may directly 
contribute to disease or, alternatively, may reflect a downstream consequence of the 
dysregulated immune environment in RA. 
Considering that I did find β₂ integrins to be dysregulated in RA, it is furthermore 
interesting to speculate if these changes are specific to RA and autoimmune disease 
more generally, or if this change in CD11a is likely to occur in any inflammatory 
environment. It is interesting that the difference in steric hindrance was seen in both 
active RA and remission patients, suggesting that this dysregulation exists even in 
the absence of inflamed joints. One could therefore speculate that CD11a would not 




how the change in CD11a affects DC function in RA and potentially other immune 
diseases would be necessary to understand the aspect of chronic versus acute 
inflammation and infection versus autoimmunity better.  
My data showing that tolerogenic and mature Mo-DCs differ in their expression of 
active CD11a and CD11b, and that treating mature Mo-DCs with a blocking antibody 
against CD11b reduced their ability to effectively stimulate T cells, further supports 
the possibility that alteration of β₂ integrins might affect immune functions such as 
antigen presentation and cytokine production.  In the following section, I will therefore 
explore the potential opposing roles of the β₂ integrin α subunits CD11a and CD11b 
evidence of support from throughout my thesis. 
6.3 Summary of opposing roles of CD11a and CD11b 
A theme that was persistent throughout my thesis were the differences observed 
specifically between β₂ integrin subunits CD11a and CD11b, which led me to 
conclude that they likely play opposing roles on DCs. In the following paragraphs, I 
will summarise the findings presented in my three results chapters, put them into 
context with the published literature and explore what they can tell us about the 
respective roles of CD11a and CD11b on DCs. 
Opposing roles of CD11a and CD11b on Mo-DCs  
I quantified β₂ integrin expression and conformation in mature and tolerogenic Mo-
DCs to investigate if they are involved in respective immunogenic and tolerogenic 
roles of mature and tolerogenic Mo-DCs. While I detected no differences in total 
CD11a or total CD11b expression, active CD11a was significantly increased in 
tolerogenic compared to mature Mo-DCs, while active CD11b was significantly 
decreased (Chapter 4, sections 4.2.3 & 4.2.4, Figure 4.7 and Figure 4.10). Especially 
as the active CD11a antibody (clone MEM-83) likely also contributes to activation of 
CD11a, one could speculate that tolerogenic Mo-DCs were able to activate CD11a to 
a higher degree compared to mature Mo-DCs. Furthermore, surprising adhesion 
assay data suggested a potential role for CD11c, which would further support that a 
fine balance between different b2 integrin alpha subunits has to be maintained to 
mediate tolerogenic Mo-DC function. Lastly, blocking CD11b on mature Mo-DCs in 
the context of an MLR reduced the level of T cell proliferation and cytokine 
production. Although this result was not repeated in tolerogenic Mo-DCs, which 




fits well with the data showing that active CD11b is significantly reduced on 
tolerogenic Mo-DC surfaces (Chapter 4, section 4.2.4, Figure 4.10). Therefore, it 
suggests that active CD11b is somehow maintained in its inactive state or 
downregulated on tolerogenic Mo-DCs to mediate immunoregulatory functions, 
potentially via an increase in active CD11a and that blocking CD11b on mature Mo-
DC surfaces makes them assume a more tolerogenic phenotype. The mechanism of 
how integrins could be maintained in an inactive state have not been reported, but 
one could speculate that as inside-out signalling is largely mediated via talin and 
kindlin binding to the β₂ integrin β subunit CD18, that specific inactivation of CD11b 
could be mediated by increasing non-covalent interactions between CD11b and 
CD18. Possibly, phosphorylation of CD11b intracellular domains might thereby keep 
leg regions of CD11b and CD18 close together despite talin and kinlin binding to 
CD18 to induce activation. 
So how could differences in active CD11a and active CD11b relate to the function of 
mature and tolerogenic Mo-DCs respectively? One could speculate that increasing 
active CD11a on tolerogenic DCs would make them adhere tighter to T cells via 
binding to ICAM-1, thereby prolonging contact time, which was previously shown to 
reduce T cell activation (Balkow et al., 2010). However, contact with T cells is not the 
only aspect that could be affected: changing the balance of active CD11a and active 
CD11b on tolerogenic Mo-DCs could alter ligands the cells primarily interact with and 
thereby affect cell signalling. For example, it is possible that tolerogenic Mo-DCs 
resistance to restimulation with LPS is partially mediated by their low active CD11b 
expression, as LPS-mediated gene changes were shown to be dependent on CD11b 
signalling in macrophages (Perera et al., 2001). Increasing signalling mediated via 
CD11a and decreasing signalling mediated via CD11b might also alter type and 
levels of cytokines released by tolerogenic Mo-DCs by shifting downstream signalling 
processes, potentially explaining why tolerogenic Mo-DCs do not induce as much 
IFN-γ production by T cells.  
To summarise, active CD11a and CD11b were found to be differentially expressed 
between mature and tolerogenic Mo-DCs. In addition to other mature and tolerogenic 
Mo-DC properties that were hypothesised to be due to altered β₂ integrin expression, 
such as cell adhesion, clustering and ability to stimulate T cell responses, targeting 




stimulate T cells. This provided first concrete evidence that β₂ integrin α subunits 
CD11a and CD11b play opposing roles in immune activation versus tolerance.  
Opposing roles for CD11a and CD11b in RA 
As I found evidence of opposing functions of CD11a and CD11b in a model of 
immune versus tolerogenic environments (mature vs. tolerogenic Mo-DCs), I went on 
to validate these findings in real human DCs from relevant clinical samples (healthy 
controls vs. RA patients). As previously mentioned, no opposing functions for β₂ 
integrin α subunits were observed in PB, with only CD11a being implicated to be 
dysregulated between RA patients and healthy controls. Importantly, the finding that 
CD11a and CD11b might play opposing roles on DCs was further supported when 
comparing PB monocytes and DCs to their counterparts located in SF. Compared to 
PB APCs, SF APCs showed significantly increased expression of total and active 
CD11b, while expression of total and active CD11a was significantly decreased 
compared to PB (Chapter 5, sections 5.3.4 and 5.3.5, Figure 5.18, Figure 5.23 and 
Figure 5.24). Therefore, in the joint, where DCs have been shown to be in a mature 
state, I found CD11b expression to be increased and CD11a expression decreased, 
compared to PB. This mirrors my finding that mature Mo-DCs expressed more active 
CD11b and less active CD11a compared to tolerogenic Mo-DCs. Especially as 
CD11a, the proposed immunoregulatory mediator, was found to be shed from cell 
surfaces in large quantities in the synovium (Evans et al., 2006), one could speculate 
that to maintain joint inflammation, the immunoregulatory roles of CD11a have to be 
actively down modulated, while the pro-inflammatory functions of CD11b are 
increased. 
In line with my findings in tolerogenic Mo-DCs, I proposed that increased presence of 
pro-inflammatory cytokines within the inflamed joint cavity likely cause 
downregulation of immunoregulatory mediators, such as CD11a, while 
simultaneously stimulating pro-inflammatory mediators, such as CD11b. Cytokines 
that could mediate driving DCs to a mature state could be IFN-γ, IL-1β and IL-6, 
which have all been found at increased levels in RA synovial fluid (Lettesjö et al., 
1998; Schlaak et al., 1996). To test if this was true, I therefore quantified expression 
of total and active β₂ integrins on monocytes and DCs when exposed to pro- and 
anti-inflammatory stimuli, as well as RA synovial fluid. Expression of CD11b in 
response to pro- and anti-inflammatory stimuli did not support my hypothesis, with 




decreased by both the pro-inflammatory stimulus LPS and the anti-inflammatory 
stimulus IL-10/TGFβ in cDC1 DCs. However, total CD11a expression was 
significantly decreased specifically in cDC1 and cDC2 DCs when treated with the 
pro-inflammatory stimuli LPS or IL-1/TNFα, further supporting my hypothesis that 
CD11a holds immunoregulatory roles on DCs that are downregulated in the presence 
of inflammation.  
Overview of opposing roles of CD11a and CD11b 
To summarise, evidence that roles of CD11a and CD11b might be different and 
potentially even in direct opposition of each other was presented in both Mo-DCs and 
in RA clinical samples. Due to CD11a being upregulated on tolerogenic Mo-DCs 
(chapter 4) while being downregulated in a setting of inflammation (chapter 5), I 
propose that CD11a plays an immunoregulatory role on DCs. While very little 
research on the role of CD11a on DCs exists, this conclusion finds support in the 
group reporting that constitutively active CD11a on DCs decreased their ability to 
induce T cell proliferation (Balkow et al., 2010; Semmrich et al., 2005). This previous 
publication fits well with data presented in this thesis on both Mo-DCs and in RA SF 
DCs. Increased levels of active CD11a on tolerogenic Mo-DCs, could thereby 
contribute to their variety of tolerogenic functions, such as low expression of 
costimulatory molecules, reduced expression of pro-inflammatory cytokines and 
increased expression of immunoregulatory cytokines (Chapter 4, section 4.1.1), 
alongside their reduced abilities to induce IFN-γ production by T cells ( Chapter 4, 
section 4.2.1, Figure 4.4). Conversely, in an inflamed RA joint, it is likely that local 
pro-inflammatory factors, such as IFN-γ, IL-1β IL-6 (Lettesjö et al., 1998; Schlaak et 
al., 1996), would activate DCs present in the joint and increase their ability to 
stimulate T cells (Grohmann et al., 2001), therefore explaining the shedding of 
CD11a from DC surfaces. On the other hand, I suggested CD11b to be pro-
inflammatory due to its significantly decreased expression on tolerogenic Mo-DCs, 
while being upregulated on APCs found in RA SF. Evidence from the literature on 
this topic is more conflicting, as there are a number of studies to suggest 
immunoregulatory roles for CD11b in DCs (Chapter 1, section 1.4.3) (Behrens et al., 
2007; Ehirchiou et al., 2007; Nowatzky et al., 2018b; Podgrabinska et al., 2009; 
Škoberne et al., 2006; Varga et al., 2007; Yee and Hamerman, 2013). However, one 




T cells by restricting endocytosis of TLR4 (Ling et al., 2014), suggesting that CD11b 
can mediate pro-inflammatory functions under some circumstances.  
How can this discrepancy between findings presented in this thesis and the wider 
published literature be explained? First, it is possible that CD11b has both pro-
inflammatory and immunoregulatory functions that are mediated depending on 
context. It is therefore possible that both inducing mature Mo-DCs from CD14+ 
monocytes and APCs present in an inflamed joint represent an environment where 
pro-inflammatory functions of CD11b are more prevalent in comparison to its 
immunoregulatory roles. This is further supported by the fact that the study reporting 
a pro-inflammatory role for CD11b in TLR4 signalling (Ling et al., 2014) found this in 
murine BMDCs that were matured with LPS. Another possibility would be that CD11a 
and CD11b are reciprocally regulated, potentially together with CD11c, with a change 
in expression of CD11a automatically altering the balance of β₂ integrins on the cell 
surface and therefore affecting expression and conformation of CD11b. One can 
speculate that such a reciprocal regulation of β₂ integrin α subunits could be 
mediated by downstream signalling processes causing increased internalisation of a 
certain β₂ integrin subunit or by altering their ability to assume their active 
conformation in response to either outside-in or inside-out signalling. 
6.4 Targeting β₂ integrins therapeutically 
Data presented in this thesis highlight opposing roles of CD11a and CD11b, with 
CD11a potentially being more immunoregulatory and CD11b potentially playing pro-
inflammatory roles on DCs. Therefore, therapeutic manipulation of this β₂ integrin 
axis, for example by blocking CD11b and/or promoting CD11a, might have benefit in 
RA and other autoimmune conditions by inducing DCs with a more tolerogenic 
phenotype. 
A major challenge in interpreting scientific results as well as developing therapeutic 
strategies involving β₂ integrins is the difficulty in distinguishing how mAbs or 
therapeutic agents mediate their effects. To explain, an agent binding specifically to a 
β₂ integrin subunit could be ‘blocking’ β₂ integrin function, by obstructing their access 
to ligands. However, a mAb or therapeutic agent could equally well mediate outside-
in signalling by ‘ligating’ the β₂ integrins, which might elicit phenotypic changes to 
cells via downstream outside-in signalling pathways. Interestingly, both approaches 




DCs to T cells might reduce the amount of T cells becoming activated and blocking 
adhesion to endothelium would restrict access of cells to sites of tissue inflammation, 
thereby potentially contributing to resolving inflammation. On the other hand, 
downstream β₂ integrin signalling in DCs has been described to be immunoregulatory 
(Chapter 1, section 1.4.3), suggesting that ligating β₂ integrins might increase control 
of TLR signalling (Yee and Hamerman, 2013), thereby contributing to limiting 
immune responses. Therapeutically, it might therefore even be desirable to block 
access of immune cells into tissues, while simultaneously inducing immunoregulatory 
signalling in DCs already present in either inflamed tissues or LNs.  
6.5 Future Directions 
 
The finding that β2 integrin subunits CD11a and CD11b appear to be reciprocally 
regulated, with one increasing when the other decreases in surface expression under 
several circumstances, is one of the main findings of this thesis (Figure 6.1). It 
generates a variety of novel questions and directions for future research. The most 
Figure 6.1 Graphical summary 
The work presented in this thesis suggests that β2 integrin subunits CD11a and CD11b are 
reciprocally controlled on immune cell surfaces. This raises a variety of novel questions for 
future research, including involvement of other subunits, underlying molecular mechanism 
and role of found gender differences as well as potential alterations in autoimmune disease 




obvious questions would be how such a system of integrin regulation works on a 
molecular basis and how other subunits, such as CD11c and CD11d are involved. 
Another question that was touched on by my finding that β2 integrins, especially 
CD11a, do seem to be dysregulated in RA, is if this system is altered in autoimmune 
disease or infection and if it is therefore a viable therapeutic target. Lastly, gender 
differences in CD11a total expression suggest that this mechanism might operate 
differently in males and females, adding a further dimension. In the following 
paragraphs, I will explore how these questions could be answered in the future. 
While the evidence presented in the previous section supports a role for 
dysregulation of the β₂ integrin subunit, CD11a, in RA, the question of cause and 
effect is especially difficult to answer in a human setting. Continuing this work, I 
would focus on the functional aspects of β₂ integrins on DCs, including adhesive, 
migratory and T cell stimulatory functions, between male and female healthy controls 
and healthy controls and RA patients. One could here hypothesise that such CD11a-
mediated functions would be altered in RA patients, and might even be shown to 
contribute to on-going inflammation. Here, it would be especially important to 
compare RA patient samples functionally to healthy controls, as the specific nature of 
CD11a dysregulation is not yet clear and would therefore be difficult to recreate in 
vitro. This furthermore suggests that while measuring both total and active β₂ integrin 
expression yields novel information, this is not exhaustive of integrin function. Even 
though expression of the active integrin conformation likely reflects functional ability, 
further measurements, such as receptor avidity, might affect function as well and 
might therefore be important to take into account. 
For further exploring the potential opposing functions of CD11a and CD11b in the 
future, targeting CD11a and CD11b specifically on human DCs would be a top 
priority to investigate the respective functional importance of CD11a and CD11b on 
DCs. RNAsilencing of individual β₂ integrin subunits, which would allow for 
quantification of expression and conformation of other β₂ integrins to test if any 
reciprocal regulation between β₂ integrin subunits exists, could potentially do this. 
This approach would also allow to pinpoint the functional significance of different β₂ 
integrin subunits, as it would allow testing of DC abilities to migrate, stimulate T cells 
and produce cytokines. Furthermore, as the read-outs used to detect differences in 
specifically tolerogenic function of Mo-DCs were limited, further read-outs could be 




could include measuring cytokine signalling, such as the presence of IL-12 or TGF-β 
after blocking or activating integrin subunits to test if tolerogenic functions are altered. 
Similarly, surface marker expression of CD83, CD86, HLA-DR, LAP or TLR2 might 
give insight in how far integrins are actually involved in these differences between 
mature and tolerogenic Mo-DCs. Lastly migratory and clustering properties could be 
similarly assessed to test how functionally important the different subunits are. 
6.6 Concluding remarks 
In this thesis I present evidence that the β₂ integrin CD11a is dysregulated in RA. 
These alterations of CD11a may indicate a downstream consequence of 
inflammation or actively contribute to disease pathology, or potentially even do both. 
Especially the finding that expression of CD11a differed between healthy men and 
women, but was found to be the same between men and women with RA, could 
provide valuable insights into how gender might contribute to the development of 
autoimmune disease. Furthermore, my work uncovered potentially opposing roles of 
β₂ integrin subunits CD11a and CD11b on DCs, with CD11a being likely to mediate 
immunoregulatory roles, while CD11b was suggested to play more pro-inflammatory 
roles. Although technical problems with β₂ integrin targeting therapies persist and 
would need to become more targeted to specific cell types or cell locations, together, 
this suggests that β₂ integrins represent a viable therapeutic target on DCs 
specifically to treat RA and potentially other autoimmune disorders by driving a more 













Appendix figure 1 Expression of total CD11a does not differ between genders in RA 
Total CD11a expression was compared between female (red circles) and male (blue squares) RA 
patients in five APC types of interest. Both active RA (left, female n=26, male n=5) and remission 








Appendix figure 2 Total CD18 expression in healthy controls compared to RA patients 
Total CD18 expression in RA samples and RA samples compared to healthy controls A. Total 
expression of CD18 (MFI) compared between active RA (orange squares, n=31) and disease in 
remission (blue triangles, n=24) on five APC types of interest isolated from PB. Unpaired student’s t 
test. B. Total CD18 expression (MFI) between healthy controls and RA patients. One way ANOVA, 










Appendix figure 3 Active CD18 expression in healthy controls compared to RA patients 
Active CD18 expression in RA samples and RA samples compared to healthy controls A. Expression 
of active CD18 (MFI) compared between active RA (orange squares, n=31) and disease in remission 
(blue triangles, n=24) on five APC types of interest isolated from PB. Unpaired student’s t test. B. 
Active CD18 expression (MFI) between healthy controls and RA patients. One way ANOVA, n=29 for 
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